

For personal use only



2026
ANNUAL
REPORT

AFT *pharmaceuticals*
Working to improve your health

For personal use only



For personal use only

"AFT is a growing multinational pharmaceutical company that develops, markets, and distributes a broad portfolio of pharmaceutical products across a wide range of therapeutic categories."

Contents

FY26 Financial and Strategic Highlights	2
Chair and Managing Director's Report	4
Business Focus:	
• Regional Performance	8
• Research and Development	12
Sustainability	14
Reconciliation of EBITDA to GAAP	36
Governance:	37
• An Experienced and Skilled Board	38
• Our Senior Management Team	40
• Corporate Governance Statement	42
Remuneration	59
Consolidated Financial Statements	64
Statutory Disclosures	98
Appendices:	
• Appendix 1 – Climate Resilience	103
• Appendix 2 – The Material Sustainability Matters Definitions	114
Directory and Financial Calendar	116

This report provides a summary review of AFT's operational and financial performance for the year to 31 March 2026. It should be read in conjunction with the company's financial statements on pages 64 to 97 of this report. The information provided in this report has been compiled in accordance with relevant law, rules, and corporate governance recommendations for investor reporting. Financial information has been prepared in accordance with appropriate accounting standards and has been audited by Deloitte Limited.

Throughout this report we have focused on what we believe matters most to our stakeholders and our business. We have endeavoured to ensure all information is accurate through internal verification and other approval processes.



David Flacks
Chairman

Dr Hartley Atkinson
Managing Director

For personal use only

We are extending our reach around the world, building our product range, and growing our research and development portfolio to extend our record for delivering long-term sustainable growth and better health outcomes globally.

Double digit revenue growth across all territories and record earnings

\$254.7m



Total revenue, rose 22% from \$208.0 million in FY25, with strong growth in all territories and rising license income

\$24.4m



Operating profit rose 39% from \$17.6 million in FY25 as earnings growth offset significant investment in international business hubs and R&D

\$38.6m



Net debt* at 31 March 2026 within the company target range

2.5 cents



Dividend per share, up 0.7 cents on 1.8 cents in FY25

OUR STRATEGIC ACHIEVEMENTS

Our products are now

sold in 87 countries

up from 80 in FY25

We are

scaling our international business hubs

with the UK and South Africa flagged to contribute in FY27

Multiple out-licensing agreements

progressing with broad programme of negotiations across key assets

We extended our R&D portfolio, with

seven projects

being commercialised in multiple countries

* Net debt is net interest bearing liabilities less cash and cash equivalents.

For personal use only

For personal use only

AUSTRALIA
Revenue:
\$150.8 million
up 19%

Operating profit
\$30.3 million
up 19%

Key growth drivers:
 Broad based growth across
 OTC and pharmacy brands.

NEW ZEALAND
Revenue:
\$59.7 million
up 11%

Operating profit
\$9.4 million
up 7%.

Key growth drivers:
 Eyecare, pain relief,
 dermatology and prescription

ASIA
Revenue:
\$15.6 million
up 41%

Operating profit
\$3.8 million
up 111%.

Key drivers:
 Normalisation of trading after
 1H 25 disruptions



INTERNATIONAL
Revenue:
\$28.5 million
up 78%

Operating loss
\$6.0 million
down 19%



Key drivers:
 Normalisation of trading and
 scaling of AFT's international
 business hubs

A Growing Contribution From Our International Operations

FY26 Revenue




FY25 Revenue



Extending Our Decades Long Record of Growth

AFT Pharmaceuticals Revenue



For personal use only



We expect to extend our growth record in FY27 as we drive towards our revenue goal of at least \$300 million.

Setting our sights on \$300 million revenue

Dear Shareholders,

AFT has delivered another strong result. We saw double digit growth across all our territories, delivered a record operating profit of \$24.4 million, ahead of guidance and 39% ahead of the prior year's \$17.6 million. And now, in the new financial year (FY27), we are confident of hitting the aspirational revenue target we set in 2024 of more than \$300 million.

We have achieved this result – the latest in an unbroken record of year-on-year revenue growth – through continued investment for long-term value creation, including progressing our international hubs, executing licensing opportunities, and advancing a portfolio of innovative products that can support our growth ambitions.

It is a result that demonstrates continued execution against our strategy. We are growing in our established markets, and we are building a wider, more diversified AFT through disciplined international expansion, out-licensing the intellectual property from our research and development programmes and further advancing our efforts to address unmet clinical needs.

Financial Results

Total revenue, which includes licensing income, rose 22% to \$254.7 million from \$208.0 million in FY25. Growth was driven by: i) continued momentum in Australia; ii) steady expansion in New Zealand; iii)


a growing contribution from AFT's international and Asian hubs as they scale and iv) a return to normal patterns of trading in Asia and International markets.

Australasia remained the cornerstone of AFT's earnings and cash generation growing revenue by 16% to reach \$210.5 million. In the Australian market we saw broad-based strength across OTC and pharmacy brands and ongoing uptake across prescription medicines. The growth was also supported by a steady cadence of new launches and portfolio expansion, which remains a key focus. New Zealand delivered steady growth with continued opportunities across key categories including allergy, dermatology and eyecare.

International and Asian markets recorded a stronger year, respectively rising by 66% (to \$25.5 million) and 41% (to \$15.6 million) on product sales and royalties reflecting ongoing execution on expansion initiatives. However, were it not for some shipping delays related to the geopolitical tensions, revenue growth would have been stronger.

Licensing income rose to \$3.1 million as AFT progressed multiple out-licensing agreements and expanded its pipeline of negotiations across key assets, a rise that is consistent with the ongoing progression of commercialisation of the near-term development portfolio.

AFT Operating Profit*



* FY20 normalised to exclude non-cash valuation gain

Gross margin on product sales and royalties decreased slightly to 42.7% (FY25: 43.9%), reflecting primarily portfolio mix and foreign currency but AFT sees this margin improving in FY27 and onwards.

Operating expenses increased as planned as AFT continued to fund growth initiatives, including: (i) start-up and ongoing scaling costs for international hubs; (ii) brand and market entry investments to support launches; and (iii) higher R&D expenditure to advance late-stage projects and new pipeline initiatives. However, and importantly, overall expenses were lower as a proportion of sales at 33.8% of sales (FY25 35.6%) as increased operating leverage is achieved. The resulting net profit after tax was \$14.1 million (FY25: \$11.4 million) and included increasing amortisation on some existing projects.

International Development

AFT continued to advance its strategy of building international business hubs in markets that share similar commercial and regulatory dynamics to its Australasian operations.

During FY26, the company continued to expand its footprint across the UK, Europe, North America, and South Africa, progressing each hub along the path from establishment to development.

In the United Kingdom, AFT continued to broaden distribution of Maxigesic tablets (marketed as Combogesic) from Boots and SuperDrug to now include independent pharmacies. The initial launches of Combogesic IV in several London NHS hospitals continued to progress, with sales momentum linked to formulary inclusion.

In Europe, AFT is making progress with its portfolio of injectables acquired from an insolvent company in 2025, with updated regulatory dossiers and licenses now supporting planned EU launches that are expected to make a meaningful contribution in FY27.

In North America, AFT launched Combogesic IV in Canada during FY26 and has a healthy pipeline of further product launches planned. AFT has taken back distribution of Combogesic tablets and is relaunching them in the new financial year.

In the US, Combogesic Rapid will be distributed primarily through Mark Cuban's CostPlus platform, reaching all 50 states, while Hikma continues to distribute Combogesic IV. AFT's consumer range – including Liposachets, Kiwisoothe, and Optisoothe – is available through Amazon with additional channels being finalised and expected to be commercialised during the FY27 time period.

In South Africa, AFT has successfully integrated several inventory products acquired directly from Pharma Dynamics. In addition, after year end we also finalised the purchase of a product portfolio.

Research and Development

FY26 R&D expenditure (expensed and capitalised) was \$18 million (FY25: \$15 million), reflecting continued investment across a diversified portfolio spanning pain, dermatology, eyecare and injectables. We intend to further increase R&D expenditure to \$25 million in FY27 in order to execute the larger R&D portfolio including the late-stage injectable iron project which requires a large clinical study.

More detail on the programme is covered on pages 12 and 13 of this report. However, highlights of the year include:

- A new partnership with Stablepharma UK to develop room-temperature storage versions of several fridge-stored injectables – opening a potential global market worth in excess of US\$6 billion¹. The first two fridge-free drugs are in development and progressing well.
- Intravenous iron: Following a positive Phase III trial, AFT and its development partners progressed preparations for a large global confirmatory study involving 1,366 patients across multiple geographies (planned New Zealand, China, India, Japan, Armenia, Europe and US) and filed three additional patent applications to further strengthen protection of the asset. The project targets an addressable market estimated at US\$7.41 billion².
- Pascomer: Regulatory resubmissions for the Facial Angiofibroma indication have started this calendar year after adding a new contract manufacturing site to address previous regulatory manufacturing questions. Additionally, a Port Wine Stain Phase II study will be underway in both Spain and USA this year.
- Migraine Treatment: a formulation project is underway in order to file a dossier in the 2027 calendar year.
- Antibiotic eyedrop: AFT advanced the IND submission pathway with the US Food and Drug Administration (FDA) to support first-in-human studies.

We also continued to execute an active out-licensing and in-licensing programme, progressing multiple agreements and advancing regulatory dossiers across the portfolio to support a multi-year launch schedule.

¹ Data on file.

² <https://www.biospace.com/intravenous-iron-drugs-market-size-to-worth-around-us-7-41-billion-by-2033>

Balance Sheet and Dividend

AFT remains well funded. Net debt at 31 March 2026 was \$38.6 million (31 March 2025: \$14.5 million) and remains within the company's target leverage range. This increase partly reflects the decision to increase inventory, to support growth and ensure continuity of supply given the current geopolitical tensions. Inventory acquired with the new South African pharmaceutical licenses, also contributed to the increase. The company secured a new and increased facility of \$50 million in December 2025.

Reflecting the strength of the business, Directors have declared a dividend of 2.5 cents per share (FY25: 1.8 cents per share).

Outlook

We expect to extend our growth record in FY27 as we drive towards our revenue goal of at least \$300 million through: (i) continued expansion in Australasian markets; (ii) a strong programme of launches across International hubs; (iii) increasing contributions as those hubs scale, with the UK and South Africa expected to make a contribution to earnings in the current financial year; (iv) continued progress in R&D and regulatory milestones; and (v) an active licensing programme that starts to monetise AFT's intellectual property and broadens our geographic reach.

We are well positioned to continue to grow by focusing on what we do best - identifying unmet clinical needs, in-licensing or developing medicines, and commercialising them to improve health globally. Importantly, our increasing geographic and product diversification supports the resilience of the business.

We will continue to make significant investment this financial year and we expect FY27 operating profit to reach between \$28 million to \$32 million.

We thank shareholders for their continuing support, our customers and our partners for the trust they put in AFT and its products and our team for their continuing commitment and hard work. We look forward to updating you on our progress in our July quarterly update.

David Flacks
Chair

Dr Hartley Atkinson
Managing Director



A FAREWELL TO CFO MALCOLM TUBBY

After many years of dedicated service, our Chief Financial Officer Malcolm Tubby retires at the end of this month, and we wish to take this opportunity to acknowledge his extraordinary contribution to AFT.

Malcolm has been with AFT since its earliest days – a time when the company operated on a very different scale to the one it does today. Over the course of his tenure, he has played a key role in shaping AFT's financial strategy and governance as the company grew from a small New Zealand operation into a business selling across 87 countries, dual-listed on the NZX and ASX, and tracking toward \$300 million in annual revenue.


That journey – from the garage to the global stage – is a remarkable one, and Malcolm was a key architect of its financial foundations.

We are deeply grateful for his professionalism, his integrity, and his unwavering commitment to the company and everyone in it. Malcolm's steady hand has given the Board, management, investors, and partners alike a great deal of confidence over the years, and his legacy will endure in the strength of the business he helped build.

We are deeply grateful for his professionalism, his integrity and his unwavering commitment to the company...

AFT's Global Reach

A decades-long record of growth and global expansion




Australia

SUSTAINED MOMENTUM IN OUR LARGEST MARKET

AUSTRALIAN REVENUE:

Continuing to offer strong potential



AUSTRALIAN OPERATING PROFIT
\$30.3m
 (FY25: \$25.5 million)

Australia continued to be the primary driver of group performance in FY26, supported by broad-based strength across key OTC and pharmacy brands and ongoing uptake in prescription medicines.


Growth remained led by our established eyecare, and pain relief medicines as well as iron supplements, the liposomal vitamin range and AFT's expanding portfolio of injectables and prescription products.

New product launches complemented performance and support longer-term organic growth. AFT's active business development programme continues to add to the pipeline, alongside ongoing investment in our proprietary R&D portfolio.

We continue to see opportunities to improve operating leverage in Australia as the business scales.

New Zealand SEEING BROAD-BASED GROWTH

NEW ZEALAND REVENUE:
Steady expansion in our home market



NEW ZEALAND OPERATING PROFIT
\$9.4m
(FY25: \$8.8 million)


New Zealand delivered another year of steady growth, supported by continued momentum across key categories including eyecare, pain relief and dermatology, and the ongoing expansion of our hospital injectables and prescription portfolio.

The New Zealand business remains an important contributor to group cash generation and provides a strong base to support AFT's investment in international expansion and R&D initiatives.



ASIA RETURN TO NORMALISED TRADING; BUILDING MOMENTUM IN CHINA

ASIA REVENUE:
Recovery in Korea, and progress in China.



ASIA OPERATING PROFIT
\$3.8m
(FY25: \$1.8 million)

Asia delivered a stronger FY26 result, reflecting a return to normalised trading conditions following the one-off disruption in 1H25 (including the doctors' strike in South Korea that impacted demand for Maxigesic IV). This normalisation, combined with ongoing growth initiatives, supported improved regional performance through FY26.


China continues to be a key strategic focus, supported by continued growth in iron and vitamin supplements via cross-border e-commerce and an expanding portfolio of launches and distribution agreements. During FY25 AFT's antiseptic cream Crystaderm was launched into mainland China and additional distribution agreements were completed for multiple products, supporting a broader launch schedule.

International

BUILDING REVENUE MOMENTUM IN NEW MARKETS

INTERNATIONAL REVENUE:

Significant improvement in revenue as our footprint expands.



INTERNATIONAL OPERATING PROFIT/(LOSS) **\$(6.0)m**
(FY25: \$(7.3) million)

International performance improved significantly in FY26, reflecting the continued recovery from the customer de-stocking that impacted FY25 and the ongoing scaling of AFT’s international business hubs. As these platforms moved from establishment to development, the focus remained on building sustainable revenue streams and positioning the hubs to contribute to earnings.

South Africa

AFT South Africa has successfully integrated several inventory products acquired from Pharma Dynamics. In addition, after year end we finalised the purchase of a product portfolio, which has been a significant undertaking. The company is in a position to make a contribution in FY27.

AFT SA is driving out costs from the business and driving efficiencies. Including the Pharma Dynamics hospital portfolio, it now has a portfolio of 18 products, up from four at the end of September 2026, demonstrating the expanding footprint and acceleration in the business. AFT SA has recruited three new staff in finance, logistics and regulatory affairs to maintain this momentum.

United Kingdom and Europe

In the UK, AFT extended distribution of Maxigesic tablets (marketed as Combogesic) beyond major pharmacy groups to include independent pharmacies, while the roll-out of Combogesic IV in London NHS hospitals progressed through the bedding-in phase. Momentum in hospital settings continues to be linked to formulary inclusion, with ongoing regulatory filings supporting a growing launch pipeline.

In Europe we are making good progress with our portfolio of injectables, purchased from an insolvent company in 2025. We have updated the relevant regulatory dossiers and licenses and are now pursuing launches across the European Union. We expect these products to make a meaningful contribution in the first half of the current financial year.

North America

AFT launched Combogesic IV in Canada during FY26 and progressed a pipeline of additional products through regulatory and dossier preparation. We have a healthy programme of product launches planned. Combogesic Rapid is set to be the first in the new financial year. We have partnered with a local sales agency to extend our reach in this market.

In the US, Combogesic Rapid will be primarily distributed through Mark Cuban’s CostPlus platform, reaching all 50 states, while Hikma continues to distribute Combogesic IV. AFT’s consumer range — including Liposachets, Kiwisoothe, and Optisoothe — is available through Amazon with additional channels being finalised and expected to be commercialised during the FY27 time period



First shipment: We selected Qilu as a new supplier of Maxigesic Rapid into the US. We were impressed by The Chinese company’s commitment to AFT and its manufacturing expertise.

For personal use only

Maxigesic IV in US Hospitals

Maxigesic IV is AFT's proprietary non-opioid intravenous formulation combining paracetamol and ibuprofen for the treatment of mild to moderate acute pain. The product has been licensed to partners in over 100 countries, approved in more than 50, and launched across 30 markets worldwide — a testament to its broad global acceptance.

The US market represents a significant opportunity. The opioid crisis continues to exact a devastating toll, with approximately 81,700 overdose deaths in 2024³ and nearly US\$ 11 billion⁴ in associated hospital costs.


Marketed in the US as Combogesic IV, our product offers clinicians an effective, opioid-free alternative at a critical point of care. We have been issued a permanent HCPCS J-code by the Centers for Medicare & Medicaid Services. It gives hospitals a clear and reliable reimbursement pathway for Combogesic IV. This removes a significant barrier to formulary inclusion and is expected to assist our US distribution partner Hikma as it seeks to step up promotion this year.

In China, our distribution agreement is subject to a termination notice from the current partner, and AFT is in discussions with alternative partners to ensure continuity in this important market. Intellectual property protection for Maxigesic IV continues to strengthen, with additional patents granted in Europe in 2025.



³ <https://www.axios.com/2025/05/20/opioid-use-disorder-costs>

⁴ <https://www.waldenu.edu/online-masters-programs/master-of-healthcare-administration/resource/opioid-crisis-the-strain-it-places-on-the-healthcare-system>



Affordable Pain Relief

COMBOGESIC RAPID JOINS MARK CUBAN'S LOW-COST DRUG PLATFORM

Maxigesic Rapid (marketed as Combogesic Rapid in the US) is now set to be distributed primarily through Cost Plus, the public benefit organisation founded in 2022 with the backing of the US billionaire and Shark Tank star Mark Cuban.

Cost Plus was established to lower the distribution costs of medicine. Since its founding in 2022 it has grown rapidly and now stocks more than 2,300 commonly prescribed medicines. It distributes these medicines, online and through affiliated pharmacies at cost plus a 15% markup⁵ and its reach extends to all 50 US states.

AFT is now concentrating on this channel to market Maxigesic Rapid for the main markets in the US, while Alexso will continue to distribute the medicine for the market segments of its distribution arrangements we disclosed in 2024 and Hikma will continue to distribute the intravenous form of the medicine.

Finally, AFT continues to expand its portfolio of medicines in this market including our Liposachet range, Kiwisothe, and Optisothe range. These medicines are available through Amazon presently with other channels currently under negotiation.

⁵ Cost plus also charges distribution fees on top of the 15% mark up

EXTENDING OUR RESEARCH AND DEVELOPMENT PIPELINE

We are continuing to invest in our research and development pipeline, recognising that it represents the foundation of growth and shareholder value creation.

AFT continued to expand and advance its research and development portfolio in FY26, with progress across a diversified set of programmes spanning pain, dermatology and eyecare, alongside a targeted range of hospital injectables.

Our R&D strategy is closely linked to our active out-licensing and in-licensing programme, enabling us to convert development progress into value through clinical and regulatory milestones, while broadening the product base available for our international hubs.

FY26 R&D expenditure (expensed and capitalised) was \$18 million (FY25: \$15 million). We intend to further increase R&D expenditure to \$25 million in FY27 in order to execute the larger R&D portfolio including the late-stage injectable iron project, which requires a large clinical study.

During FY26, AFT made notable progress across several late-stage programmes:

- **Intravenous iron:** Following a positive Phase III study, AFT and its development partners progressed preparations for a large global confirmatory study (~1,000 patients) and filed additional patent applications to further protect the asset (see page 13)
- **Antibiotic eyedrop:** AFT progressed its regulatory pathway with the US FDA, with IND⁶ submission targeted to enable first-in-human studies. The programme targets drug-resistant ocular infections, where current options are limited and compounding is common.
- **Topical strawberry birthmarks:** Pre-IND work advanced and FDA feedback was incorporated to guide the IND submission pathway and Phase I-III study designs.
- **Maxigesic IV paediatric:** Preparations progressed to commence a paediatric study following FDA approval of the paediatric study plan.

⁶ Investigational New Drug

- **Vulvar Lichen Sclerosis:** Multiple formulation strategies have been evaluated in partnership with our development partner Hyloris, with development advancing toward a novel, user-friendly topical candidate designed to reduce inflammation and deliver long-term symptom control for this underserved condition.
- **Burning Mouth Syndrome:** Two promising pre-prototypes are advancing in co-development with Hyloris, targeting a differentiated, patent-eligible formulation for progression into clinical validation — addressing a significant gap in care where no approved treatments currently exist.
- **Topical Keloid Scars:** Formulation work is underway.
- **Injectables pipeline:** AFT continued to progress the Sinoject pipeline, including filing regulatory dossiers for at least five injectables before the end of FY27.
- **A new agreement:** we have signed a new agreement with a company owned by Massey Ventures to develop a novel injectable formulation treatment which would compete in a market estimated presently to be around US\$2 billion growing to US\$3-3.7 billion by 2032-2034⁷. Provided the novel formulation is stable, then AFT would exercise the option agreement and proceed with the full development. It is planned that this decision would occur within this financial year.
- **Two developments** primarily aimed at the Australian market with high sales potential.

AFT meanwhile executed multiple out-licensing agreements and advanced a pipeline of further term sheets and negotiations, including an out-licensing agreement for our novel IV iron therapy for China with Chengdu-based Grand Life Sciences Group, featuring upfront, development and sales milestone payments and recurring royalties, with contribution to global development funding.

Consistent with prior years, AFT expects these R&D and international expansion efforts to support a broader, more diversified product and geographic footprint, underpinning resilience and supporting the company's longer-term growth ambitions.

Injectable Iron – A Significant Opportunity

A high-potential product backed with clinical evidence and significant commercial potential. Iron deficiency affects approximately 15% of the global population, and the market for intravenous iron therapies — valued at US\$3 billion in 2024 — is projected to exceed US\$7.4 billion by 2033⁸.

AFT is well positioned to capture a share of this growing market with an innovative injectable iron therapy it is commercialising in partnership with Belgian speciality pharmaceutical company Hyloris.

Current intravenous iron therapies, while effective, present tolerability challenges and typically require multiple infusions. The new product is designed to address these shortcomings. Phase I and Phase II studies have demonstrated strong tolerability, lower indicators of toxicity compared to leading intravenous therapies, and comparable efficacy — potentially delivered in a single injection.

Following productive engagement with the FDA, AFT is now advancing toward a pivotal Phase III study involving approximately 1,360 patients across New Zealand, India, China, Japan, the US, Armenia, and Europe. A licensing agreement with Chengdu-based Grand Life Sciences Group will support both development and commercialisation in China.

Global interest in the product remains strong, with unsolicited approaches continuing from companies worldwide — a clear signal of the product's commercial promise.

AFT continues to strengthen its existing OTC iron portfolio which includes Ferro-Liquid, Ferro-Tab, Ferro-sachets, Ferro LipoSachets, and FerroMalt. We are presently completing two clinical studies targeted at supporting promotion in existing territories and enabling further regulatory approvals in other AFT affiliate markets.

Additionally, we are developing a further new OTC iron formulation to add to our extensive range of iron products.



⁸ <https://www.biospace.com/intravenous-iron-drugs-market-size-to-worth-around-us-7-41-billion-by-2033>

⁷ Data on file.

For personal use only

SUSTAINABILITY

Working to improve your health

AFT Pharmaceuticals has delivered a decades-long record of sales growth built on integrity and a clear purpose of working to improve the health of our customers and the communities we serve.

It is a mission that has at its heart a commitment to sustainability, the maintenance of corporate governance practices that are aligned with best practice and high ethical standards, and a determination to contribute positively to environmental and social outcomes.

We understand accounting for and managing environmental, social and governance (ESG) considerations is critical to our long-term ability to create value and improve the health of the customers and communities we serve.

We established a formal sustainability framework in 2022 following the completion of an analysis of the material issues to the business. Since then, we have evolved the framework to ensure we work towards the opportunities it identifies, manage the risks to our business, and create shared value with our stakeholders.

This year, the New Zealand Government took the pragmatic decision in October 2025 to raise the market capitalisation threshold at which equity issuers are required to report against the Aotearoa

New Zealand Climate Standards to \$1 billion.

As a result, AFT Pharmaceuticals will no longer be classified as a Climate Reporting Entity (CRE) once the Financial Markets Conduct Amendment Bill comes into effect in 2026.

In light of these changes AFT Pharmaceuticals is applying the Financial Markets Authority's interim relief under its 'no action' approach, together with NZX Regulation Limited's class waiver under the NZX Listing Rules. Accordingly, AFT Pharmaceuticals will not publish a Climate-related Disclosure for the year to the end of March 2026

AFT Pharmaceuticals remains committed to building a resilient business in a changing climate and to managing emissions across its value chain. Understanding climate-related risks and taking action continues to be a key focus within AFT's sustainability framework. While a standalone Climate-related Disclosure will no longer be published, AFT will continue to provide updates on its progress through its Annual Report in a way that is meaningful to our stakeholders.

An overview of our climate reporting is covered on pages 31 and 34 of this report, while our latest climate statement is provided in Appendix 1 on Pages 103 to 113.



AFT's Sustainability Framework

Our Mission: Working to Improve Your Health

AFT's sustainability framework is aligned with its commitment to operating sustainably and enhancing the health and wellbeing of the people and communities in the markets we serve.






It sets out our material ESG issues and identifies what we see are the six priorities for the business. The priority areas demonstrate where we believe we can create the most value for our business, investors, and other stakeholders.

Underneath each of the six priorities, we have identified areas of focus, which set out what we

will do to deliver on our priorities. We have detailed the metrics we use to measure our performance.

In some of these areas, we have established targets. We expect to evolve and refine these measures and targets in line with the evolution of our ESG framework.

The development of the framework and our performance against it is led by the CFO and overseen by the Board. As in previous years, we aim to align our business and community initiatives onto the United Nations Sustainable Development Goals.

	SOCIAL	GOVERNANCE	GOVERNANCE
PRIORITIES	1. Working to improve health and well being  	2. Best practice corporate governance 	3. Ethical and sustainable value chains  
	Better health and wellbeing for patients and communities Performance measures: <ul style="list-style-type: none"> Product reach and breadth of therapeutic applications Product portfolio expansion Contributions to communities 	Complying with all relevant legal and listing requirements Performance measures: <ul style="list-style-type: none"> Regulatory and Governance Code compliance Training and education 	ESG performance in our value chain Performance measures: <ul style="list-style-type: none"> Compliance with our Supplier Code of Conduct and our Modern Slavery commitments Supplier visits
	Best quality and safety systems for manufacturing and distributing medicines Performance measures: <ul style="list-style-type: none"> Compliance with best practice standards in medicine manufacture Our pharmacovigilance practices and relationships with our regulators Monitoring for counterfeit medicines Product recalls 	ESG reporting and transparency Performance measures: <ul style="list-style-type: none"> Policy adherence by the Board and Management Governance of climate risk 	Ethical marketing and sales practices Performance measures: <ul style="list-style-type: none"> Compliance with our Code of Culture and Ethics and our Anti-bribery and Corruption Policy Compliance with regulatory advertising codes.
	Innovation in response to need Performance measures: <ul style="list-style-type: none"> Investment in research and development Product development portfolio Compliance with clinical trial standards 		
AREAS OF FOCUS			

UN Sustainable Development Goals

The UN sustainable development goals are a collection of 17 interlinked global goals designed to be a blueprint to achieve a better and more sustainable future for all. The United Nations General Assembly established these goals in 2015. At AFT we believe we can contribute to six of the goals.

More information on the goals can be found here: sdgs.un.org/goals



Good Health and Wellbeing

Ensure healthy lives and promote well-being for all at all ages.



Gender Equality

Achieve gender equality and empower all women and girls.



Decent Work and Economic Growth

Promote sustained, inclusive, and sustainable economic growth, full and productive employment, and decent work for all.



Reduced Inequalities

Reduce inequality within and among countries.






Responsible Production and Consumption

Ensure sustainable consumption and production patterns.



Climate Action

Take urgent action to combat climate change and its impacts.

SOCIAL	ENVIRONMENT	ENVIRONMENT
<p>4. Supporting and developing our people</p> 	<p>5. Understanding our climate related risks and taking action</p> 	<p>6. Waste minimisation</p> 
<p>Developing our people</p>	<p>Understanding how climate affects our business</p>	<p>Improving our consumer packaging</p>
<p>Performance measures:</p> <ul style="list-style-type: none"> • Training • Staff turnover • Wellbeing support 	<p>Performance measures:</p> <ul style="list-style-type: none"> • Integrated climate governance and voluntary disclosure of relevant climate-related performance 	<p>Performance measures:</p> <ul style="list-style-type: none"> • Continuous improvements in reducing packaging weight • Introducing recycled material into our packaging • Making more of our packaging recoverable
<p>Diversity and inclusion</p>	<p>Working with suppliers to take action</p>	<p>Reducing waste in the supply chain</p>
<p>Performance measures:</p> <ul style="list-style-type: none"> • Compliance with our Code of Culture and Ethics • Compliance with our Employment Policy suite • Remunerating fairly and transparently • Monitoring gender, culture identity, nationality to ensure diversity. • Living wage, parental leave, and pay parity commitments 	<p>Performance measures:</p> <ul style="list-style-type: none"> • Engaging with fleet partners on phasing of hybrid electric vehicles • Engaging suppliers to measure their emissions 	<p>Performance measures:</p> <ul style="list-style-type: none"> • Reducing packaging consumption • Reducing material towards landfill
<p>Health and safety</p>		
<p>Performance measures:</p> <ul style="list-style-type: none"> • Health and Safety Policy compliance • Supplier Code of Conduct compliance • Lost time to injury reporting 		

For person only PRIORITIES AREAS OF FOCUS

Materiality: How We Set Our Priorities


AFT has built its Sustainability Framework and ESG reporting programme on a robust process of assessing what is material to the company. As a publicly listed company, material matters are those that a reasonable person would consider impacting on the company’s valuation or the sustainability of our operations.

In line with best practice ESG standards, we also considered those topics that reflect AFTs most significant contribution to, and impacts on, the economy, environment, and people. To develop and review our materiality assessment, we use the support of an independent consultancy. We reviewed materiality topics in the global and pharmaceutical industry against our business operations.

We also reviewed media, stakeholder, and investor commentary on AFT’s business. This enabled the creation of a list of potential material topics. From there, we interviewed external stakeholders and investors on their perceptions of materiality and the relative significance of these topics.

Management then reviewed this feedback; the topics; and their relative importance to business strategy and value creation. The assessment was then presented to the Board for input and approval. AFT used the NZX ESG Guidance Note to inform this approach. AFT first reported on materiality in its FY22 Annual Report. We reviewed this materiality assessment externally in FY24 and reviewed them internally over the last year.

ESG Matters Material to Our Business



For personal use only



Our Values and Our Culture

At AFT Pharmaceutical we strongly believe it is our people who make the company a success. We hire the ‘best person’ for the job, regardless of gender, age, culture/religion. We are fully accepting and tolerant of other people and respect one another.

In all our business interactions with customers, business associates, and colleagues, we treat others as we would like to be treated, regardless of their position. Our workplace is safe and free of discrimination of any kind.

We Work Hard

– to ensure best practice in all that we do.

We Believe

– in honesty and integrity, and this is always at the forefront of our business practices.

We Share

– ideas across teams and strive and encourage open flow of ideas and opinions from our people at all times.

We Speak

– many languages and come from all walks of life and over 23 different birth countries, reflecting our diversity as a company and our worldwide customer base.

We Aim

– to succeed on an internationally by taking our products to the world and putting New Zealand on the worldwide pharmaceutical map, delivering the highest growth and profitability possible for our investors.

Our Stakeholders

AFT considers the interests of a broad range of stakeholders. We recognise that this is pivotal to operating a sustainable business and creating long-term value.



Patients & Customers

They are the focus of the company's efforts: to improve healthcare outcomes.

Employees

AFT is its people; their well-being is fundamental to successful execution of our strategy.

Investors & Lenders

Investors and lenders support our business financially.

Healthcare Providers

They are crucial in spreading sustainable healthcare practices that align with the company's health improvement goals.

Regulators

We work with them to ensure compliance with health, safety, and other sustainability standards and support our work to provide health solutions.

Suppliers, Distributors & Vendors

They produce our products, take them to market and help us to operate our business. We work with them to ensure ethical sourcing and environmental stewardship.

Local Communities

Engagement with communities helps to align company operations with local health needs, enhancing our social license.

Government Agencies

We work with them to support public health policy initiatives.

Media

It plays a role in communicating the company's health initiatives to the public.

PRIORITY 1:

Working to Improve Health and Wellbeing

FOCUS AREA:

Better Health and Wellbeing for Patients and Communities



Improving the health of our customers is the reason we exist, we work to research, develop, commercialise, and distribute medicines and other healthcare products.

Performance:

- We expanded our portfolio of medicines and the geographies where we operate.
- We contributed to causes and people that promote the health and wellbeing in the communities in which we operate.

Extending Our Reach With New and Innovative Medicines

Our portfolio of 150 plus medicines spans our seven core therapeutic categories of pain, eyecare, vitamins, allergy, gastrointestinal medications, dermatology, and hospital products. The portfolio continues to expand with the launch of additional new products in FY 27. We have also expanded the territories where our products are sold in more than 80 countries.


Access to Medicines

We recognise access to medicines is an important issue. We work hard to ensure a continuous and uninterrupted supply of our critical products to our customers and markets by holding significant stock holdings as opposed to a just-in-time delivery schedule. During the period we did not suffer any significant supply interruptions.

Using Promotion for Good

AFT regularly leverages its promotional budget to deliver profile and goodwill to broad range of deserving charities. This year we supported:

- Medical Aid Abroad, an organisation that takes donated medical supplies and delivers life-changing support for communities overseas. We provided financial support and office equipment.



CURE PARKINSON'S NZ

NO DREAM TOO BIG

- Cure Parkinson's New Zealand, a charity to shape and fuel effective research leading to a cure for Parkinson's disease, namely, therapies that can slow, stop or reverse the progression of the disease.



OVARIAN CANCER AUSTRALIA

- Ovarian Cancer Australia via a partnership with Australian pharmacy chain TerryWhite Chemmart in which AFT donated a proportion of the sale price to the charity, which supports those affected by ovarian cancer, and their families – from mental health support to understanding treatment and so much more.



helping kids in hospital

- The Humpty Dumpty Foundation, which provides essential and often lifesaving paediatric medical equipment for sick children in hospitals in the community.



- Save Our Sons Duchenne Foundation, a charity for those living with Duchenne and Becker muscular dystrophy across Australia.
- We also donated products to a wide range of community organisations including Women's Refuge, Rainbow Youth, Dress for Success, Westlake Boys Basketball Team, St Cuthberts and the North Harbour Club.

These support packages follow support in prior years to charities sponsored by the New Zealand Super Rugby Franchises and the Wesleyan Medicine Mission to Bougainville.

FOCUS AREA:**Innovation in Response to Need****Performance:**

- Research and Development expenditure was \$18 million in the year to 31 March 2026 and we expect to increase it to \$25 million in FY27.
- Our product development portfolio expanded to 10 projects from 9 in the prior year.
- All clinical trials are conducted within international codes and standards.

We work to create innovative medical solutions in areas of high unmet need, creating future value for the business. We achieve this by leveraging our global partnerships and by developing our own intellectual property. In the past year, we spent \$18 million on research and development, an increase on the spending in the prior year.

These resources have been devoted to advancing our research and development portfolio towards commercialisation. AFT's research and development pipeline now extends to 8 patented products.

A key addition in the current year was an agreement commercialise a new technology that will allow the storage of a range of injectables at room temperature (see below). All these projects offer strong potential to further accelerate our long-term growth and support the global diversification of the business across the OTC, Hospital and Prescription channels and across multiple markets internationally.

Meeting International Clinical Trial Standards

AFT is committed to ensuring all its clinical trials are conducted in a manner that not only respects the participants but also produces reliable, meaningful, and internationally accepted data, thereby contributing to the advancement of medical knowledge and the development of new treatments.

All our trials are conducted within the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines and specifically the ICH E6 and E8 standards (see below)

These standards cover the ethical and scientific quality of designing, conducting, recording, and reporting trials that involve human subjects. They also provide for a unified standard

to facilitate the mutual acceptance of clinical data by regulatory authorities in the core ICH regions, which include the European Union, Japan, and the United States, and are recognised globally by many countries including New Zealand, Australia, and many countries in Asia.

In these countries these standards are overseen and administered by independent regional oversight bodies such as the US Food and Drug Administration. Meanwhile, wherever we conduct clinical research, it is always overseen by ethical research bodies.

FOCUS AREA:**Best Practice Quality and Safety Systems for Manufacturing and Distributing Medicines****Performance:**

- No products were sold into markets without meeting regulatory requirements.
- No notifications of concern were received in relation to counterfeit medicines.
- We made no product recalls.
- No inspections of our manufacturing sites by regulators have revealed any concerns over the medicines that we are selling.

Delivering Safe and Quality Medicines

Medicine safety and quality are at the foundations of our business, our financial well-being, and our corporate reputation. We also understand that the multiple national regulators that approve our products for sale, as well as our customers and sales and distribution partners, will accept nothing less.

Whenever we take a new medicine to market or in-license a product we must meet the stringent regulatory requirements set and administered by national food and medicine regulators.

Registration of a medicine requires independent analysis and approval of the therapeutic claims we make by relevant regulators and the evidence and research we have undertaken to make those claims. Registration also requires AFT to file and update safety information with regulators and maintain product traceability information. It also requires compliance with Good Manufacturing Practice (GMP) to ensure our products are consistently produced, controlled, and shipped according to nationally mandated quality standards.

The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) aims to achieve greater harmonisation worldwide for the development and approval of safe, effective, and high-quality medicines in the most resource-efficient manner.

It specifies several key standards relevant to AFT including good clinical practice, general considerations for clinical trials and good manufacturing practice. We are dedicated to managing and complying with regulatory processes and overseeing our research and development processes. We and our licensees monitor the markets in which we operate for counterfeits or copies of our medicines.

Meanwhile, anti-tamper devices in our packaging such as seals, and blister packs protect us against product interference, and we continually review new technologies and practices to ensure we evolve with the industry.

We operate a Board-level committee, the Regulatory and Product Development Oversight Committee, which oversees our regulatory and product risk management framework.

The committee charter is available on the investor section of our website. Over the last year we have maintained our strong record for product safety and quality. No products have been sold into the market without meeting regulatory requirements, we have received no notifications of concern in relation to counterfeits, nor have we issued any product recalls.



ICH E6: Good Clinical Practice (GCP)

The ICH E6 guideline provides a unified standard to facilitate the mutual acceptance of clinical data by regulatory authorities in the ICH regions, which include the European Union, Japan, and the United States.

ICH E8: General Considerations for Clinical Trials

ICH E8: General Considerations For Clinical Trials

The ICH E8 guideline provides general considerations for the conduct of clinical trials, emphasising the importance of scientific quality in the design, conduct, recording, and reporting of clinical trials. It aims to ensure that clinical trials are ethically justifiable and scientifically sound.

Good Manufacturing Practice Regulators Enforcing Manufacturing Standards

Good Manufacturing Practice (GMP) is a baseline requirement we and international regulators impose on all suppliers of medicines. It plays a crucial role in ensuring the quality of pharmaceutical products, focusing on minimising risks inherent in pharmaceutical production that cannot be eliminated through testing the final product.

GMP practices are primarily specified by the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) (see below). They cover all aspects of production, from the raw materials, facilities, and equipment to the training and personal hygiene of staff.

While GMP does not specifically target environmental matters, it can also indirectly contribute to environmental safety through the efficient use of resources and the reduction of waste production, as the practices encourage the efficient and responsible use of raw materials and energy.

GMP standards are enforced by national regulatory food and drug regulators. These agencies conduct regular inspections and audits of pharmaceutical manufacturing facilities to ensure compliance, and where breaches of process are found, they have a range of enforcement actions at their disposal that range from fines to mandating a cessation of production.





Inspired by nature: the resurrection plant survives in droughts using the same chemicals that are at heart of Stablevax (TM) ambient storage technology

CASE STUDY:

Improving patient care: ambient temperature injectables

Access to life saving injectable medicines should never depend on the reliability of a cold chain. Yet for many patients —particularly those receiving oncology and anti infective treatments — temperature sensitive products can limit availability, delay care, and increase the risk of supply disruptions. That is why AFT is investing in innovation that directly overcomes these challenges.

A new partnership with the based Stablepharma, to develop its StablevaX™, technology for these products. StablevaX™, is currently being used to reformulate existing and new vaccines and pharmaceuticals into thermostable products that remain stable at temperatures 40°C and above, removing the need for refrigeration or freezing throughout manufacture, distribution, and administration.

StablevaX™ is built on the remarkable survival biology of the resurrection plant, a desert species capable of withstanding years of extreme drought. When water becomes scarce, the plant protects itself by entering a state of suspended animation—curling tightly into a ball and coating its cells with trehalose, a naturally occurring sugar that preserves biological structures during dehydration. Once moisture returns, the plant “resurrects,” returning to full function.

This mechanism inspired Stablepharma’s founders, whose research revealed that trehalose could be used to stabilise vaccines and pharmaceuticals in a similar way: by forming a protective sugar glass that maintains potency at high temperatures and allows products to be revived simply by rehydration. This plant derived principle underpins StablevaX™ and enables the creation of thermostable, fridge free formulations with significant benefits for global health logistics.

PRIORITY 2:

Best Practice Corporate Governance

The Board and Management of AFT are committed to ensuring that the company maintains corporate governance practices in line with best practice and adheres to the highest ethical standards.

FOCUS AREA:

Complying With All Relevant Legal and Listing Requirements



FOCUS AREA:

ESG Reporting and Transparency



Performance:

- We have reviewed all key governance policies and received management confirmation of compliance.
- The Board and its standing committees have reviewed and evaluated their performance and considered training needs.

- No issues of concern or policy breaches have been notified to the Board in relation to our Code of Culture and Ethics, Modern Slavery, Securities Trading, Conflicts of Interest, Whistleblowing and Market Disclosure policies.
- We have complied with all disclosure standards.

The AFT Board has this year continued to evolve AFTs corporate governance framework to ensure it is aligned with advances in global and regional expectations and regulations. In line with the government's pragmatic decision to lift the threshold at which issuers are required to report against the Aotearoa New Zealand Climate Standards from \$60 million to \$1 billion, we have in the current year moved to align our reporting on these measures in a way that is meaningful and valuable to our stakeholders. As part of this process, we have identified no material climate risks in FY26.

AFTs governance charters and policies can be found in the Investor Centre on the Company's website.



PRIORITY 3:

Ethical and Sustainable Value Chains

AFT is committed to operating an ethical and sustainable supply chain. Our supply chains are extensive and sometimes complex, with a high proportion of products sourced from large and reputable pharmaceutical companies and manufacturers based in regions including Europe, North America, India, and Asia. Due to the extent of these networks, it is critical to provide appropriate governance and oversight of them.

FOCUS AREA:

ESG Performance of Our Value Chain



Performance:

- Our key product suppliers have confirmed their compliance with our Supplier Code of Conduct and our Modern Slavery Policy.
- The visits we have made to suppliers during the year have not revealed any instances of concern related to ESG performance in our value chain.

AFT has put in place a broad range of measures related to our commitments to ethical and sustainable value chains. At the heart of these measures is a comprehensive system of monitoring and control across AFT, the companies that it controls and its supply chain. Specifically, the Board Charter requires the Board to review and ratify group systems of internal compliance and control to determine the effectiveness of those systems.

The Board operates an Audit and Risk Committee (ARC) to assist with its responsibilities and commitments. The ARC, among other things, is charged with assisting the board in overseeing managements implementation of the Company's risk management framework and that management has appropriate processes for identifying, responding to, and regularly reporting on risks (including Modern Slavery and climate-related risks) and that those processes are operating effectively.

We also have a range of internal policies and codes that set standards for Directors, employees, consultants, contractors, interns, and secondees of AFT Pharmaceuticals and our related companies that are focused on the management of these risks. They notably include:

- A Code of Culture and Ethics.
- A Modern Slavery Policy to address potential Modern Slavery risks in our business and in our supply chain.
- An Anti-Bribery and Anti-Corruption policy.
- A Whistle Blowing Policy.

We operate a Supplier Code of Conduct that among other things, requires attestation to our Modern Slavery Policy (see above), compliance with applicable, national, and international laws and international labour standards, and strong environmental practices. It also requires suppliers to observe and model ethical business practices; and establish and follow effective policies and procedures to promote workplace health and safety.

Our key suppliers have attested compliance with our Supplier Code of Conduct and Modern Slavery policy. In addition, ahead of engaging new suppliers we undertake due diligence to ensure we select and collaborate with those that align with our values and the way we do business.

We periodically visit key manufacturing sites, and none of these visits have revealed any instances of concern. All manufacturers of our medicines are required to operate under GMP requirements (see page 23).

For further detail on our approach, please see our Governance Statement on pages 42 to 62 of this report and the governance section of our website.

FOCUS AREA:

Ethical Marketing and Sales Practices



AFT is committed to following ethical sales and marketing practices in all the markets where we operate and license our products. We understand this commitment is vital to maintaining trust in our business.

Performance:

- No notification of breaches of regulatory advertising codes in any of the markets where our products were sold.

The sale and marketing of our products is regulated in all the markets where we sell our products or where we out-license them to third parties.

In Australia, our largest market, the marketing, and advertising of pharmaceutical consumer products is largely governed by the Therapeutic Goods Advertising Code. For prescription medicines we observe the Medicines Australia Code of Conduct. Both regimes are overseen by the regulator, the Therapeutic Goods Administration.

Similarly, in New Zealand, our practices align with the Therapeutic and Health Advertising Code. In both markets we regularly engage third parties to ensure compliance and have processes in place to ensure compliance with broader regulations.

Beyond these regions, we are committed to complying with local codes. Licensees' adherence to relevant legal frameworks and sales and marketing codes form part of our contractual engagement with them.



PRIORITY 4:

Supporting and Developing Our People

AFT is committed to ensuring equal opportunity for all its people regardless of race, nationality, gender, sexual orientation, age, religion, or physical ability. We are also committed to developing our people through education, training and providing workplace flexibility, including flexible work hours to accommodate employee needs.

FOCUS AREA:

Diversity and Inclusion



Performance:

- Strong gender, age, cultural diversity across AFTs workforce.
- We have a loyal and stable workforce.
- Annual internal review reveals no gender remuneration disparities.
- All staff and contractors are paid at least the living wage.

We recognise that building a culture of diversity, accountability, and fair reward will deliver improved business performance and help to ensure we can attract and retain highly skilled people.

These commitments are underpinned by Board-level policies including a Code of Culture and Ethics, Diversity & Inclusion, Remuneration and Whistleblowing, all of which are available on the investor section of our website.

We are proud of the diversity we have achieved at AFT and believe it is one of our core strengths. As at the end of March 2026, we had 126 employees up from 119 in FY25.

Our workforce continues to reflect the diversity of New Zealand and Australia and the other markets where we operate. At the end of March 2026, the team hailed from 33 different cultural identities and 23 birth countries, with a gender split of 57% women and 43% men (FY25 61% women, 39% men) and an age spread of employees ranging from 22 years to 74 years.

Gender Composition of AFT's Workforce


The respective numbers and proportions of men and women at various levels within the AFT workforce as of 31 March 2026 and 31 March 2025 are set out in the following table:

	Female		Male	
	2026	2025	2026	2025
Directors	2 33%	2 33%	4 67%	4 67%
Officers ¹	4 44%	4 50%	5 56%	4 50%
Workforce	72 57%	73 61%	54 43%	46 39%

¹ Officers are considered to be the Managing Director and his direct reports. Managing Director Hartley Atkinson and Chief of Staff Marree Atkinson are included in both the number of Directors and the number of Officers.


Employees by Age Diversity

(%, as at 31 March 2026)



Employees by Gender Diversity

(%, as at 31 March 2025)



FOCUS AREA:

Remuneration and Gender Pay Equity



We strive to ensure all employees and contractors receive equal and fair treatment in all aspects of the Company's employment policies and practices and that they are incentivised towards the success of the company.

We hire the best person for the job, regardless of gender, age, and culture, and incentivise our people in a way that is aligned with the long-term success of the company.

To ensure we deliver on these commitments we undertake an annual merits-based remuneration review, which provides visibility to management in relation to the parity of working conditions and pay across the workforce. The review compares our core (directly comparable roles) with other listed companies of a similar market cap each year.

We also manually check each person is being paid according to their role within the company and cross check there is no disparity between male and female where they are employed for the same role. We are comfortable that we have achieved gender pay equity through a series of reviews detailed in previous reports, but it is clear that in some teams there is over-representation of one gender over the other. However, this reflects the higher applicant rate of those genders when recruiting new members to teams. This factor is taken into consideration when making future hires, with the aim to improve the balance over time, where possible.

We are meanwhile committed to paying the living wage at a minimum but reflecting the nature of our business and the capabilities and skills of our people, the vast majority receive remuneration well above this level. Further detail is covered in the remuneration section on pages 60 to 63 of this report.

FOCUS AREA:

Developing Our People



We continue to upskill our people recognising the role they play in maintaining our competitive advantage and building the company's reputation as a great place to work. In addition to the formal induction processes into our company culture and policies, we support our staff in pursuing development of skills in their chosen fields. AFT pays for all professional membership fees such as pharmacists, accountants, and lawyers to ensure their continued education and professional memberships are maintained.



AFT team after the Takapuna beach cleanup.

Building Culture

We actively work to create a team spirit and culture of engagement in our offices. An example of our efforts is the ongoing programme to take our share of responsibility for keeping the beach in front of our Takapuna Auckland office clean and free from plastic pollution.

AFT staff volunteers again spent several sessions over the year picking up rubbish on the beach and disposing of it responsibly. This is an ongoing initiative driven by the AFT Social Committee, which not only supports our local area but also builds awareness and stewardship of our environment. We also have monthly meetings to celebrate birthdays and staff anniversaries as well as cultural celebrations.

FOCUS AREA:

Health and Safety



AFT has a Health and Safety Policy and both the Board and Management are committed to promoting a safe and healthy working environment for everyone working in or interacting with AFTs business.

Performance:

Health and Safety indicator	Target	2026	2025
Lost time to injuries	Zero	Achieved	Achieved
Total recordable injuries	Zero	Achieved	Achieved

AFT has recorded zero lost time to injuries and zero recordable injuries over the last five years. Our Health and Safety Policy requires AFT people to take all practicable steps to provide a working environment that promotes health and wellbeing, while minimising the potential for risk, personal injury, ill health, or damage.

AFT operates an employee-led Health and Safety Committee, and it meets regularly to monitor and manage health and safety risks, including hazards, within the business. We assist employee health by providing vaccinations and we train our people in first aid and responses to emergencies such as cardiac arrests.

We undertake monthly audits of health and safety practices and performance, and the outcomes of these audits are reported to the Board. We have a strong record in health and safety as evidenced by our performance against the health and safety targets set out to the left. Health and safety in our supply chain is covered through standards laid out in the Supplier Code of Conduct.

First Aid Training

St Johns provided in house first aid training to staff this year. It is a bi-annual programme that helps ensure our people are equipped to respond confidently in an emergency and reflects AFT's ongoing commitment to health, safety and wellbeing across the business. It is also aligned with our commitment to supporting and developing our people through education, training and workplace flexibility.



For personal use only

PRIORITY 5:

Understanding Our Climate-Related Risks and Taking Action

We are committed to understanding and transparently communicating to our stakeholders the implications of climate change on our business. We are also committed to ensuring the measures we are taking to mitigate the material risks, leverage the opportunities presented and reduce our Greenhouse Gas (GHG) emissions are robust, and evidence based.

FOCUS AREA:

Understanding How Climate Affects Our Business



Performance:

- We leveraged our climate risk assessments undertaken in FY24 and FY25 and have identified no material climate-related physical or transition impacts in FY26
- We measured our GHG emissions and expanded the scope of emissions reported to include Scope 3. We have also improved the way we present this information for stakeholders to provide more granular information of emissions activities by global jurisdiction (see page 33)
- We affirmed our findings that our business model, and strategy is largely resilient to future climate related risks

Assessing Our Climate Risk

As noted on page 15, while AFT will no longer be classified as a Climate Reporting Entity (CRE) once the Financial Markets Conduct Amendment Bill comes into effect in 2026, understanding and managing climate-related risks remains a key focus within AFT's sustainability framework.

Based on a review of climate-related risks and opportunities identified in previous assessments, AFT considers the most significant risks to the business to be the potential for extreme weather events to disrupt manufacturing and distribution. AFT is well positioned to continue refining and implementing its strategy to manage these risks over time.

Overall, AFT considers its business model and strategy to be largely resilient to future climate-related risks.



AFT's Greenhouse Gas Emissions

Over the FY26 year our combined location-based Scope 1 and 2 emissions (disclosed below and in Appendix 1 on pages 103 to 113 of this report) have decreased by 17.72% since our base year (FY24). This is largely due to the transition of our hybrid electric vehicles into our vehicle fleet over this period.

AFT Pharmaceuticals is voluntarily reporting its Scope 3 emissions in FY26. While it was not required to report these emissions in prior years under the New Zealand Climate Standards (NZ CS), the company is taking this step to give a fuller picture of its impact across its value chain and demonstrate its commitment to transparency and climate action.

This year AFT has also reported emissions by the regional jurisdictions in which it operates to provide greater visibility of its global footprint. Many of these operations are distribution-based and do not include physical offices, controlled facilities, or vehicle fleets. As a result, there are no Scope 1 or Scope 2 emissions associated with these locations. Emissions related to these activities are primarily captured within Scope 3, reflecting the outsourced and value chain nature of these operations.

AFT's GHG emissions are presented as tonnes of carbon dioxide equivalents (tCO₂e). No base year restatements have been made. AFT voluntarily discloses its greenhouse gas (GHG) emissions and endeavours to align this disclosure with the principles of the New Zealand Climate Standards (NZ CS) and the GHG Protocol Corporate Accounting and Reporting Standard as a matter of good practice.

AFT Pharmaceuticals NZ Limited Consolidated GHG Emissions FY24 – 26 (t CO₂e)

Scope	Category	FY24 (base year)	FY25	FY26	% change from base year
Scope 1	Mobile combustion	331.16	290.33	271.10	-18%
	Fugitive sources	0.06	N/A	N/A	-100%
	Total Scope 1	331.76	290.33	271.10	-18%
Scope 2	Purchased electricity				
	Location-based	18.57	16.19	17.14	-8%
	Market-based	17.32	18.74	20.38	+15%
	Total Scope 2 (location-based)	18.57	16.19	17.14	-8%
	Total Scope 2 (market-based)	17.32	18.74	20.38	+15%
Scope 3	Category 3: Fuel- and energy-related activities	-	-	67.84	-
	Category 4: Upstream transportation and distribution	-	-	2,340.56	-
	Category 6: Business travel	-	-	231.39	-
	Category 7: Employee commuting	-	-	59.98	-
	Total Scope 3	-	-	2,699.76	-
Total GHG Emissions (location-based)				2,988.00	
Total GHG Emissions (market-based)				2,991.24	

Scope	Category	AFT (Consolidated) t CO ₂ e	NZ	AU	UK	US	CAN	HK	EU	ASIA
Scope 1	Mobile combustion	271.10	33.82	237.28	-	-	-	-	-	-
	Total Scope 1	271.10	33.82	237.28	-	-	-	-	-	-
Scope 2	Purchased electricity (location-based)	17.14	9.17	7.97	-	-	-	-	-	-
	Purchased electricity (market-based)	20.38	10.29	10.09	-	-	-	-	-	-
	Total Scope 2 (location-based)	17.14	9.17	7.97	-	-	-	-	-	-
	Total Scope 2 (market-based)	20.38	10.29	10.09	-	-	-	-	-	-
Scope 3	Category 3: Fuel and energy- related activities	67.84	9.01	58.83	-	-	-	-	-	-
	Category 4: Upstream transportation and distribution	2,340.56	1,146.95	991.44	0.73	129.99	2.53	21.09	47.41	0.42
	Category 6: Business travel	231.39	142.48	88.80	0.11	-	-	-	-	-
	Category 7: Employee commuting	59.98	49.89	7.93	2.16	-	-	-	-	-
	Total Scope 3	2,699.76	1,391.32	1,392.24	3.00	129.99	2.53	21.09	47.41	0.42
Total GHG Emissions (location-based)		2,988.00	1,391.32	1,392.24	3.00	129.99	2.53	21.09	47.41	0.42
Total GHG Emissions (market-based)		2,991.24	1,392.44	1,394.36	3.00	129.99	2.53	21.09	47.41	0.42

Our emissions inventory covers the period 1 April 2023 to 31 March 2024, 1 April 2024 to 31 March 2025 and 1 April 2025 to 31 March 2026. An operational control consolidation approach has been used.

Emissions data is reported on a 10+2 basis - covering the first 10 months of the financial year using actual invoiced and metered data, with the final two months estimated to enable independent assurance review within the timelines required for annual report publication. This approach is commonly used where audit timelines preclude the use of a full 12-month actual dataset. The basis for estimation is described in the Methods section in Appendix 1.

The inventory has undergone independent assurance from Toitū Envirocare to ensure accuracy and completeness.

FOCUS AREA:

Working With Suppliers to Take Action



We are committed to mitigating the risks and taking advantage of the opportunities of climate change and aligning our business model with a future that's climate resilient.

Performance:

- We have affirmed science-aligned targets for our Scope 1, 2 and 3 emissions, consistent with limiting global warming to 1.5 degrees Celsius. These targets apply to AFT's UK subsidiary operations, reflecting specific requirements within that market.
- We have taken action to work with our suppliers to manage our emissions, including gradually transitioning our vehicle fleet to hybrid electric and engaging with suppliers to measure their own Scope 1 and 2 emissions.

Climate Change Strategy

AFT has affirmed its commitment to responsible environmental stewardship by taking steps to manage our GHG emissions. Our near-term commitments apply to AFT's UK subsidiary operations, reflecting specific requirements within that market.

These targets are to reduce Scope 1, Scope 2, and Scope 3 by 42% by 2030 on a FY24 base year. At the time the target was established, AFT measured Scope 3 emissions on a consolidated group basis and did not disaggregate by regional jurisdiction. From FY26, AFT has begun measuring emissions by jurisdiction, with FY26 representing the first year of UK-specific Scope 3 data. As such, FY26 UK Scope 3 emissions of [3.0 tCO₂e] are reported as the current performance position. A FY24 UK Scope 3 baseline is not available, and progress against the 42% reduction target therefore cannot yet be quantified. We have yet to develop a plan to achieve our longer-term net zero target.

Further detail is covered in Appendix 1 on pages 103 to 113 of this report.



PRIORITY 6:

Waste Minimisation

AFT is working to minimise the waste it generates. Our immediate approach towards this vision and to make a meaningful difference is to take a life-cycle approach to packaging from manufacture to disposal, with a keen focus on supply-chain, distribution, consumer, and hospital packaging.

FOCUS AREA:

Improving Our Consumer Packaging



FOCUS AREA:

Reducing Waste in the Supply Chain



AFT is a member of the Australian Packaging Covenant Organisation (APCO), which partners with government and industry to reduce the harmful impact of packaging on the environment. It achieves this by promoting sustainable design and recycling initiatives, waste to landfill reduction activities and circular economy projects.

Our latest APCO assessment of our organisational efforts recognises AFT as 'leading' in its efforts against the organisation's goals. It is the same rating as FY25, but we have continued to make improvements with the recoverability of our packaging and disposal labelling moving to an 'advanced' rating from 'making good progress'. We retain a 'beyond best practice', the highest APCO rating for the governance of our packaging governance and strategy and the design and procurement of packaging and our management of on-site waste.

Our report covers primary packaging (the material that contacts the medicine), secondary packaging (encompasses the primary packaging) and the outer packaging. Primary packaging is regulated according to strict pharmacopeial standards and therefore poses unique challenges to our recoverability efforts. Nevertheless, nearly 60% of our packaging now contains recycled materials. The latest APCO report will be available on our website when finalised.

Performance:

Governance and Strategy

APCO Rating: 'Beyond Best Practice'

AFT has integrated sustainable packaging strategies into its procurement processes. We have achieved all the APCO 2026 goals

with our clear strategy for packaging sustainability, internal and external communication of the strategy and objectives, and participation in initiatives to promote packaging sustainability.

Design and Procurement

APCO Rating: 'Beyond Best Practice'

All our packaging was reviewed against sustainability principles, in line with the prior year and optimised for material efficiency. We added recycling disposal information to all our packaging.

Recycled Content

APCO Rating: 'Advanced'

We maintained our efforts to use recycled materials in packaging. Recycled content in our packaging fell to 59% from 65% in FY25, but still a substantial improvement on the 24% achieved in FY24.

Recoverability

APCO Rating: 'Advanced'

Our rating this year improved from 'Good Progress' to 'Advanced' as we moved to exploring opportunities to provide our customers with re-useable packaging. Around 97% of packaging materials are designed to be recyclable, steady on the prior year's result.

Disposal Labelling

APCO Rating: 'Advanced'

Our rating this year improved from 'Good Progress' to 'Advanced' as we lifted the proportion of packaging that carries disposal labelling and we introduced the 'Tidy Man' logo which serves as a widely-recognised reminder to dispose of packaging responsibly rather than dropping it as litter.

On-site Waste

APCO Rating: 'Beyond Best Practice'

We maintained our strong record of waste management on-site, with 99% of waste now recyclable.

Problematic Materials:

APCO Rating: 'Advanced'

We continue to benefit from the introduction of the Pharmacycycle, Teracycle and RedCycle schemes in Australia, which allows the recycling of PVC blister packs and PET for bottles that are required to protect the integrity of our medicines. The scheme represents a substantial advance in the reduction of problematic materials in our supply chain.

Reconciliation of EBITDA to GAAP

AFT's standard profit measure prepared under New Zealand GAAP is net profit after tax. AFT has used the non-GAAP profit measure of performance in this document. AFT directors and management believe that this measure is used internally to evaluate performance of business and to allocate resources. Non-GAAP profit measures are not prepared in accordance with New Zealand International Financial Reporting Standards (NZ IFRS) and are not uniformly defined, therefore the non-GAAP profit measures reported in this document may not be comparable with those that other companies report and should not be viewed in isolation or considered as a substitute for measures reported by AFT in accordance with NZ IFRS.

GAAP to Non-GAAP reconciliation line item

NZ\$'000's	2026	2025
Year ended 31 March		
Net profit after tax attributable to owners of the parent	14,730	11,962
Less: Finance income	(6)	(25)
Add back: Interest costs	2,486	2,821
Add back: Other finance loss/(gain)	91	(1,182)
Add back: Depreciation	1,081	\$994
Add back: Amortisation	2,618	1,675
Add back: Income tax expense/(benefit)	7,795	4,634
EBITDA	28,795	20,879



For personal use only

GOVERNANCE & MANAGEMENT

An Experienced and Skilled Board

AFT has an experienced and balanced Board with a diverse range of skills. It comprises an Independent Chairman, three other Non-Executive Independent Directors and two Executive Directors. Their names and information about their skills, experience, and background, together with information about AFT's management team, are set out below and on the following pages.



David Flacks

CHAIRMAN

Appointed 22 June 2015

David has a number of governance roles and has been chair of AFT since the IPO in 2015. David is a former Chair and former Director of the Suncorp New Zealand group of companies and is the Chair of Todd Corporation and a number of environmentally focused pro bono organisations. He is a former chair of the NZ Markets Disciplinary Tribunal and the NZX Regulatory Governance Committee and a former member of the Takeovers Panel. He is a Director of boutique corporate law firm Flacks & Wong. David was for many years a Senior Corporate Partner at Bell Gully and was General Counsel and Company Secretary of Carter Holt Harvey during the 1990's. He is a law graduate from Cambridge University.



Dr Hartley Atkinson

CHIEF EXECUTIVE OFFICER,
EXECUTIVE DIRECTOR,
AND CO-FOUNDER

Appointed 4 September 1997

Hartley founded AFT in 1997. Before founding AFT, Hartley worked at Swiss multinational pharmaceutical company, Roche, for eight years where he held positions as Sales & Marketing Director, Medical Director, Product Manager and Medical Manager. Prior to his work at Roche, Hartley was a Drug Information Pharmacist and Researcher at the Department of Clinical Pharmacology, Christchurch Hospital.

Hartley is the author of a number of scientific publications, and his work has been published in the prestigious New England Journal of Medicine. Hartley holds a doctorate in Pharmacology, a Masters in Pharmaceutical Chemistry with distinction, and a Degree in Pharmacy, all from the University of Otago



Marree Atkinson

CHIEF OF STAFF,
EXECUTIVE DIRECTOR,
AND CO-FOUNDER

Appointed 4 September 2012

Marree has been involved in all aspects of AFT's business since its establishment in 1997, including roles in sales, regulatory affairs, customer services and logistics. Marree's role as Chief of Staff sees her involved in the day-to-day running of AFT's head office including managing staffing requirements and special projects involving AFT's head and affiliate offices. Marree is a registered nurse previously practising at Waikato Hospital.



Andrew Lane

INDEPENDENT
NON-EXECUTIVE DIRECTOR

Appointed 28 September 2023

Andrew has more than 30 years' experience of leadership in the global pharmaceuticals industry with expertise across a broad range of disciplines including finance, manufacturing, sales, marketing, and strategy. Most recently he was Global President of Abbott Laboratories Pharma Division where he led a multi-billion-dollar operation that had 30 manufacturing plants, 12 Innovation and Development sites and 40,000 staff covering more than 100 countries. Before that he was Vice President of Takeda, Asia Pacific, where he managed the company's operations in 12 countries, which included three factories and 2,000 staff. He has also held senior roles with multi-national pharmaceutical companies Nycomed, DKSH, Novartis, and Sandoz.



Allison Yorston

INDEPENDENT
NON-EXECUTIVE DIRECTOR

Appointed 12 November 2024

Allison brings to AFT more than 20 years of blue-chip fast-moving consumer goods, telecommunications and retail marketing experience gained across Australia and New Zealand at senior management and C-suite levels. She has managed brand turnarounds and grown and developed marketing teams to deliver share gains in competitive markets and is experienced at managing multi-brand portfolios including both product and corporate brands. She is currently Director of Marketing at Griffins Snacks and is a former Director of the Australian Beverages Council and a former Chief Marketing Officer at Suntory Beverage & Food Oceania. Prior to Suntory she held senior marketing roles at Vodafone, Fonterra and Sanitarium. Allison is a Graduate of the Australian Institute of Company Directors Course and a member of the AICD.



Dr Ted Witek

INDEPENDENT
NON-EXECUTIVE DIRECTOR

Appointed 23 December 2020

Ted served Boehringer Ingelheim Pharmaceuticals for nearly 25 years in clinical research and leadership roles, including CEO of its Canadian and Portuguese operations.

Ted was also Chief Scientific Officer & Senior Vice President, Corporate Partnerships, at Innoviva and on the Board of Directors of Canada's Research-Based Pharmaceutical Companies.

He is currently Professor & Senior Fellow at the University of Toronto's School of Public Health & Leslie Dan Faculty of Pharmacy.

He holds a Doctor of Public Health from Columbia University and a Master of Public Health from Yale University and an MBA from Henley Management College in the UK.

Our Senior Management Team



Malcolm Tubby

CHIEF FINANCIAL OFFICER

Malcolm is a qualified Chartered Accountant in the United Kingdom, Australia, and New Zealand and has a wealth of senior corporate governance expertise, including roles in significant public companies as Chief Financial Officer. He has experience in senior positions in public and private companies in pharmaceuticals, beverages, insurance and aged care facilities in Australia and New Zealand, Malcolm has been involved with AFT since its foundation. He retires later this month.



Ioana Stanescu

CHIEF SCIENTIFIC OFFICER

Ioana joined AFT in 2012 and has overall responsibility for AFT's research and development. She has over 30 years' experience in the pharmaceutical industry including positions such as Vice President Quality Assurance & Regulatory Affairs and Head of Vaccine Business Area in Finland, and a WHO Adviser within Central and Eastern Europe. She has also coordinated several European Union funded research grants and was selected as an Expert by the European Health Committee Council of Europe to participate in a research study in 1999.



Vladimir Ilievski

REGULATORY AFFAIRS MANAGER

Vladimir holds a master's degree in pharmacy from the University of Ljubljana, Slovenia, where he started his career as a pre-clinical researcher before moving to New Zealand. Prior to joining AFT in 2006, Vladimir worked for Douglas Pharmaceuticals in various roles including as a Quality Control and Quality Assurance Analyst and as a Regulatory and Senior Regulatory Associate. Vladimir has responsibility for product registrations in countries in Australasia, Asia, the Middle East, Canada and the United Kingdom.



Louise Clayton

**DIRECTOR
INTERNATIONAL BUSINESS**

Louise joined AFT in 2017 and is responsible for global international business development, alliance management and marketing. Louise has more than 25 years' experience in driving international brands within sales, brand marketing, product sourcing, new product development, and new market expansion. Her core focus is global expansion, brand growth and alliance management through strong partnerships with licensees, distributors, and AFT affiliates.



Scott Crawford

**GENERAL MANAGER
PROMOTED PRODUCTS**

Scott joined AFT in 2013 and is responsible for sales in Australia and New Zealand across all channels including hospital, primary care, pharmacy, supermarkets, petrol, and convenience. His role as General Manager ANZ involves the coaching and development of account managers, field supervisors and trade marketing across Australia and New Zealand. Scott has more than 20 years' experience in fast-moving consumer goods in both Australia and New Zealand and has previously held roles with Red Bull, Ferrero Confectionery, Smiths Snackfoods and National Foods.



Murray Keith

GROUP MARKETING MANAGER

Murray joined AFT Pharmaceuticals in 2011 and is responsible for managing our marketing function, across the Australian New Zealand markets and international markets. With over 30 years' experience, his extensive marketing career prior to joining AFT included roles with a number of blue-chip brands and companies, including Nestlé, Lion Nathan, Bay of Plenty Rugby, Nestlé Purina, New Zealand Lotteries and Fonterra Brands.

Corporate Governance Statement

The Board and management of AFT Pharmaceuticals Limited ('AFT' or 'the Company') are committed to ensuring that the Company maintains corporate governance practices in line with best practice and adheres to the highest ethical standards. The Board has had regard to the NZX Listing Rules and a number of corporate governance recommendations when establishing its governance framework, including:

- the NZX Corporate Governance Code as dated 31 January 2025 ('NZX Code'); and
- the ASX Corporate Governance Council's Corporate Governance Principles and Recommendations¹ (notwithstanding AFT is not required to follow these recommendations owing to its ASX Foreign Exempt Listing).

The NZX Listing Rules require AFT to formally report its compliance against the recommendations contained in the NZX Code and it sets out in this Corporate Governance Statement how it has implemented the recommendations in the current version of the NZX Code.

Except to the extent outlined in this Corporate Governance Statement, the Board considers that AFT's corporate governance structures, practices and processes have followed all the recommendations in the NZX Code in the financial year ended 31 March 2026. For ease of reference, relevant sub-headings in this Corporate Governance Statement include a reference to the primary relevant recommendation(s) in the NZX Code to which the disclosures under that sub-heading relate.

This is a general guide only, and disclosures under a particular sub-heading are not limited

solely to the recommendation(s) referred to in that sub-heading. AFT's governance charters and policies can be found in the Investor Centre on the Company's website (<https://investors.aftpharm.com/investors/>).

AFT's corporate governance charters and policies have been approved by the Board and are regularly reviewed by the Board and amended (as appropriate) to reflect developments in corporate governance practices. This Corporate Governance Statement was approved by the Board on 21 May 2026 and is current as at that date.

David Flacks

Chair

Stock Exchange Listings

AFT is incorporated in New Zealand and is listed on the NZX Main Board and on the Australian Securities Exchange ('ASX') as an ASX Foreign Exempt Listing. As an ASX Foreign Exempt Listing, AFT needs to comply with the NZX Listing Rules (other than as waived by NZX) but does not need to comply with the vast majority of the ASX Listing Rule obligations.



¹ The ASX Corporate Governance Council's Corporate Governance Principles and Recommendations was last updated on 27 February 2019.



Overview of AFT's Governance Structure



The AFT Board of Directors has been appointed by shareholders to protect and enhance the long-term value of AFT and to act in the best interests of AFT and its shareholders. The Board is the ultimate decision-making body of the Company and is responsible for the corporate governance of it.

The role and responsibilities of the Board are set out in the Board Charter, which can be found in the Investor Centre on the Company's website. The Board currently comprises a Non-Executive Chair, three other Non-Executive Directors, and

two Executive Directors, as detailed in the Investor Centre on the Company's website and pages 38 and 39 of this report.

The Board has established three standing Board committees to assist in the execution of the Board's responsibilities:

- Audit and Risk Committee;
- Remuneration and Nominations Committee; and
- Regulatory and Product Development Oversight Committee.

PRINCIPLE 1:

Ethical Standards

“Directors should set high standards of ethical behaviour, model this behaviour and hold management accountable for these standards being followed throughout the organisation.”

Code of Culture and Ethics

(Recommendation 1.1)

The Board recognises that high ethical standards and behaviours are central to good corporate governance. It has implemented a Code of Culture and Ethics (‘the Ethics Code’) to guide the behaviour of its Directors, Senior Managers, and Employees.

The Ethics Code establishes the framework by which Directors and staff of AFT are expected to conduct their professional lives by facilitating behaviour and decision-making that meets AFT’s business goals and is consistent with AFT’s values, policies, and legal obligations.

The Ethics Code is available to staff on AFT’s intranet and forms part of the induction process for new employees. Existing staff receive refresher courses at least once every three years. Regular reminders are provided to staff about the application of the Ethics Code.

The Ethics Code addresses:

- AFT’s values and commitments to establishing an inclusive culture;
- conflicts of interest;
- receipt of gifts;
- corporate opportunities;
- confidentiality;
- behaviours and responsibilities;
- proper use of AFT property and information;
- compliance with laws and AFT policies;
- reporting issues regarding breaches of the Ethics Code, legal obligations, or other AFT policies; and
- additional Director responsibilities.

Compliance with Company policies is included in employment agreements and forms part of the induction process. Periodic reminder communications are sent to staff about the Code and its application bi-annually.

There is a standard agenda item for each Board and management meeting in which all (or confirmation of none) reported incidents or breaches of the

code are raised. No incidents or breaches of the Code have been reported to Board members or management during the period.

AFT encourages staff to report any concerns they have about compliance with the Ethics Code, AFT policies, or legal obligations. It achieves this with staff-wide communications and has established a designated email address, independentdirector@aftpharm.com, that is directed to the personal emails of all Non-Executive Independent Directors, for staff to confidentially raise any concerns they may have. All Directors, including Non-Executive Directors, confirm at each Board meeting whether they have received any complaints.

An employee conflict of interests’ register was established in 2019 to record any perceived personal conflicts of interest. Management confirm there are no new entries to report to the Board, noting that the only entry in the register is Marree Atkinson who reports to her spouse Hartley Atkinson. This is mitigated by reviews being signed off by the remuneration and nominations committee and the Board.

The Board holds six-monthly reviews of the Ethics Code.

AFT’s process for managing any breach of the Ethics Code is detailed in the Ethics Code. In addition, AFT has implemented the following stand-alone policies to support the application of the Ethics Code and define the process for raising concerns about actual, suspected, or anticipated wrongdoings within the AFT group of companies:

- Diversity and Inclusion Policy;
- Anti-Bribery and Anti-Corruption Policy;
- Whistleblowing Policy;
- Conflicts of Interest Policy;
- Modern Slavery Policy; and
- Supplier Code of Conduct.

The Ethics Code and the policies listed above are available on the Company’s intranet and in the Investor Centre on the Company’s website.

Securities Trading Policy

(Recommendation 1.2)

The Company is committed to ensuring that its people comply with legal requirements not to trade AFT securities while in possession of inside information. AFT's Securities Trading Policy accordingly applies to all Directors, Officers, Employees, and Contractors of AFT and its subsidiaries.

The Securities Trading Policy seeks to ensure that those subject to the Policy do not trade in AFT securities if they hold undisclosed price-sensitive information. The Policy sets out additional rules, which includes the requirement to seek Company consent before trading and prescribes certain

black-out periods during which trading in the Company's securities is prohibited.

Compliance with the Securities Trading Policy is monitored through the consent process, through education and periodic reminders and via notification by AFT's share registrar when any Director or Senior Manager trades in AFT securities.

All trading by Directors and Senior Managers (as defined by the Financial Markets Conduct Act 2013) is required to be disclosed to NZX and in AFT's Interests' Register. AFT's Securities Trading Policy is available in the Investor Centre on the Company's website.



PRINCIPLE 2:

Board Composition and Performance

“To ensure an effective Board, there should be a balance of independence, skills, knowledge, experience and perspectives.”

Role of the Board

(Recommendation 2.1)

The business and affairs of the Company are managed under the direction of the Board of Directors. At a general level, the Board is elected by shareholders to:

- provide leadership to the Company;
- build sustainable value for shareholders;
- establish the Company's values and objectives;
- develop major strategies for achieving the Company's objectives;
- manage financial and non-financial risks including those associated with sustainability and climate;
- determine the overall policy framework within which the business and Company are operated; and
- monitor management's performance and remuneration with respect to these matters.

The Board has adopted a Board Charter that regulates internal Board procedure and describes the Board's specific roles and responsibilities. The Board delegates management of the day-to-day affairs and responsibilities of the Company to the management team under the leadership of the Chief Executive Officer ('CEO'), to deliver on the strategic direction and goals determined by the Board.

The Chief Executive Officer has, in some cases, formally delegated certain authorities to his direct reports within set limits. The Board regularly monitors and reviews management's performance in the execution of its delegated responsibilities and the appropriateness of its delegated authority policy.

Board Membership, Size, and Composition

(Recommendation 2.2, 2.3)

The size of the Board is determined by the Board from time to time, in accordance with the limitations prescribed in the NZX Listing Rules and in accordance with the provisions of AFT's Constitution and the Board Charter. As at 31 March 2026 the Board comprised six Directors:

Director	Role
David Flacks	Chair and Non-Executive Director
Andrew Lane	Non-Executive Director
Allison Yorston	Non-Executive Director
Dr Ted Witek	Non-Executive Director
Dr Hartley Atkinson	Executive Director and Chief Executive Officer
Marree Atkinson	Executive Director and Chief of Staff

The average tenure of Non-Executive Directors at the date of this report is five years. A biography of each Director, their qualifications and relevant experience can be found on pages 38 and 39 of this report and in the Investor Centre on the Company's website.

The Board has delegated to the Remuneration and Nominations Committee the responsibility for identifying and recommending Director candidates for the approval of the Board. When recommending candidates, the Committee takes into account factors it deems appropriate, including the diversity of background, experience, and qualifications of the candidates.

When appointing Directors, the Board undertakes appropriate background checks. Newly appointed Directors are required to enter into letters of appointment, setting out the terms of their appointments. As AFT operates in specialised markets, the Board believes that it is important to have Directors with a broad range of experience and skills, gained both locally and internationally, that are appropriate to meet its objectives.

The Board has developed (and periodically reviews and updates) a comprehensive skills matrix to inform

Board succession planning and considers each Director’s experience against identified industry specific and broader governance-related skills.

Industry-specific skills identified as being particularly relevant include:

- global pharmaceutical industry experience;
- pharmaceutical regulatory and ethics experience;
- research and development product development for drugs and devices;
- commercial operations experience – both domestic and international; and
- pharmaceutical sales and marketing.

A summary of the Board’s assessment of its aggregate capability against these criteria is set out below, with an assessment of 100% representing very high Board capability. The Board arrived at these assessments by calculating the aggregate scores of the three most highly skilled Directors in each of these domains.

This approach recognises that a diversity of skills is important to delivering best practice governance and that it is unrealistic and unnecessary for all Directors to be highly skilled in each of the relevant

domains. It also balances these considerations against the need to ensure a diversity of well-informed perspectives is brought to bear on any issue brought before the Board.

Board Appointment, Training and Evaluation

(Recommendation 2.6, 2.7)


The procedure for the appointment and removal of Directors is ultimately governed by the Company’s Constitution and relevant NZX Listing Rules. A person may be appointed as a Director by the Board or by appointment at a meeting of shareholders.

A Director appointed by the Board must not hold office (without standing for re-election) past the next Annual Shareholders Meeting following their appointment. Directors are otherwise subject to the rotation requirements set out in the NZX Listing Rules.


Allison Yorston joined the Board on 12 November 2024 and accordance with the applicable NZX listing rules, Allison was elected to the Board at the 2025 Annual Meeting.

Board Capability

Board Skills Specific to AFT Pharmaceuticals



Generic Board Skills



Additionally, in accordance with the rotation requirements of the NZX Listing Rules, Managing Director Hartley Atkinson was re-elected to the Board at the 2025 Annual Shareholders Meeting.

At the time of appointment, each Director receives a copy of AFT's Corporate Governance Manual (comprising all AFT's core governance documents) and is introduced to the business through a tailored induction programme. All Directors are regularly updated on relevant industry and Company issues and undertake training to remain current on how to best perform their duties as Directors of AFT.

During the Board's annual evaluation process, training needs are considered to assist Directors to remain upskilled on the business and industry and legislative developments. All Directors have access to Senior Management to discuss issues or obtain information on specific areas or items to be considered at a Board meeting or other areas they consider appropriate.

The Board, Board Committees and each Director have the right to seek Independent professional advice at AFT's expense to assist them in carrying out their responsibilities. During the financial year ended 31 March 2026, the Board undertook a review of its own and its committees' composition and performance to ensure they are effectively governing AFT and monitoring AFT's performance in the interests of shareholders.

Independence of Directors

(Recommendation 2.4, 2.8, 2.9, 2.10)

A majority of AFT's Directors are Independent. The factors the Company takes into account when assessing the independence of its Directors are set out in the NZX Code and the Board Charter and include factors such as the Director's professional and personal relationships with the Company and its subsidiaries and the Director's length of tenure as applicable.

Generally, a Director is considered to be Independent if that Director is not an employee of AFT and does not have any direct or indirect interest, position, association, tenure, or relationship that could reasonably influence, or be perceived to influence, in a material way, the Director's capacity to:

- bring an independent view to decisions in relation to AFT;
- act in AFT's best interests; and
- represent the interests of AFT's shareholders generally.

The Board has determined, based on information provided by Directors regarding their interests and the criteria specified in the Board Charter, and for the purposes of the NZX listing rules

that at 31 March 2026 (and the date of this Annual Report), each of David Flacks, Allison Yorston, Andrew Lane, and Dr Ted Witek is an Independent Director.

None of the criteria, as set out in table 2.4 of the NZX Corporate Governance Code that may cause a Board to determine that a Director is not Independent applied to any of these Independent Directors.

The Board has also determined that Hartley Atkinson and Marree Atkinson are not Independent Directors owing to also being executives of the Company; and, in Hartley Atkinson's case, he is also a trustee of a substantial product holder of the Company, and each of Hartley and Marree is a discretionary beneficiary of that substantial product holder.

The Board will review any determination it makes on a Director's independence on becoming aware of any new information that may affect that Director's independence. For this purpose, Directors are required to ensure they immediately advise AFT of any new or changed relationship that may affect their independence or result in a conflict of interest.

The Board supports the separation of the role of Chairman and Chief Executive Officer. The current Chairman has been elected by the Board from the Independent Directors, in accordance with the terms of the Board Charter. The Chairman's role is to manage and provide leadership to the Board and to facilitate the Board's interface with the Chief Executive Officer.

Conflicts of Interest

The Board is conscious of its obligations to ensure that Directors avoid conflicts of interest (both real and perceived) between their duty to AFT and their own interests. The Board Charter and the Conflicts of Interest Policy outline the Board's policy on conflicts of interest.

AFT maintains an Interests' Register in which relevant disclosures of interest and securities dealings by the Directors are recorded. Directors' interest disclosures are carried in the Statutory Information Section on pages 98 to 101 of this report.

Company Secretary

The Company Secretary, Malcolm Tubby, is responsible for supporting the effectiveness of the Board by ensuring that its policies and procedures are followed and for coordinating the completion and dispatch of the Board agendas and papers. The Company Secretary is accountable to the Board, via the Chair, on all governance matters.

Diversity and Inclusion

(Recommendation 2.5)

The Board recognises that building diversity across AFT will deliver enhanced business performance. AFT has adopted a Diversity and Inclusion Policy and is committed to achieving diversity in the skills, attributes and experience of its Board members, management, and staff across a broad range of criteria (including, but not limited to, culture, gender, and age).

AFT is proud to have a workforce consisting of many individuals with diverse skills, values, backgrounds, ages, genders, and ethnicities, and experiences. The Company works to ensure that its selection processes for recruitment and employee development opportunities are free from bias and are based on merit.

The Board as a whole is responsible for overseeing and implementing the Diversity and Inclusion Policy but has delegated to the Remuneration and Nominations Committee the responsibility to develop and to recommend measurable objectives to the Board that are designed to adhere to the Policy.

AFT's Diversity and Inclusion Policy is implemented by promoting the following principles:

- reviewing progress against measurable diversity objectives and initiatives developed by AFT to deliver outcomes consistent with the Policy;
- promoting a working environment free from discrimination, harassment, and victimisation;

- emphasising the accountability of AFT's leaders to cultivate a culture of inclusion in which the strengths of every individual are recognised and valued;
- raising employee awareness of workplace diversity by designing, delivering, and measuring the effectiveness of programmes that promote workforce diversity, inclusion, and gender equity;
- striving to ensure that all employees and contractors receive equal and fair treatment in all aspects of the Company's employment policies and practices;
- promoting a culture that empowers employees to act in accordance with the Policy; and
- regularly benchmarking AFT's diversity standpoint, status, and objectives against appropriate external comparators.

The Board has conducted its annual assessment of its diversity objectives and the Company's progress towards achieving these objectives in respect of the financial year ended 31 March 2026. The steps AFT took during the year to develop and maintain a diverse and inclusive working environment and fair remuneration, including gender pay gap reporting, are detailed on pages 28 and 29 of this report. In accordance with the NZX listing rules it also lists on those pages the gender composition of the Directors and Officers at balance date alongside the gender composition of its workforce.

In the year ahead (the financial year ending 31 March 2027) the Company will continue to monitor and benchmark against the diversity and inclusion objectives agreed by the Board for the financial year ended 31 March 2027.



PRINCIPLE 3:

Board Committees

“The Board should use committees where this will enhance its effectiveness in key areas, while still retaining Board responsibility.”

The Board uses committees to deal with issues requiring detailed consideration, thereby enhancing the efficiency and effectiveness of the Board. However, the Board retains ultimate responsibility for the functions of its committees and determines each committee’s roles and responsibilities.

The current committees of the Board are:

- Audit and Risk Committee;
- Remuneration and Nominations Committee; and
- Regulatory and Product Development Oversight Committee.

Details of the roles and responsibilities of these committees are described in their respective charters and summarised below. The committee charters are available in the Investor Centre on the From time to time the Board may constitute an ad-hoc committee to deal with a particular issue that requires specialised knowledge and experience. Proceedings of each committee meeting are reported back to the Board to allow other Directors to question committee members and to keep apprised on matters being considered by each committee.

Audit and Risk Committee

(Recommendation 3.1, 3.2)

The primary function of the Audit and Risk Committee is to assist the Board in fulfilling its oversight responsibilities relating to the Company’s risk management and internal control framework, the integrity of its financial and non-financial reporting (including reports on sustainability, corporate social responsibility, and environmental activities) and the Company’s auditing processes and activities.

Under the Audit and Risk Committee Charter, the Committee must be comprised of a minimum of three members. All members of the Committee must be Non-Executive Independent Directors. At least one Independent Non-Executive Director on the Committee must have an accounting or financial background. Further, the Chairman of the Committee is required to be Independent and not be the Chairman of the Board.



Employees are not permitted to attend meetings of the Audit and Risk Committee without an invitation. The Chairman of the Committee should not have a long-standing association with AFT's external audit firm as a current, or retired, audit partner or senior manager at the firm.

The current members of the Committee are Andrew Lane (Chairman), David Flacks and Allison Yorston. All members are Independent, Non-Executive Director. Andrew Lane is considered to have a financial background for the purposes of the NZX Listing Rules.

The Audit and Risk Committee held four formal Committee meetings during the financial year ended 31 March 2026

The Remuneration and Nominations Committee

(Recommendation 3.3, 3.4)

The Remuneration and Nominations Committee's role is to oversee remuneration policies and practices at AFT, oversee management succession planning, consider the composition of the Board, and recommend candidates to fill Board vacancies as and when they arise. The Committee is also tasked with annually monitoring and evaluating the Company's performance with respect to its Diversity and Inclusion Policy.

Under the Remuneration and Nominations Committee Charter, the Committee must be comprised of a minimum of three members, a majority of whom are Independent Directors. Management of the Company are not permitted to attend the Remuneration and Nominations Committee unless invited. The Chairman of the Committee is required to be Independent.

The current members of the Committee are Andrew Lane (Chairman), David Flacks and Ted Witek. The Remuneration and Nominations Committee held two meetings during the financial year ended 31 March 2026.

Regulatory and Product Development Oversight Committee

(Recommendation 3.5)

The Regulatory and Product Development Oversight Committee's role is to, at least bi-annually, review the Company's regulatory risk management framework relating to product development; oversee the Company's strategy relating to key clinical and product development projects and monitor the Company's compliance framework against applicable regulations regarding the sale and distribution of pharmaceutical products.

Committee members also meet frequently on an informal basis to discuss regulatory and new product development matters. The functioning of the Committee complements the monthly monitoring undertaken by the Board on the status of new product development and filings.

Under the Regulatory and Product Development Oversight Committee Charter, the Committee must be comprised of a minimum of three members. The current members of the Committee are Ted Witek (Chairman), Hartley Atkinson, and Marree Atkinson. The Regulatory and Product Development Oversight Committee met twice during the financial year ended 31 March 2026

Board and Committee Attendance

(Recommendation 3.5)

The Board met for nine regularly scheduled meetings during the financial year ending 31 March 2026. There were also separate meetings of the Board Committees during the year. In addition, the Board and management met during the year to undertake strategic planning.

Director	Board	Audit and risk committee	Remuneration and nomination committee	Regulatory and New Product Development Oversight Committee ¹
David Flacks	9/9	4/4	2/2	-
Hartley Atkinson	9/9	-	-	2/2
Marree Atkinson	8/9	-	-	2/2
Andrew Lane	9/9	4/4	2/2	-
Dr Ted Witek	9/9	-	2/2	2/2
Allison Yorston	9/9	4/4	-	-

¹ Committee members also met frequently through-out the year on an informal basis to discuss regulatory and new product development matters.

Control Transaction Guidelines

(Recommendation 3.6)

AFT's Independent Directors have received legal advice on their Directors' duties, and the process to be followed, in the event of a takeover offer. The Board has formally adopted this advice as the protocols to be applied in the event of a control transaction. Any takeover of AFT shares would require the support of the Atkinson Family Trust, which at present holds approximately 69% of the shares on issue.

PRINCIPLE 4:

Reporting and Disclosure

“The Board should demand integrity in financial and non-financial reporting, and in the timeliness and balance of corporate disclosures.”

AFT is committed to the promotion of investor confidence by ensuring that the trading of Company shares takes place in an efficient, competitive, and informed market. The Board is tasked with ensuring the integrity of financial and non-financial reporting to shareholders and other stakeholders.

Market Disclosure Policy

(Recommendation 4.1)

AFT's Market Disclosure Policy establishes the Company's procedures for meeting the continuous disclosure requirements of both the NZX Main Board and the ASX. A copy of the Market Disclosure Policy is available in the Investor Centre on the Company's website. In addition to the procedures set out in that Policy, Directors and Management consider at each meeting whether there are any issues that require disclosure to the market.

Governance Policy Availability

(Recommendation 4.2)

AFT's governance charters and policies and its code of ethics can be found in the Investor Centre on the Company's website.

Financial and Non-Financial Reporting

(Recommendation 4.3, 4.4)

The Board is responsible for ensuring the integrity of its financial and non-financial reporting. AFT is committed to providing shareholders and other stakeholders with a balanced and, clear, objective, understandable and easily accessible assessment of its performance, business model, strategic objectives, and its progress against them. To achieve these goals the Company reports a range of financial and non-financial information at each results announcement and in its full-year reports.

Reporting Oversight

The Audit and Risk Committee closely monitors financial and other reporting risks in relation to the preparation of the financial statements and accompanying non-financial information. With the assistance of management, the Audit and Risk Committee works to ensure that the financial statements and accompanying non-financial information are founded on a sound system of risk management and internal control and that the system is operating effectively in relation to financial reporting and other material risks.

As part of this process, the Chief Executive Officer and Chief Financial Officer are required to state in writing to the Board that, to the best of their knowledge, the Company's financial reports and accompanying non-financial statements:

- present a true and fair view of the Company's financial condition and operational performance;
- are prepared in accordance with the relevant accounting standards; and
- are founded on a sound system of risk management and internal controls that are operating effectively.

The Board receives copies of all material announcements made to the NZX and ASX.

Non-Financial Environmental Social and Governance (ESG) reporting

(Recommendation 4.4)

AFT has incorporated strategies to account for and manage the ESG factors that are material to the Company's ability, and commitment, to create value long-term.

It is also reporting its progress against those strategies in a way that is aligned with the Company's broader reporting standards and commitments. The Company has aligned its ESG reporting to the United Nations Sustainable Development Goals, which reflect the most urgent global environmental, political, and economic challenges.

AFT has completed and regularly reviews its systematic and robust assessment of the ESG issues that are material to the Company and continues to evolve the breadth and depth of measures against which it can assess the Company's performance in managing these issues. The Company has this year resolved to report voluntarily, in part, against the Aotearoa New Zealand Climate Standards after the Government indicated that it would raise the market capitalisation threshold at which public companies are required to report against the standards from \$60 million to \$1 billion and the Financial Markets Authority granted 'no action' relief to those entities that under the proposals would no longer be climate reporting entities. These disclosures are overseen by the Board. Further detail is covered in the sustainability section (on pages 14 to 35) of this report and in the appendix on pages 103 to 113 of this report.

PRINCIPLE 5:

Remuneration

"The remuneration of Directors and executives should be transparent, fair and reasonable."

AFT is committed to remunerating its Non-Executive Directors, Executive Directors, and employees fairly, transparently, and reasonably. The policies, procedures and outcomes on these commitments are detailed in the Company's Remuneration Report on page 59 to 63 of this report.

Director Remuneration and Senior Executive Remuneration

(Recommendations 5.1, 5.2, 5.3)

Please see pages 59 to 63 of this report for Non- Executive Director and Executive Director and Senior Executive remuneration governance and the relevant disclosures.



PRINCIPLE 6:

Risk Management

“Directors should have a sound understanding of the material risks faced by the issuer and how to manage them. The Board should regularly verify that the issuer has appropriate processes that identify and manage potential and material risks.”

Risk Management Framework

(Recommendation 6.1)

Like other businesses, AFT manages a range of risks that have the potential to impact its performance, operations, reputation, and customers' safety. While some risks can never be eliminated, AFT works hard to identify their significance and manage them. AFT has designed and implemented a risk framework for the oversight and management of financial and non-financial business risks, as well as related internal compliance systems that are designed to:

- optimise the return to, and protect the interests of its stakeholders;
- safeguard the Company's assets and maintain its reputation and social licence to operate;
- improve the Company's financial and operating performance;
- fulfil the Company's strategic objectives; and
- manage the risks associated with the sale and distribution of pharmaceutical products.

The Board has ultimate responsibility for AFT's risk management and internal control system, setting the 'tone at the top' with regards to risk culture. It reviews the risk management framework and risk register at least twice a year.

The Audit and Risk Committee and Regulatory and Product Development Oversight Committee, under delegation from the Board, assists the Board in discharging its responsibilities. The Audit and Risk Committee monitors compliance with the overarching risk and compliance framework, while the Regulatory and Product Development Oversight Committee oversees the Company's regulatory risk management framework regarding the development, quality assurance and sale and distribution of pharmaceutical products.

The Audit and Risk Committee, in conjunction with management, regularly reports to the Board on the effectiveness of the Company's management of its material business risks and whether the risk management framework and systems of internal compliance and control are operating effectively and efficiently in all material respects.

The Audit and Risk Committee conducts six-monthly reviews of AFT's risk management framework and principal risks register and satisfies itself that AFT's approach to risk is sound. Information regarding AFT's internal audit functions can be found under the section headed "Internal Audit Function" below.









Principal Risks

(Recommendation 6.2)

AFT's current principal risks and their mitigations are summarised below. AFT risk management framework has positioned the Company well to respond to the challenges the Company faces. Further detail is included in the sustainability section of this report on pages 14 to 35 of this report.

Risk	Mitigation
 <p>Regulatory Approval Delay or failure in the development, manufacture commercialisation, or regulatory approval process for AFT products</p>	<ul style="list-style-type: none"> - Adopting a low risk and low-cost development programme. - Using multiple manufacturing sites for our key products and maintaining close working relationships with our suppliers. - Engaging both in-house and external regulatory experts in our key markets. - Monitoring regulatory timetables and maintaining regular dialogue with licensees to anticipate and manage delays proactively where necessary
 <p>Competition Competition of pharmaceutical products and devices.</p>	<ul style="list-style-type: none"> - Product innovation. - Diversification of our product portfolio. - Maintaining a broad range of distribution channels, partners, and geographies.
 <p>Intellectual Property Intellectual Property infringement and protection for AFT products.</p>	<ul style="list-style-type: none"> - Taking actions to protect our IP, including filing patent applications, and entry into confidentiality agreements with licensees, suppliers, and employees to protect trade secrets. - Undertaking extensive "freedom to operate" reviews before we make our IP applications to ensure that they do not infringe any other IP and are protectable. - Regularly monitoring pharmaceutical patent registrations.
 <p>Third Parties Reliance on third parties for the manufacture, distribution, and licensing of AFT products</p>	<ul style="list-style-type: none"> - Using multiple manufacturers where possible for our key products. - Operating an inventory policy of holding a minimum of three months' inventory to minimise interruption of supply. - Being selective in our choice of distribution and licensing partners and having performance obligations in our commercial agreements. - Requiring all suppliers to attest to compliance with our Supplier Code of Conduct and our Modern Slavery Policy, which together require third party suppliers to foster and encourage respect for Human & Labour Rights, Ethical Business Practices, Environmental Responsibility, Product and Service Quality and Safety. The policy and the code also require suppliers to report on any ethical sourcing risks, including Modern Slavery risks, in their supply chains
 <p>Product Liability Product liability and risks associated with marketing drugs and conducting clinical trials.</p>	<ul style="list-style-type: none"> - Adopting compliance and regulatory systems to monitor our compliance with applicable laws and regulations. - Manufacturing products in compliance with Good Manufacturing Practice and other relevant regulatory requirements, including supplying products for use only with approved Certificates of Analysis. - Maintaining and regularly reviewing a register of known adverse events. - Focusing on novel dose forms, combinations, and delivery systems of approved drugs, meaning clinical trial risks are relatively low. - Contracting out clinical trials to specialists. - Implementing a comprehensive product, clinical trial, and contamination insurance programme. - Ensuring that product labelling declares reported risks and ensuring that adverse events are incorporated in the product package insert, in accordance with licensors' advice, and local regulatory accepted rules and labels.

Risk	Mitigation
 <p>Growth Strategy Failure to execute growth strategy.</p>	<ul style="list-style-type: none"> - Adopting expansion strategies that are scalable and are not capital intensive, for example using out-licensing and distributor arrangements in markets where the Company has not elected to maintain a presence. - Closely monitoring our personnel, internal Company structures and systems to ensure they remain appropriate to support our growth plans. - Regular review and close monitoring of progress of growth strategies against business plans and targets
 <p>Capital Management</p>	<ul style="list-style-type: none"> - Closely monitoring forecasts, cash flows and our financial covenants to ensure they are not breached. - Actively monitoring key revenue growth plans. - Managing the mix of equity capital and borrowings. - Maintaining an active investor relations programme should a further equity raise be considered
 <p>Key Personnel Loss</p>	<ul style="list-style-type: none"> - Succession planning and promoting a culture of diversity and inclusion. - Adopting a competitive remuneration policy designed to assist us in retaining key personnel. - Carefully selecting our personnel to ensure that they fit with our culture and growth plans.
 <p>Health and Safety Risks</p>	<ul style="list-style-type: none"> - Adopting a Health and Safety Policy and monitoring performance against it. The Board and management are committed to promoting a safe and healthy working environment for everyone working in/or interacting with AFT's business. The Health and Safety Policy requires AFT people to endeavour to take all practicable steps to provide a working environment that promotes health and wellbeing, while minimising the potential for risk, personal injury, ill health, or damage. - Agreeing a detailed (Board-approved) programme of work, which aims to ensure AFT remains compliant with its health and safety obligations. The Board is updated on health and safety (including wellness) matters and metrics at each Board meeting and there is a detailed review on health and safety risks each quarter. - Operating an employee-led Health and Safety Committee. The committee meets regularly to monitor and manage health and safety risks, including hazards, within the business, and inform Board reporting. Further detail on the Company's management of health and safety risks is covered on page 30 of this report.
 <p>Cyber Risk</p>	<ul style="list-style-type: none"> - Maintaining robust systems and processes to support our information and communication technology (ICT) system security. - Commissioning regular independent reviews of our ICT systems. - Maintaining and regularly reviewing business continuity and disaster recovery plans and systems. - Promoting a culture of cybersecurity in the organisation through regular training; and communication.
 <p>Climate Change Risk</p>	<ul style="list-style-type: none"> - Embedding oversight and management of climate related risks within the Board Charter and the incorporation of programmes to manage these risks into the Company's strategy. - Transparently reporting its approach and strategies to identify monitor and manage climate related risks and opportunities.

PRINCIPLE 7:**Auditors**

“The Board should ensure the quality and independence of the external audit process.”

External Auditor Independence

(Recommendation 7.1)

AFT has adopted an Audit Independence Policy that requires, and sets out the criteria for, the external auditors to be independent. The Policy recognises the importance of facilitating frank dialogue between the Audit and Risk Committee, the auditor and management.

The Policy prescribes the services that can and cannot be undertaken by the external auditors, which are designed to ensure that services provided by AFT’s external auditors do not conflict, and are not perceived as conflicting, with their independent role.

The Policy also requires that the key audit partner be changed at least every five years so that no person shall be engaged in an audit of AFT for more than five consecutive years.

AFT engaged a new audit firm in February 2018 and in accordance with this Policy and in accordance with NZX Listing Rule 2.13.3 rotated to a new audit partner for the year to 31 March 2023.

The Audit and Risk Committee Charter requires the Committee to facilitate the continuing independence of the external auditor by assessing the external auditor’s independence and qualifications and overseeing and monitoring its performance. This involves monitoring all aspects of the external audit, including the appointment of the auditor, the nature and scope of its audit, and reviewing the auditor’s service delivery plan.

In carrying out these responsibilities the Audit and Risk Committee meets regularly with the auditor

without Executive Directors or management present. The auditor is restricted in the non-audit work it may perform, as detailed in the Auditor Independence Policy.

For further details on the audit and non-audit fees paid and work undertaken during the period, refer to page 80 in the Financial Statements of this report.

The Audit and Risk Committee regularly monitors the ratio of fees for audit to non-audit work.

Internal Audit Function

(Recommendation 7.3)

AFT does not have a dedicated internal auditor. Instead, internal controls are managed on a day-to-day basis by the finance team. Compliance with internal controls is reviewed annually by AFT’s auditors who provide feedback on AFT’s control environment, which is reviewed by the finance team and Board.

The Board and finance team regularly consider how AFT can improve its internal audit and risk management practices during AFT’s annual governance review, bi-annual risk reviews, preparation of interim and full-year financial statements and following AFT’s annual audit.

PRINCIPLE 8:

Shareholder Rights and Relations

"The Board should respect the rights of shareholders and foster constructive relationships with shareholders that encourage them to engage with the issuer."

Information for Shareholders

(Recommendation 8.1, 8.2)

AFT is committed to maintaining a full and open dialogue with its shareholders (and other interested stakeholders). The Company has in place an investor relations programme to facilitate effective two-way communication with shareholders.

The aim of the Company's communication programme is to ensure fair recognition of the value the Company creates, provide stakeholders with information to help them accurately assess the Company's performance and prospects.

It also seeks to enable shareholders to actively engage with the Company and exercise their rights in an informed manner. The Company facilitates communication with shareholders through written and electronic communication, and by facilitating shareholder access to Directors, Management, and the Company's auditors.

The Company provides shareholders with communication through the following channels:

- the Investor Centre on the Company's website;
- full-year and half-year results and/or reports;
- quarterly investor updates of non-material strategic developments within the Company
- the Annual Shareholders Meeting;
- regular disclosures on Company performance and news via the NZX and ASX online disclosure platforms;
- disclosure of presentations provided to analysts, investors, and the media during regular briefings; and
- engagement with media and social media.

The Company's website is an important part of the Company's communication programme. Included on the website is a range of information relevant to shareholders and others concerning the financial position, operation, and governance of the Company, including information about the Company and its history, biographies of the Company's Directors and senior management, the Company's Constitution, Board Charter (and the charters of the various

committees) and other corporate governance policies of the Company.

Shareholders may, at any time, direct questions, or requests for information to Directors or management through the Company's website or by sending an email to:

investor.relations@aftpharm.com

The Company provides shareholders with the option to receive communications from, and send communications to, the Company and its share registrar electronically. A majority of AFT's shareholders have elected to receive electronic communications.

Shareholder Voting Rights

(Recommendation 8.3)

In accordance with the Companies Act 1993, AFT's Constitution and the NZX Listing Rules, AFT refers major decisions which may change the nature of AFT to shareholders for approval.

In the financial year ended 31 March 2026, there were no such transactions requiring shareholders' approval under the Companies Act 1993, AFT's Constitution and/or the NZX Listing Rules.

As required by the NZX Listing Rules, AFT conducts voting at its shareholder meetings by way of polls, reflecting the principle of one share, one vote. Further information on shareholder voting rights is set out in AFT's Constitution.

Annual Shareholders Meeting

(Recommendation 7.2, 8.2, 8.5)

AFT's 2026 Annual Shareholders Meeting is currently intended to be held in early August 2026.

Shareholders will be given an opportunity to participate, vote and ask questions and comment. In addition, the Company's auditors, Deloitte, will be available to answer any questions about their audit report. A Notice of Meeting will be posted on AFT's website as soon as possible and will be posted to shareholders at least 20 working days prior to the meeting.

For personal use only

REMUNERATION

Remuneration

AFT Pharmaceuticals remuneration policies are targeted at supporting the company to attract, retain and motivate high calibre people to achieve AFT Pharmaceuticals' business objectives and create shareholder value. They are guided by the principles that remuneration practices should:

- be clearly aligned with AFT Pharmaceuticals' values, culture, risk appetite and corporate strategy;
- support the attraction, retention, and engagement of employees;
- be understood by employees;
- be equitable and flexible;
- appropriately reflect market conditions and organisational context;
- recognise individual performance and competency, rewarding individuals for achieving high performance; and
- recognise team and company performance and the creation of shareholder value

Remuneration Governance

AFT's policies regarding the remuneration of Directors and its people are set out in the Board Charter and the company's Remuneration Policy, both of which are available on the Investor Centre on the company's website. There have been no changes to the Company's approach to remuneration during the period.

As detailed in the Board Committee Section (page 50 of this report), the governance arrangements relating to remuneration are overseen by the Board's Remuneration and Nominations Committee.

Director Remuneration

The current maximum total monetary sum permitted to be paid by the Company by way of Non-Executive Directors' fees is \$575,000 per annum. This sum has not been increased since it was approved by shareholders in 2015.

Non-Executive Directors' fees were last reviewed and increased at the May 2025 Board meeting and are detailed in the table below. Committee fees were held steady at that meeting and are payable to Non-Executive Directors, as detailed in the table below.

Non-Executive Directors' fees are still within the \$575,000 per annum limit noted above.

Directors may hold shares in the Company, the details of which are set out in the Statutory Information section on pages 98 to 101 of this report. It is the Company's policy to encourage Directors to hold shares in the Company.

The Non-Executive Directors are entitled to be reimbursed for all reasonable travel, accommodation and other expenses incurred by them in connection with their attendance at Board or shareholder meetings or otherwise in connection with AFT's business.

No retirement allowances will be paid to the Non-Executive Directors on their retirement. The current approved fixed annual fees payable to Non-Executive Directors are detailed in the table below.

Governance body	Position	Annual Fees	
		FY2026 ¹	FY2025
Year to 31 March			
Board of Directors	Chair	\$154,000	\$150,000
	Director	\$82,400 ²	\$80,000
Audit and Risk Committee	Committee Chair	\$20,600 ³	\$20,000
	Committee Member	\$6,180 ³	\$6,000
Remuneration and Nominations committee	Committee Chair	\$7,725	\$7,500
	Committee Member	\$6,180 ³	\$6,000
Regulatory and Product Development Oversight Committee	Committee Chair	\$15,540 ⁴	\$15,000
	Committee Member	\$6,180	\$6,000

¹ All fees are paid in NZD unless stated.

² Fee payable to non-United States (US) based Directors. US-based Directors receive USD\$82,400.

³ Fee payable to non-US based Directors. US based Directors receive USD\$6,180.

⁴ Fee payable to non-US based Directors. US based Directors receive USD\$15,450.

Non-Executive Directors received the following Directors' fees, remuneration and other benefits from the Company in the financial year ended 31 March 2026:

Non-Executive Director	David Flacks		Dr Ted Witek ²		Andrew Lane		Allison Yorston ³	
	Year to 31 March							
	2026	2025	2026	2025	2026	2025	2026	2025
Non-Executive Director Board fees	\$154,500	\$150,000	\$138,966	\$134,943	\$82,400	\$80,000	\$82,400	\$30,521
Audit and Risk Committee fees	\$6,180	\$6,000	-	\$4,200	\$20,600	\$20,000	\$6,180	\$181
Remuneration and Nomination Committee fees	\$6,180	\$6,000	\$10,422	\$10,120	\$7,725	\$7,500	-	-
Regulatory and Product Development Oversight Committee fees	-	-	\$26,056	\$25,301	-	-	-	-
Shares and other payments or benefits ¹	-	-	-	-	-	-	-	-
Total remuneration¹	\$166,860	\$162,000	\$175,444	\$174,564	\$110,725	\$107,500	\$88,580	\$30,701

¹ In addition to Directors' fees, AFT meets costs incurred by Non-Executive Directors that are incidental to the performance of their duties. This includes paying the costs of Directors' travel. As these costs are incurred by AFT to enable Directors to perform their duties, no value is attributable to them as benefits to Directors for the purposes of this table.

² Fees disclosed in NZD. Ted Witek receives fees paid in USD. These fees have been converted into NZD in the above table, calculated at an weighted average exchange rate of 1:0.593.

³ Allison Yorston joined the Board on 12 November 2024 and joined the Audit and Risk Committee on 20 March 2025.

Executive Director Remuneration

The remuneration of the Executive Directors – Managing Director and Chief Executive Hartley Atkinson and Executive Director and Chief of Staff Marree Atkinson – is covered in the 'Senior Executive Remuneration' section below.

Senior Executive Remuneration Policy

AFT has adopted a formal Remuneration Policy, the purpose of which is to outline the remuneration principles that apply to all employees to ensure that remuneration practices within AFT are fair and appropriate for the organisation and its Directors and employees.

AFT's Remuneration Policy supports the Company to attract, retain and motivate high-calibre people to achieve the Company's business objectives and create shareholder value. The Remuneration Policy is available in the Investor Centre on the Company's website.

Under AFT's remuneration framework, remuneration paid to the Chief Executive Officer and Senior Officers includes a mix of the following fixed and variable components:

- fixed remuneration, which includes base salary and employer KiwiSaver (or overseas equivalent) contributions (where relevant) and relates to the base requirements of the role;
- a discretionary Short-Term Incentive (STI) may be offered to some employees, at the discretion of the CEO (or be offered to the CEO and/or Chief of Staff, at the discretion of the Board). AFT's short-term incentive is performance based, with any short-term incentive plan payment being conditional on satisfaction of pre-determined Company and individual performance objectives.
- potential short-term incentive payments are generally between 10% to 30% of base salary, depending on seniority and role, and this increases to 75% for the Chief Executive Officer.
- a Long-Term Incentive (LTI) Plan may be offered, generally only to permanent senior management, as approved by the Board. AFT currently operates an option scheme. This is designed to attract and retain senior managers within the business and to align the interests of management with shareholder interests.

Under the LTI Plan, participants are granted options to acquire ordinary shares in AFT. One option will give the participant the right to subscribe for (or otherwise purchase) one ordinary share, subject to meeting any vesting conditions set by the Board and payment of the exercise price.

The Board has an absolute discretion to invite employees to participate in the LTI Plan and to set the terms and conditions of options at the time they are granted.

The maximum aggregate number of options that may be granted under the LTI Plan is 5% of the total number of ordinary AFT shares on issue immediately after the issue of options, unless shareholder approval is obtained.

With respect to AFT's LTI Plan, no Director or employee is permitted to enter into financial products or arrangements that operate to limit the economic risk of their vested or unvested entitlements.

In addition, AFT may offer provisions that have a monetary benefit to employees but are not considered part of remuneration. Each year an internal review against our public company peers is carried out to benchmark salaries with market increases and adjustments made accordingly.

The Remuneration and Nominations Committee is responsible for reviewing the remuneration of the Company's senior executives in consultation with the CEO. The Company's senior executives are subject to regular performance reviews.

The performance of senior executives is reviewed by the CEO who meets with each senior executive to discuss their performance, as measured against key performance targets (both financial and non-financial) previously established and agreed with that executive.

Chief Executive and Chief of Staff Remuneration

The Executive Directors, Hartley Atkinson and Marree Atkinson, receive remuneration and other benefits in their respective executive roles as CEO and Chief of Staff and, accordingly, do not receive Directors' fees. Their remuneration packages are set by the Board to reflect the scope and complexity of each role, with reference to comparative market data. The executive Directors' performance is reviewed by the Board annually.

During the financial year ended 31 March 2026, performance reviews took place in accordance with that process. No termination payments are payable to the Executive Directors in the event of serious misconduct. During the financial year ended 31 March 2026, Hartley Atkinson, and Marree Atkinson's remuneration both comprised a fixed cash component and an at-risk short-term incentive. The breakdown of the short-term incentive and the performance hurdles required to achieve them are set out below.

Neither Executive Director was issued any form of long-term incentive during the financial period. The table below sets out the total remuneration and value of other benefits earned by, or paid to, each Executive Director of AFT during, and in respect of, the financial years ended 31 March:

Executive Director remuneration, including short-term performance incentives, is set with reference to the company's strategic objectives and the factors material to delivering on those objectives.

For Managing Director and Chief Executive Dr Hartley Atkinson these objectives include company revenue and profit targets; key innovative product development; and key product registration and licensing. For Marree Atkinson these objectives include company revenue and profit targets; human resources objectives; and overhead cost savings.

Executive Directors – Remuneration Table (FY2026 & FY2025)

Base salary		Taxable benefits		Short-term incentive ¹		Long-term incentive ²		Total remuneration	
FY2026	FY2025	FY2026	FY2025	FY2026	FY2025	FY2026	FY2025	FY2026	FY2025
Dr Hartley Atkinson									
\$752,200	\$730,300	-	-	\$338,067	\$340,695	-	-	\$1,090,267	\$1,070,995
Marree Atkinson									
\$267,800	\$260,000	-	-	\$22,609	\$12,094	-	-	\$290,409	\$272,094

¹ The short-term incentives (STI) paid in each year were earned in the prior year and paid in the year stated. The FY2026 STI has not been finalised.

² Neither Executive Director was issued any form of long-term incentive during the financial period.

Employee Remuneration

The table below sets out the number of employees or former employees of AFT and its subsidiaries, not being Directors of AFT, who, in their capacity as employees received remuneration and other benefits during the financial year ended 31 March 2026 totalling at least \$100,000 per annum.

The remuneration of those employees paid outside of New Zealand has been converted into New Zealand dollars. The table includes base salaries and short-term incentives paid during the financial year ended 31 March 2026 and long-term incentives vested or exercised during the financial year ended 31 March 2026.

The table does not include long-term incentives that have been granted, but which have not yet been vested. Where the individual is a KiwiSaver member, contributions of 3% of gross earnings towards that individual's KiwiSaver scheme are included in the table. Where the individual works in Australia, contributions of 9.5% of gross earnings towards Australian Superannuation are included in the table.



Employee Remuneration Table (NZD)

Remuneration range (NZ\$)	Total number of employees
100000 - 110000	17
110001 - 120000	17
120001 - 130000	14
130001 - 140000	11
140001 - 150000	5
150001 - 160000	1
160001 - 170000	2
170001 - 180000	1
190001 - 200000	2
200001 - 210000	1
210001 - 220000	2
220001 - 230000	1
230001 - 240000	2
240001 - 250000	2
250001 - 260000	1
260001 - 270000	2
290001 - 300000	2
300001 - 310000	1
330001 - 340000	1
370001 - 380000	1
510001 - 520000	1
Total employees and former employees earning more than \$100k	87

Employee Long-Term Incentive Scheme

At 30 April 2026 AFT had issued 164,400 options with exercise price of \$3.46 as part of the company's Long-Term Incentive scheme (LTI). Certain of the options vest (and therefore become available for exercise) over one or more minimum vesting periods, the details of which are particular to each option holder (during which time the option holder must remain employed by the Company).

Vesting of some of the options is also conditional on one or more performance hurdles, specific to the option holder. However key objectives include meeting their budget for the financial year and being employed by the company and the CEO's assessment of a person's overall performance.

The Options have a final exercise date of the date four years and two months from the Grant Date of the options.

For personal use only

AFT Pharmaceuticals Limited

CONSOLIDATED FINANCIAL STATEMENTS

For The Year Ended 31 March 2026



Independent Auditor's Report

To the Shareholders of AFT Pharmaceuticals Limited

Opinion

We have audited the consolidated financial statements of AFT Pharmaceuticals Limited and its subsidiaries (the 'Group'), which comprise the consolidated balance sheet as at 31 March 2026, and the consolidated income statement, consolidated statement of comprehensive income, consolidated statement of changes in equity and consolidated statement of cash flows for the year then ended, and notes to the consolidated financial statements, including material accounting policy information.

In our opinion, the accompanying consolidated financial statements, on pages 68 to 97, present fairly, in all material respects, the consolidated financial position of the Group as at 31 March 2026, and its consolidated financial performance and cash flows for the year then ended in accordance with New Zealand Equivalents to IFRS Accounting Standards ('NZ IFRS') as issued by the External Reporting Board and IFRS Accounting Standards ('IFRS') as issued by the International Accounting Standards Board.

Basis For Opinion

We conducted our audit in accordance with International Standards on Auditing ('ISAs') and International Standards on Auditing (New Zealand) ('ISAs (NZ)'). Our responsibilities under those standards are further described in the *Auditor's Responsibilities for the Audit of the Consolidated Financial Statements* section of our report.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

We are independent of the Group in accordance with Professional and Ethical Standard 1 *International Code of Ethics for Assurance Practitioners (including International Independence Standards) (New Zealand)* issued by the New Zealand Auditing and Assurance Standards Board and the International Ethics Standards Board for Accountants' *International Code of Ethics for Professional Accountants (including International Independence Standards)* ('IESBA Code') as applicable to audits of financial statements of public interest entities. We have also fulfilled our other ethical responsibilities in accordance with PES 1 and the IESBA Code.

Other than in our capacity as auditor, we have no relationship with or interests in the entity.

Audit Materiality

We consider materiality primarily in terms of the magnitude of misstatement in the financial statements of the Group that in our judgement would make it probable that the economic decisions of a reasonably knowledgeable person would be changed or influenced (the 'quantitative' materiality). In addition, we also assess whether other matters that come to our attention during the audit would in our judgement change or influence the decisions of such a person (the 'qualitative' materiality). We use materiality both in planning the scope of our audit work and in evaluating the results of our work.

We determined materiality for the Group financial statements as a whole to be \$2.25 million.

Key audit matters

Key audit matters are those matters that, in our professional judgement, were of most significance in our audit of the consolidated financial statements of the current period. These matters were addressed in the context of our audit of the consolidated financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

Key audit matter	How our audit addressed the key audit matter
<p>Revenue recognition – Rebate accrual</p> <p>Revenue is recognised net of volume discounts, other rebates and various other payments to customers for promotional support. Volume discounts and rebates not invoiced at reporting date are estimated based on agreements with customers and estimated depletions during the period. High levels of judgement are required at year end to estimate the accrual for rebates.</p> <p>As disclosed in note 9, the value of outstanding rebates as at 31 March 2026 was \$15,460k (2025: \$10,414k).</p> <p>The rebate accrual is a Key Audit Matter due to the high levels of judgement involved in the calculation of the outstanding rebate accrual. Management must estimate the mix of sales that will ultimately be made to each end user in order to calculate the rebate accrual as well as the time lag between the sale of the product and its respective rebate claim.</p>	<p>Our procedures included, but were not limited to:</p> <ul style="list-style-type: none"> • Held discussions with management to update our understanding of the process and models for estimating the rebates; • Evaluated the design and implementation of relevant controls over the accrual and associated revenue recognition; • Obtained the calculation of the 31 March 2026 outstanding rebates and checked the calculation for mathematical accuracy; • Evaluated key judgements and assumptions including considering actual historical sales and claims made by product; and • Developed an independent expectation of the accrual balance, and compared it to the accrual recorded to evaluate the appropriateness of the year end accrual position.

Other information

The directors are responsible on behalf of the Group for the other information.

The other information comprises the information in the Annual Report that accompanies the consolidated financial statements and the audit report.

Our opinion on the consolidated financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

Our responsibility is to read the other information and consider whether it is materially inconsistent with the consolidated financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If so, we are required to report that fact. We have nothing to report in this regard.

Directors' responsibilities for the consolidated financial statements

The directors are responsible on behalf of the Group for the preparation and fair presentation of the consolidated financial statements in accordance with NZ IFRS and IFRS, and for such internal control as the directors determine is necessary to enable the preparation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, the directors are responsible on behalf of the Group for assessing the Group's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the Group or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the consolidated financial statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs and ISAs (NZ) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements.

A further description of our responsibilities for the audit of the consolidated financial statements is located on the External Reporting Board's website at:

<https://www.xrb.govt.nz/standards/assurance-standards/auditors-responsibilities/audit-report-1-1/>

This description forms part of our auditor's report.

Restriction on use

This report is made solely to the Company's shareholders, as a body. Our audit has been undertaken so that we might state to the Company's shareholders those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the Company's shareholders as a body, for our audit work, for this report, or for the opinions we have formed.

Deloitte Limited

**Bryce Henderson, Partner
for Deloitte Limited**

Auckland, New Zealand

21 May 2026

Consolidated Income Statement

For the Year Ended 31 March 2026

	Note	2026 \$'000	2025 \$'000
Revenue	4	254,705	208,021
Cost of sales		(144,154)	(116,308)
Gross profit		110,551	91,713
Other (expenses)/income		(410)	753
Selling and distribution expenses		(58,663)	(51,095)
General and administrative expenses		(15,957)	(12,228)
Research and development expenses		(11,076)	(11,495)
Operating profit		24,445	17,648
Finance income		6	25
Interest costs	7	(2,486)	(2,821)
Other finance (loss)/gain	7	(91)	1,182
Profit before tax		21,874	16,034
Income tax expense	13	(7,795)	(4,634)
Net Income		14,079	11,400
Profit is attributable to:			
Equity holder of the parent		14,730	11,962
Non-controlling interests		(651)	(562)
Earnings per share			
Basic and diluted earnings per share (\$)	18	\$0.14	\$0.11

The accompanying Notes form an integral part of the consolidated Financial Statements.

Consolidated Statement of Comprehensive Income

For the Year Ended 31 March 2026

	Note	2026 \$'000	2025 \$'000
Profit after tax		14,079	11,400
Other comprehensive income			
Items that may be subsequently reclassified to profit and loss:			
Foreign exchange difference on translation of foreign operations		(252)	(342)
Other comprehensive loss for the year, net of tax		(252)	(342)
Total comprehensive income		13,827	11,058
Total comprehensive income is attributable to:			
Equity holder of the parent		14,478	11,620
Non-controlling interests		(651)	(562)
		13,827	11,058

The accompanying Notes form an integral part of the consolidated Financial Statements.

Consolidated Statement of Changes In Equity

For the Year Ended 31 March 2026

	Share capital	Share options reserve	Foreign currency translation reserve	Retained earnings	Total	Non-controlling interests	Total
	\$'000	\$'000	\$'000	\$'000	\$'000	\$'000	\$'000
Balance 31 March 2024	78,240	139	159	9,257	87,795	-	87,795
31 March 2025							
Profit after tax	-	-	-	11,962	11,962	(562)	11,400
Other comprehensive income	-	-	(342)	-	(342)	-	(342)
Total comprehensive income	-	-	(342)	11,962	11,620	(562)	11,058
Movement in share options reserve	-	41	-	-	41	-	41
Transfer to retained earnings	-	(139)	-	-	(139)	-	(139)
Dividends paid	-	-	-	(1,678)	(1,678)	-	(1,678)
Balance 31 March 2025	78,240	41	(183)	19,541	97,639	(562)	97,077
31 March 2026							
Profit after tax	-	-	-	14,730	14,730	(651)	14,079
Other comprehensive income	-	-	(252)	-	(252)	-	(252)
Total comprehensive income	-	-	(252)	14,730	14,478	(651)	13,827
Movement in share options reserve	-	52	-	-	52	-	52
Transfer to retained earnings	-	-	-	-	-	-	-
Dividends paid	-	-	-	(1,887)	(1,887)	-	(1,887)
Balance 31 March 2026	78,240	93	(435)	32,384	110,282	(1,213)	109,069

The accompanying Notes form an integral part of the consolidated Financial Statements.


Consolidated Balance Sheet

As at 31 March 2026

	Note	2026 \$'000	2025 \$'000
ASSETS			
Current assets			
Cash and cash equivalents		10,240	11,110
Trade and other receivables	9	64,237	48,564
Inventories	10	74,066	48,476
Derivative assets	23	-	192
Total current assets		148,543	108,342
Non-current assets			
Property, plant and equipment	11	399	479
Intangible assets	12	64,301	58,223
Right of use assets	11	2,963	2,771
Deferred tax	13	804	-
Total non-current assets		68,467	61,473
Total assets		217,010	169,815
LIABILITIES			
Current liabilities			
Trade and other payables	15	39,218	33,105
Provisions	16	6,639	5,665
Lease liabilities	14	935	728
Related party loan	14	1,694	1,083
Derivative liabilities	23	937	-
Current income tax liability		7,040	2,675
Interest bearing liabilities	14	9,884	-
Total current liabilities		66,347	43,256
Non-current liabilities			
Lease liabilities	14	2,594	2,586
Interest bearing liabilities	14	39,000	25,600
Deferred tax	13	-	1,296
Total non-current liabilities		41,594	29,482
Total liabilities		107,941	72,738
EQUITY			
Share capital	17	78,240	78,240
Retained earnings		32,384	19,541
Share options reserve	20	93	41
Foreign currency translation reserve		(435)	(183)
Equity attributable to equity holder of the parent		110,282	97,639
Non-Controlling Interests		(1,213)	(562)
Total equity		109,069	97,077
Total liabilities and equity		217,010	169,815

The accompanying Notes form an integral part of the consolidated Financial Statements.

On behalf of the Board on 21st May 2026


David Flacks
 Chair


Dr Hartley Atkinson
 Founder and Chief Executive Officer

Consolidated Statement of Cash Flows

For the Year Ended 31 March 2026

	2026 \$'000	2025 \$'000
CASH FLOWS FROM OPERATING ACTIVITIES		
Receipts from customers	240,390	204,766
Payments to suppliers and employees	(244,805)	(189,376)
Tax paid	(5,124)	(2,214)
Net cash generated from operating activities	(9,539)	13,176
CASH FLOWS FROM INVESTING ACTIVITIES		
Purchases of property, plant and equipment	(116)	(281)
Purchase of intangible assets	(9,641)	(6,670)
Net cash used in investing activities	(9,757)	(6,951)
CASH FLOWS FROM FINANCING ACTIVITIES		
Dividends paid	(1,887)	(1,678)
Payment for lease liabilities	(850)	(820)
New borrowings	92,400	16,600
Borrowings repaid	(79,000)	(19,200)
Related party loan	611	1,083
Interest received	6	25
Interest paid on lease liabilities	(269)	(279)
Interest costs paid on borrowings	(2,217)	(2,542)
Net cash used in financing activities	8,794	(6,811)
Net increase/(decrease) in cash	(10,502)	(586)
Impact of foreign exchange on cash and cash equivalents	(252)	(344)
Opening cash and cash equivalents	11,110	12,040
Closing cash and cash equivalents	356	11,110
Made up of:		
Cash and cash equivalents	10,240	11,110
BNZ overdraft	(9,884)	-
	356	11,110

The accompanying Notes form an integral part of the consolidated Financial Statements.

Reconciliation of Profit After Tax With Net Cash Flow From Operating Activities

	2026 \$'000	2025 \$'000
Profit after tax	14,079	11,400
Non-cash items and items classified as financing activities		
Depreciation	208	163
Depreciation ROU assets	873	831
Amortisation	2,618	1,675
Intangible disposals	945	231
Other non cash items	(12)	-
Share options expense	52	41
Interest on lease liabilities	269	279
Interest and finance expense	2,217	2,542
Unrealised loss/(gain) on foreign currency movements	1,129	81
Provision for tax expense	2,265	2,420
Interest received	(6)	(25)
Movement in working capital		
(Increase)/decrease in inventories	(25,590)	581
(Increase)/decrease in trade and other receivables	(15,673)	(4,342)
Increase/(decrease) in trade and other payables, provisions	7,087	(2,701)
Net cash generated from operating activities	(9,539)	13,176

The accompanying Notes form an integral part of the consolidated Financial Statements.

Notes to the Financial Statements

For The Year Ended 31 March 2026

1. Reporting Entity

AFT Pharmaceuticals Ltd (the “Company” or “Parent”) together with its subsidiaries (the “Group”) is a pharmaceutical distributor and developer of pharmaceutical intellectual property. The Company is incorporated and domiciled in New Zealand; it is registered under the Companies Act 1993. The address of the Company’s registered office is 129 Hurstmere Road, Takapuna, New Zealand.

The Company is a FMC reporting entity under the Financial Markets Conduct Act 2013 and is listed on both the NZX and ASX.

These consolidated financial statements were approved for issue by the Board of Directors on 21st May 2026.

2. Basis of Preparation and Principles of Consolidation

Statement of compliance

These consolidated financial statements of the Group have been prepared in accordance with the requirements of the Companies Act 1993, Financial Reporting Act 2013 and the Financial Markets Conduct Act 2013. As Group consolidated financial statements are prepared and presented for the Parent and its subsidiaries, separate financial statements for the Company are not required to be prepared under the Companies Act 1993.

The consolidated financial statements of the Group have been prepared in accordance with Generally Accepted Accounting Practice in New Zealand (NZ GAAP). The Group is a for-profit entity for the purposes of complying with NZ GAAP. The consolidated financial statements comply with New Zealand equivalents to IFRS Accounting Standards (‘NZ IFRS’), other New Zealand accounting standards and authoritative notices that are applicable to entities that apply NZ IFRS. The consolidated financial statements also comply with IFRS Accounting Standards (‘IFRS’).

Basis of accounting

These consolidated financial statements have been prepared under the historical cost convention, as modified by the revaluation of financial assets and liabilities (including derivative instruments) at fair value through profit or loss and/or other comprehensive income.

Functional and presentation currency

The consolidated financial statements are presented in New Zealand dollars (NZD), which is

the Company’s functional currency rounded to the nearest thousand dollars unless otherwise stated. Items included in the financial statements of each of the subsidiaries are measured using the currency of the primary economic environment in which the entity operates (the functional currency).

Foreign currency transactions and balances

The results and balance sheets of all foreign operations (none of which has the currency of a hyperinflationary economy) that have a functional currency different from New Zealand dollars are translated into the presentation currency as follows:

- Monetary assets and liabilities for each balance sheet presented are translated at the closing rate at the date of that balance sheet
- Income and expenses for each income statement and statement of comprehensive income are translated at average exchange rates, unless this is not a reasonable approximation of the cumulative effect of the rates prevailing on the transaction dates, in which case income and expenses are translated at the dates of the transactions, and
- Exchange differences arising are recognised in other comprehensive income and accumulated in equity in a foreign exchange translation reserve.
- Non-monetary items carried at fair value that are denominated in foreign currencies are translated at the rates prevailing at the date when the fair value was determined. Non-monetary items that are measured in terms of historical cost in a foreign currency are not retranslated

Basis of consolidation

The consolidated financial statements incorporate the assets and liabilities of all subsidiaries of the Group as at the balance date and the results of all subsidiaries for the year then ended.

Intercompany transactions, balances and unrealised gains on transactions between subsidiary companies are eliminated. Unrealised losses are also eliminated unless the transaction provides evidence of the impairment of the asset transferred.

Critical accounting estimates and judgements

In applying the Group’s accounting policies, the directors are required to make judgements (other than those involving estimations) that have a significant impact on the amounts recognised and to make estimates and assumptions about the carrying amounts of assets and liabilities that are not readily apparent from other sources.

The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision affects only that period or in the period of the revision and future periods if the revision affects both current and future periods.

Significant estimates are disclosed in each of the applicable notes to the financial statements and are designated with an **E** symbol.

Material accounting policy information

Material accounting policies are disclosed in each of the applicable notes to the financial statements and are designated with an **AP** symbol. All mandatory amendments have been adopted in the current year. None of the amendments had a material impact on these financial statements.

Standards and interpretations in issue not yet effective

At the date of authorisation of these financial statements, the Group has not applied new and revised NZ IFRS standards and amendments that have been issued but are not yet effective. It is not expected that the adoption of these standards and amendments will have a material impact on the financial statements of the Group.

In April 2024, the International Accounting Standards Board introduced IFRS 18 Presentation and Disclosure in Financial Statements (effective for reporting periods beginning on or after 1 January 2027). This standard replaces IAS 1 Presentation of Financial Statements. An equivalent, NZ IFRS 18 was issued on 23 May 2024. NZ IFRS 18 also applies to reporting periods (including interim periods) beginning on or after 1 January 2027 and will replace NZ IAS 1. Management are still assessing the impact and note this may change the presentation of primary statements.

Goods and Services Tax (GST)

The income statement and the statement of comprehensive income have been prepared so that all components are stated exclusive of GST. All items in the balance sheet are stated net of GST, with the exception of accounts receivable and payable, which include GST invoiced. All components of the statement of cash flows are stated exclusive of GST.

Comparative Information

In some cases, comparative information has been restated to conform to this year's presentation.

3. Significant Transactions and Events in the Financial Year

On the 8th of March 2026 the Court of Appeal dismissed a claim that AFT be required to share, with PBL Solutions (PBL), any profit which AFT may earn from the application of Pascomer for the treatment of the non-orphan indication Port Wine Stain (PWS).

PBL is a company associated with a former contractor to AFT and is a 35% shareholder in AFT Orphan Pharmaceuticals Limited, a company created to pursue orphan applications.

AFT will continue to provide an account to PBL for profits (if any) earned for orphan drug applications of Pascomer and will share 35% of those profits with PBL. PBL and AFT will share costs related to the appeal.

The Court of Appeal decision has no impact on the carrying value of the Pascomer IP included in the note on page 85.

At the end of the 2024 Financial Year the Group had applied to the IRD to amend the 2018 to 2022 income tax returns to treat both capitalised product development and capitalised product registration costs as deductible. This would have been consistent with the Groups treatment of the income tax years from 2023 onwards. The IRD approved the amendment for the capitalised product development costs but declined the opportunity to offer a determination on the capitalised registrations costs. In August 2025, after further independent advice, the Group applied for a binding ruling under section 91E of the Tax Administration Act 1994 to seek clarity on the deductibility of capitalised product registration costs going forward.

There were no other significant transactions and events during the current year.

4. Revenue From Operations

	2026 \$'000	2025 \$'000
Sale of goods	248,135	204,827
Royalty income	3,511	2,527
Licensing Income	3,059	667
Total revenue from operations	254,705	208,021

AP E

Revenue is measured based on the consideration to which the Group expects to be entitled in a contract with a customer and excludes amounts collected on behalf of third parties:

- The sale of goods, excluding GST and discounts are recognised when control of the product is transferred to the customer at a point in time. For discounts not invoiced at reporting date, these are estimated based on agreements with customer and estimated depletions during the period.
- Licensing income, the Group has entered into a number of out-licencing contracts whereby the Group's obligations are the provision of territorial rights to the company's intellectual property and the provision and support of the documentation required to enable registration of the product in the territory. The Group typically receives an upfront fee, milestone payments for specific registration and/or development-based outcomes, and sales-based milestones or royalties as consideration for the license.

Licenses coupled with other services, must be assessed to determine if the license is distinct (that is, the customer must be able to benefit from the IP on its own or together with other resources that are readily available to the customer, and the Group's promise to transfer the IP must be separately identifiable from other promises in the contract). If the license is not distinct, then the license is combined with other goods or services into a single performance obligation. Revenue is then recognised as the Group satisfies the combined performance obligation.

A license will either provide:

- A right to access the entity's intellectual property throughout the license period, which results in revenue that is recognised over time;
- or
- A right to use the entity's intellectual property as it exists at the point in time in which the license is granted, which results in revenue that is recognised at a point in time. For sales- or usage-based royalties that are attributable to a license of IP, the amount is recognized at the later of:
 - when the subsequent sale or usage occurs; and
 - the satisfaction or partial satisfaction of the performance obligation to which some or all of the sales or usage-based royalty has been allocated.
- Royalty revenue is recognised on an actual and accrual basis in accordance with the substance of the relevant agreement provided that it is probable that economic benefits will flow to the Company and the amount of revenue can be measured reliably.

5. Joint Operations

Hyloris Pharmaceuticals SA and AFT have been collaborating in the development of the Maxigesic IV product. AFT has now licensed the product to a number of partners covering multiple countries. Maxigesic IV is protected by several granted and pending patent applications. Under the terms of the development collaboration agreement between Hyloris and AFT, Hyloris is eligible to receive a thirty five percent share on any product related revenues, such as license fees, royalties, milestone payments, received by AFT. The arrangement constitutes a joint operation whereby the Group recognises, in relation to its interest in the joint operation, its share of assets and liabilities in the consolidated statement of financial position and share of revenue earned and expenses incurred in the consolidated income statement. The Group accounts for the assets, liabilities, revenues and expenses relating to its interest in the joint operation in accordance with the NZ IFRS standards applicable to the particular assets, liabilities, revenues and expenses.

AP

Interests in joint operations

A joint operation is a joint arrangement whereby the parties that have joint control of the arrangement have rights to the assets and obligations for the liabilities relating to the arrangement. Joint control is the contractually agreed sharing of control of an arrangement, which exists only when decisions about the relevant activities require unanimous consent of the parties sharing control.

6. Segment Reporting

	Operating Segments					Total \$'000
	Australia \$'000	New Zealand \$'000	Asia \$'000	Rest of World \$'000	Head Office \$'000	
31 March 2026						
Revenue - Sale of goods	150,826	59,705	13,928	23,676	-	248,135
Revenue - Royalties	-	-	1,720	1,791	-	3,511
Revenue - Licensing	-	-	-	3,059	-	3,059
Total revenue	150,826	59,705	15,648	28,526	-	254,705
Other (expense)/Income	-	-	-	(410)	-	(410)
Depreciation - ROU assets	535	63	-	-	275	873
Depreciation - Other	16	-	-	-	192	208
Amortisation	-	-	-	2,618	-	2,618
Operating profit / (loss)	30,317	9,401	3,753	(5,987)	(13,039)	24,445
Finance income	-	-	-	-	6	6
Interest expense - Loans	-	-	-	-	(2,217)	(2,217)
Interest expense - Lease liabilities	(102)	(14)	-	-	(153)	(269)
Other finance gains/(losses)	-	-	-	-	(91)	(91)
Profit / (loss) before tax	30,215	9,387	3,753	(5,987)	(15,494)	21,874
Total assets	73,639	66,896	547	73,087	2,841	217,010
ROU assets	552	151	-	-	2,260	2,963
Property plant and equipment	39	-	-	-	360	399
Pascomer IP	-	-	-	12,500	-	12,500
Other intangible assets	-	-	-	51,801	-	51,801
Total liabilities	15,709	47,149	5	6,377	38,701	107,941
Capital expenditure *	-	-	-	9,641	116	9,757

*Capital expenditure includes both intangible and tangible asset additions.

	Operating Segments					Total \$'000
	Australia \$'000	New Zealand \$'000	Asia \$'000	Rest of World \$'000	Head Office \$'000	
31 March 2025						
Revenue - Sale of goods	127,101	53,789	9,997	13,940	-	204,827
Revenue - Royalties	-	-	1,092	1,435	-	2,527
Revenue - Licensing	-	-	-	667	-	667
Total revenue	127,101	53,789	11,089	16,042	-	208,021
Other income	-	-	-	753	-	753
Depreciation - ROU assets	511	59	-	-	262	831
Depreciation - Other	20	-	-	-	143	163
Amortisation	-	-	-	1,676	-	1,676
Operating profit / (loss)	25,475	8,761	1,779	(7,322)	(11,045)	17,648
Finance income	-	-	-	-	25	25
Interest expense - Loans	-	-	-	-	(2,542)	(2,542)
Interest expense - Lease liabilities	(96)	(10)	-	-	(173)	(279)
Other finance gains/(losses)	-	-	-	-	1,182	1,182
Profit / (loss) before tax	25,379	8,751	1,779	(7,322)	(12,553)	16,034
Total assets	55,542	50,403	5	63,865	-	169,815
ROU assets	814	142	-	-	1,815	2,771
Property plant and equipment	159	-	-	-	320	479
Pascomer IP	-	-	-	12,500	-	12,500
Other intangible assets	-	-	-	45,723	-	45,723
Total liabilities	12,829	28,340	-	2,388	27,886	71,443
Capital expenditure *	154	-	-	6,670	127	6,951

*Capital expenditure includes both intangible and tangible asset additions.

Operating segments are reported in a manner consistent with the internal reporting provided to the chief operating decision maker (CODM). For the purposes of NZ IFRS 8, the CODM is a group comprising the Board of Directors, together with the Chief Executive Officer, the Chief of Staff, the Chief Financial Officer and the Director of International Business Development. Management report on operating segments net of intersegment revenue so that the revenue amount reflects the end customer's reportable geography.

Inter-segment transactions are eliminated for Management reporting. This has been determined on the basis that it is this group that determines the allocation of the resources to segments and assesses their performance.

The Group has four operating segments based on geographical locations reportable under NZ IFRS 8, as described below, which are the Group's strategic groupings of business units. The following summary describes the operations in each of the Group's reporting segments:

- **New Zealand** - Includes the sales and distribution activity relating to the New Zealand market.
- **Australia** - Includes the sales and distribution activity relating to the Australian market.
- **Asia** - Includes the sales and distribution activity relating to the Asian market.
- **Rest of World** - Includes the out-licensing of IP developments to markets in which the Group does not have a presence and the export of products to export markets. The costs of research and development and new market development activity not specific to the other segments are expensed to this segment.

Head Office - Head Office functions include maintaining all supplier relationships, procurement of inventory, regulatory activity, governance, marketing activity and finance activity.

Major Customers - Revenues from one customer of the Australian segment (being a licensed wholesaler) represents approximately NZ\$49.9m (2025 NZ\$40.3m) and from one customer of the New Zealand segment (also being a licensed wholesaler) represents approximately NZ\$30.8m (2025: NZ\$27.1m) of the Group's total revenues.

7. Operating Profit

	Note	2026 \$'000	2025 \$'000
Profit before tax		21,874	16,034
After charging the following specific expenses			
Finished goods materials included in cost of sales		142,512	115,371
Inventory write off included in cost of sales		1,642	937
Fees paid to Auditors	8	424	361
Short term rental expenses - premises		191	161
Share options expense/(reversal)		52	(41)
Short term employee emoluments (*)			
Selling and distribution expenses		13,111	11,509
General and administration expenses		4,465	3,791
Research and development expenses		3,747	4,050
		21,323	19,350
Research and development expenses			
Business development		6,095	5,716
New market development		1,234	1,728
		7,329	7,444
Depreciation			
Plant and machinery		94	104
Furniture and fittings		98	35
Vehicles		16	24
ROU equipment		3	3
ROU vehicles		459	448
ROU buildings		411	380
		1,081	994
Amortisation			
Patents		215	207
Software		1	1
Development costs		2,005	1,087
Registration costs		397	380
		2,618	1,675
Finance costs/(Income)			
Interest on borrowings		2,217	2,542
Interest on ROU liabilities		269	279
Foreign exchange (gains)/losses		(757)	(725)
Derivative (gains)/losses		844	(435)
Other financing costs/(gains)		4	(22)
		2,577	1,639
* This includes contributions recognised as an expense for defined contributions		1,137	912

8. Fees Paid to Auditors

	2026 \$'000	2025 \$'000
Fees paid to Deloitte Limited		
Audit of annual financial statements	349	288
Review of interim financial statements	48	47
Total fees paid to Deloitte Limited	397	335
Fees paid for Non-Deloitte Limited audits		
Audit of annual financial statements for AFT Pharmaceutical (HK) Limited	1	1
Audit of annual financial statements for AFT Pharmaceutical (UK) Limited	12	11
Audit of annual financial statements for AFT Pharmaceutical (EUR) Limited	14	14
Total fees paid for Non-Deloitte Limited audits	27	26
Total fees paid to auditors	424	361

9. Trade and Other Receivables

	2026 \$'000	2025 \$'000
Trade receivables	73,585	53,610
Less provision for customer rebates	(15,460)	(10,414)
	58,125	43,196
Expected credit loss	-	-
Prepayments & sundry debtors	6,112	5,368
Total trade and other receivables	64,237	48,564

E

Customer rebates represent volume discounts and other rebates for which the customer has a right to offset for net payment. For rebates not invoiced at reporting date, these are estimated based on agreements with customer and estimated depletions during the period. High levels of judgement are required at year end to estimate the accrual for rebates. Management must estimate the mix of sales that will ultimately be made to each end user in order to calculate the rebate accrual as well as the time lag between the sale of the product and its respective rebate claim.

Ageing of overdue trade debtors	1-30 Days \$'000	31-60 Days \$'000	61-90 Days \$'000	90+ Days \$'000	Total \$'000
31 March 2026	3,184	1,615	771	2,036	7,606
31 March 2025	2,785	336	840	306	4,267

All balances are expected to be settled within the next 12 months.

The expected credit loss (ECL) allowance provision has been determined as follows:

	Current \$'000	Current to 1 month \$'000	Greater than 1 month \$'000	Total \$'000
As at 31 March 2026				
Expected loss rate	*	*	0.03%	
Gross carrying amount	65,979	3,184	4,422	73,585
Expected credit loss allowance provision				-
Short term loss allowance provision				-
Long term loss allowance provision				-

As at 31 March 2025	Current \$'000	+1 Month \$'000	>1 Month \$'000	Total \$'000
Expected loss rate	*	*	0.03%	
Gross carrying amount	49,343	2,785	1,482	53,610
Expected credit loss allowance provision				-
Short term loss allowance provision				-
Long term loss allowance provision				-

*Expected credit losses are negligible.

The average credit period on sale of goods is 69 days (2025: 54 days). No interest is charged on outstanding trade receivables.

The Group always measures the loss allowance for trade receivables at an amount equal to lifetime ECL.

AP

The Group has applied the simplified approach to providing for expected credit losses, which requires the recognition of a lifetime expected loss provision for trade and other receivables. NZ IFRS 9 requires the Group to consider future potential credit losses and consider items such as forecasted economic conditions.

The Group does not expect any significant expected credit losses due to the nature of the distribution and regulatory licensing structure of the industry.

The expected credit losses on trade receivables are estimated using a provision matrix by reference to past default experience of the debtor and an analysis of the debtor's current financial position, adjusted for factors that are specific to the debtors, general economic conditions of the industry in which the debtors operate and an assessment of both the current as well as forecast direction of conditions at the reporting date.

As the Group's historical credit loss experience does not show significantly different loss patterns for different customer segments, the provision for loss allowance based on past due status is not further distinguished between the Group's different customer base.

Bad debt expense for the current year was nil (2025: nil).

10. Inventories

	2026 \$'000	2025 \$'000
Inventory on hand	76,187	50,212
Provision for obsolescence	(2,121)	(1,736)
Total inventories	74,066	48,476

AP

Inventories are stated at the lower of cost and net realisable value. Cost is determined on a weighted average cost basis. Net realisable value is the estimated selling price in the ordinary course of business less the estimated costs of completion and the estimated costs necessary to make the sale.

11. Property, Plant and Equipment

	Plant and machinery \$'000	Furniture and fixtures \$'000	Vehicles \$'000	ROU Buildings \$'000	ROU Vehicles \$'000	ROU Equipment \$'000	Total \$'000
Cost							
Balance at 30 March 2024	1,432	513	202	3,918	1,875	58	7,998
Net foreign currency exchange differences	3	-	-	-	18	-	21
Additions	79	202	-	6	149	(45)	392
Disposals	(2)	-	-	-	(250)	-	(252)
Balance at 30 March 2025	1,512	715	202	3,924	1,792	13	8,158
Net foreign currency exchange differences	31	13	3	65	138	-	250
Additions	93	23	-	846	182	-	1,144
Disposals	-	-	-	(800)	-	-	(800)
Balance at 31 March 2026	1,636	751	205	4,035	2,112	13	8,752
Accumulated depreciation							
Balance at 30 March 2024	(1,280)	(378)	(126)	(1,710)	(634)	(48)	(4,177)
Net foreign currency exchange differences	(3)	-	-	(5)	-	-	(7)
Depreciation	(104)	(35)	(24)	(380)	(448)	(3)	(994)
Disposals	-	-	-	-	225	45	270
Balance at 30 March 2025	(1,387)	(413)	(150)	(2,095)	(857)	(6)	(4,908)
Net foreign currency exchange differences	(32)	(1)	(2)	(74)	(92)	-	(201)
Depreciation	(94)	(98)	(16)	(411)	(459)	(3)	(1,081)
Disposals	-	-	-	800	-	-	800
Balance at 31 March 2026	(1,513)	(512)	(168)	(1,780)	(1,408)	(9)	(5,390)
Carrying amounts							
Balance at 30 March 2025	125	302	52	1,829	935	7	3,250
Balance at 31 March 2026	123	239	37	2,255	704	4	3,362

AP

All plant and equipment is stated at historical cost less depreciation and any impairment losses. Historical cost includes expenditure that is directly attributable to the acquisition of the items. Subsequent costs are included in the asset's carrying amount or recognised as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Company and Group and the cost of the item can be measured reliably. All other repairs and maintenance are charged to the consolidated income statement during the financial period in which they are incurred.

Depreciation of property, plant and equipment is calculated using the diminishing value method which apportions the cost of the assets over their useful lives. The Group has the following classes of property, plant & equipment and depreciation rates:

Category	Depreciation rate (%)
Plant and Machinery	21% to 80%
Furniture and fixtures	9% to 60%
Vehicles	26% to 36%

An asset's carrying amount is written down immediately to its recoverable amount if the asset's carrying amount is greater than its estimated recoverable amount.

Gains and losses on disposal are determined by comparing proceeds to carrying amounts and are included in the consolidated income statement.

AP

Lease accounting

The Group assesses whether a contract is or contains a lease at inception of the contract. The Group recognises a right-of-use asset and a corresponding lease liability with respect to all lease arrangements in which it is the lessee, except for short term leases (leases less than 12 months duration), and leases of low value assets. For these leases the Group recognises the lease payments as an operating expense on a straight-line basis over the term of the lease.

The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date, discounted by using the rate implicit in the lease. If this rate cannot be readily determined the Group uses its incremental borrowing rate.

The lease liability is presented as a separate line in the consolidated balance sheet.

The lease liability is subsequently measured by increasing the carrying amount to reflect interest on the lease liability (using the effective interest rate method) and by reducing the carrying amount to reflect the lease payments made.

The Group re-measures the lease liability (and makes a corresponding adjustment to the related right-of-use asset) whenever:

The lease term has changed or there is a change in the assessment of exercise of a purchase option, in which case the lease liability is re-measured by discounting the revised lease payments using a revised discount rate

If or when the lease payments change due to changes in an index or rate or a change in expected payment under a guaranteed residual value, in which cases the lease liability is re-measured by discounting the revised lease payments using the initial discount rate (unless the lease payments change due to a change in a floating interest rate, in which case a revised discount rate is used)

If or when a lease contract is modified and the lease modification is not accounted for as a separate lease, in which case the lease liability is re-measured by discounting the revised lease payments using a revised discount rate.

The Group did not make any such adjustments during the periods presented.

The right-of-use assets comprise the initial measurement of the corresponding lease liability, lease payments made at or before the commencement day and any initial direct costs. They are subsequently measured at cost less accumulated depreciation and impairment losses.

Whenever the Group incurs an obligation for costs to dismantle and remove a leased asset, restore the site on which it is located or restore the underlying asset to the condition required by the terms and conditions of the lease, a provision is recognised and measured under NZ IAS 37. The costs are included in the related right-of-use asset.

Right-of-use assets are depreciated over the shorter period of lease term and useful life of the underlying asset. If a lease transfers ownership of the underlying asset or the cost of the right-of-use asset reflects that the Group expects to exercise a purchase option, the related right-of-use asset is depreciated over the useful life of the underlying asset. The depreciation starts at the commencement date of the lease.

The right-of-use assets are presented as a separate line in the balance sheet.

The Group applies NZ IAS 36 to determine whether a right-of-use asset is impaired and accounts for any identified impairment losses.

Variable rents that do not depend on an index or rate are not included in the measurement of the lease liability and the right-of-use asset. The related payments are recognised as an expense in the period in which the event or condition that triggers those payments occurs and are included in the line "general and administrative expenses" in the income statement.

See note 14 for interest bearing liability analysis and note 23 for lease maturity analysis.

12. Intangible Assets

	Pascomer IP \$'000	Trademarks \$'000	Capitalised registration \$'000	Capitalised development \$'000	Patents \$'000	Software \$'000	Total \$'000
Cost							
Balance at 30 March 2024	12,500	1,234	8,572	30,435	3,972	533	57,246
Additions	-	557	1,238	4,408	467	-	6,670
Disposals	-	(26)	(46)	(122)	(37)	-	(231)
Balance at 30 March 2025	12,500	1,765	9,764	34,721	4,402	533	63,685
Additions	-	196	1,692	7,209	544	-	9,641
Disposals	-	(13)	(442)	(315)	(503)	-	(1,273)
Balance at 31 March 2026	12,500	1,948	11,014	41,615	4,443	533	72,053
Accumulated amortisation							
Balance at 30 March 2024	-	-	(361)	(1,689)	(1,206)	(531)	(3,787)
Amortisation	-	-	(380)	(1,087)	(207)	(1)	(1,675)
Disposals	-	-	-	-	-	-	-
Balance at 30 March 2025	-	-	(741)	(2,776)	(1,413)	(532)	(5,462)
Amortisation	-	-	(397)	(2,005)	(215)	(1)	(2,618)
Disposals	-	-	10	-	318	-	328
Balance at 31 March 2026	-	-	(1,128)	(4,781)	(1,310)	(533)	(7,752)
Carrying amounts							
Balance at 30 March 2025	12,500	1,765	9,023	31,945	2,989	1	58,223
Balance at 31 March 2026	12,500	1,948	9,886	36,834	3,133	-	64,301

E

Pascomer IP

The Group acquired the remaining 50% of Dermatology Specialties Limited Partner (“DSLPL”) and its general partner DSGP Limited, from its joint venture partner Tardimed Sciences on 5 July 2019 and these have been fully consolidated from this date. DSLP was originally formed for the development and commercialisation of the product, Pascomer, which uses the active ingredient Rapamycin for the topical treatment of indications commencing with facial angiofibromas in tuberous sclerosis.

As a result of the transaction, the Group retained the rights to the intellectual property, future product sales and royalties.

The Group also entered into an out-license agreement with Timber Pharmaceuticals LLC, under which the Group has received revenues from the upfront milestone and expects to receive future revenues from development, registration and commercial milestones as well as product sales and royalties.

Considering the inherent uncertainties of both the successful conclusion of clinical trials and the successful registration with orphan status, the Group has recognised the Pascomer intellectual property at its fair value of \$12.5m at the time of the FY2019 business combination. It is being assessed for impairment on an annual basis.

Since initial acquisition, the group continually assesses the progress of Pascomer. In April 2022 the US Food and Drug Administration (FDA) approved a topical treatment indicated for facial angiofibroma (FA) associated with Tuberous Sclerosis Complex (TSC) developed by Japan’s Nobelpharma. This means that Nobelpharma has gained exclusivity for a period of seven years in USA which will prevent AFT filing its Pascomer for this orphan indication with the FDA during this period. Nobelpharma also gained approval in the EU in May 2023 and exclusivity for a period of ten years.

The clinical trial study was issued in July 2022 and showed Pascomer delivered statistically significant [$p < 0.05$] benefits against the clinically relevant investigator Global Assessment (IGA), FASI and patient-physician improvement scales. However, the medicine did not reach the threshold on the IGA scale that the US Food and Drug Administration (FDA) considered necessary for its registration in the United States (US) as a treatment for FA. At around the same time Timber Pharmaceuticals LLC terminated its agreements with AFT.

The clinical trial program for non-orphan drug Pascomer indications, including Port Wine Stain (PWS) will continue and the significant formulation patent for Pascomer has been granted in Australia until November 2040 which will form the basis of further patent filings around the world.

The Group assessed the recoverability of the Pascomer IP carrying value of \$12.5m plus Pascomer capitalised development costs of \$2.8m by reviewing the key assumptions made by independent registered valuer, Edison Investment Research Limited in February 2024, which had been commissioned by the board. The material assumptions made in that review were:

- a) the successful clinical trials and registration in the US, Europe and Australasia
- b) The period used for the discounted cash flow is out to 2043
- c) The discount rate used 12.5%
- d) For PWS the addressable market was taken as 0.7 million patients in the USA, 1.95 million in Europe and 0.1 million in Australasia. It was assumed there was no growth in the patient base and a peak penetration of 2.5% in all markets with a probability of success of 30%.

The valuation methodology used significant inputs which were not based on observable market data, and therefore the valuation technique was classified as level 3 of the fair value hierarchy.

The Group had the valuation reviewed during the current year. In the process of the review the assumptions used in the valuation were updated to include the markets of Switzerland, the Middle East, South Korea, and Canada using the same peak penetration and probability of success rates. Based on the review the Group remains confident in the carrying value included.

During the current year the Group signed licensing agreements for both the Port Wine Stain and Facial Angiofibroma indications for the territory of Korea.

AP

Research and development

Research is the original and planned investigation undertaken with the prospect of gaining new knowledge and understanding. This includes direct and overhead expenses for research, pre-clinical trials and costs associated with clinical trial activities. All research costs are expensed when incurred.

Development is the application of research findings to a plan or design for the production of new or substantially improved processes or products prior to the commencement of commercial production. When a project reaches the stage where it is reasonably certain that future expenditure can be recovered through the process or products produced, expenditure that is directly attributable or reasonably allocated to that project is recognised as a development asset. The asset will be amortised from the date of commencement of commercial production of the product to which it relates on a straight-line basis over the life of the relevant patent or period of expected benefit. Development assets are reviewed annually for any impairment in their carrying value.

Development and registration projects are regularly reviewed throughout the year by a staff committee comprising the CEO, CFO, GM Development and Financial Controller. The status of each project is measured against the requirements of NZ IAS 38 and the relevant costs incurred during the financial year are capitalised where projects meet those criteria. The criteria considered in this assessment are:

- a) the technical feasibility of completing the intangible asset so that it will be available for use or sale.
- b) the Group's intention to complete the intangible asset and use or sell it.
- c) the Group's ability to use or sell the intangible asset.
- d) how the intangible asset will generate probable future economic benefits. Among other things,
- e) the Group can demonstrate the existence of a market for the output of the intangible asset or the intangible asset itself or, if it is to be used internally, the usefulness of the intangible asset.
- f) the availability of adequate technical, financial and other resources to complete the development and to use or sell the intangible asset.
- g) the Group's ability to measure reliably the expenditure attributable to the intangible asset during its development.

Finite useful life

Acquired patents, capitalised development costs, capitalised registration costs and software have a finite life and are carried at cost less accumulated amortisation. Patents are amortised over a useful economic life of 20 years, capitalised development costs and capitalised registration costs over the period of expected benefit which is usually between 5 and 10 years, and software over 3 to 4 years.

Indefinite useful life

Acquired trademarks are considered to have indefinite useful lives. They are carried at cost less accumulated impairment. Indefinite useful life assets are tested for impairment annually or when impairment indicators exist. The assets carrying amount is written down immediately to its' recoverable amount if the asset's carrying amount is greater than it's estimated recoverable amount.

Impairment

Assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. An impairment loss is recognised for the amount by which the asset's carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset's fair value less costs to sell and value in use. For the purposes of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash flows (cash generating units). Indefinite useful life assets are tested for impairment annually and whenever there are indicators of impairment while finite useful life assets are tested only when there are indicators of impairment.

13. Income Tax

	2026 \$'000	2025 \$'000
Tax expense		
Profit before tax	21,874	16,034
Tax calculated at domestic tax rates applicable	6,125	4,490
Adjustment due to different tax rates of subsidiaries operating in different jurisdictions	899	602
Tax on expenses not deductible	84	21
Tax on losses recognised	-	(787)
Prior year tax adjustment	687	308
Tax expense	7,795	4,634
Comprising		
Current tax:		
Current tax on profits for the year	9,895	1,088
Adjustment for current tax of prior year	-	-
Deferred tax	(2,100)	3,546
	7,795	4,634
Deferred tax balance		
Deferred tax (liability)/asset	804	(1,296)
Deferred tax (liability)/asset	804	(1,296)

Deferred tax assets relating to unused tax loss carry-forwards and to Deductible temporary differences are recognised if it is probable that they can be offset against future taxable profits or existing temporary differences. As at 31 March 2026, the Group recognised deferred tax assets on temporary differences totalling \$804k (2025 \$nil) since it was foreseeable that temporary differences could be offset against future taxable profits. On the basis of the approved business plans of subsidiaries, the Group considers it probable that temporary differences can be offset against future taxable profits. There is no expected change in capital structure in the near future which is expected to affect the recoverability of the recognised deferred tax assets.

The movement in deferred tax is:

	Provisions \$'000	Recognised Total Tax losses \$'000	Intangible Assets \$'000	Stock Profit Elimination \$'000	Total \$'000
31-Mar-24	801	-	(3,761)	5,210	2,250
Movements	298	-	(4,767)	923	(3,546)
Prior period adjustments	-	-	-	-	-
31-Mar-25	1,099	-	(8,528)	6,133	(1,296)
Movements	149	-	(1,351)	3,302	2,100
Prior period adjustments	-	-	-	-	-
31-Mar-26	1,248	-	(9,879)	9,435	804

AP

Current and deferred income tax

The income tax expense or benefit for the year is the tax payable on the current period's taxable income (based on the national income tax rate for each jurisdiction) adjusted by changes in deferred tax assets and liabilities attributable to temporary differences between the tax bases of assets and liabilities and their carrying amounts in the financial statements, and to unused tax losses.

Deferred tax assets and liabilities are recognised for temporary differences at the tax rates expected to apply when the assets are recovered, or liabilities are settled, based on those tax rates which are enacted or substantively enacted for each jurisdiction. The relevant tax rates are applied to the cumulative amounts of deductible and taxable temporary differences to measure the deferred tax asset or liability. Such assets and liabilities are not recognised if the temporary difference arises from the initial recognition (other than in a business combination) of other assets and liabilities in a transaction that affects neither the taxable profit nor the accounting profit and at the time of the transaction does not give rise to equal taxable and deductible temporary differences. In addition, a deferred tax liability is not recognised if the temporary difference arises from the initial recognition of goodwill.

Deferred tax assets are recognised for deductible temporary differences and unused tax losses only if it is probable that future taxable amounts will be available to utilise those temporary differences and losses.

Deferred tax liabilities and assets are not recognised for temporary differences between the carrying amount and tax bases of investments in controlled entities where the parent entity is able to control the timing of the reversal of the temporary differences and it is probable that the differences will not reverse in the foreseeable future.

The Group continues to calculate the current and deferred tax balances, without claiming a tax deduction for product registration costs that were capitalised during the years 2019 to 2022. This expenditure, totalling \$4.1m, would be included in a s113 application to the Commissioner of Inland Revenue pending a successful outcome of the Group's binding ruling application (see note 3. Significant Transactions and Events in the Financial Year)

14. Interest Bearing Liabilities

	2026	2025
	\$'000	\$'000
Current lease liabilities	935	728
Non-current lease liabilities	2,594	2,586
Related party loan	1,694	1,083
BNZ overdraft	9,884	-
BNZ Term loans current portion	-	-
BNZ Term loans non-current portion	39,000	25,600
Total	54,107	29,997
Opening balance of BNZ loan	25,600	28,200
BNZ loans drawn down	92,400	16,600
Repayment of principal	(79,000)	(19,200)
Closing balance	39,000	25,600

The BNZ loans have a general security over the assets of the Group together with a Group guarantee.

On 5th December 2025 the BNZ facility was renewed for a further three-year term through to 8th December 2028. The facility retains a) a \$48 million term loan, consisting of a floating interest rate portion of \$32 million and two fixed interest rate portions of \$8 million each, with the fixed rates maturing on the 21st of December 2027 and the 8th of December 2028 respectively b) a \$2.0 million overdraft.

Interest on the floating rate portion of the term loan is the BKBM rate plus a margin of 1.98%. The fixed portions of the term loan are charged interest at rates of 5.17% and 5.31%. On the 21st of December 2027 the fixed rate of 5.17% on one fixed portion reverts to the floating rate applicable at that time, with the other fixed portion maintaining its rate until the term loan matures. Interest on the overdraft is the BNZ market connect base rate plus a margin of 0.48%. The non fixed interest rates are reset on a quarterly basis.

The draw down on the term loan at year end was \$39 million with a floating rate of 4.49% applied to \$23 million and the balance of \$16 million at the respective fixed interest rates.

To further meet the short-term cash requirements of the Group the overdraft facility was increased by an additional \$10 mil for a period of three months commencing on the 26th of February. Consistent with the three-year facility, interest on the short-term increase is the BNZ market connect base rate plus a margin of 0.48%. The interest rate applied at year end was 6.01%, inclusive of margin.

As at year end the Group overdraft balance was (9.8 mil) (2025: nil). All covenants relating to the BNZ facility have been complied with during the year.

The related party loan from Edge Group is an open term interest only loan providing working capital in the United Kingdom and South Africa. Interest is calculated based on AFT's borrowing rate plus a margin of 1.5%.

AP

Cash and cash equivalents include cash on hand, deposits held at call with financial institutions and other short-term investments with original maturities of three months or less that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities on the balance sheet.

15. Trade and Other Payables

	2026 \$'000	2025 \$'000
Trade payables	29,594	25,115
GST/VAT payable	2,533	1,544
Employee entitlements	2,717	2,589
Other payables and accruals	4,374	3,857
Total	39,218	33,105

16. Provisions

	2026 \$'000	2025 \$'000
Opening balance of profit shares at 1 April	5,665	7,331
Prior period provision utilised to date	(4,595)	(6,179)
Provision utilised	(4,970)	(1,343)
Additional provisions required	10,539	5,856
Closing balance of profit shares at 31 March	6,639	5,665

AP

Profit share provisions are based on profit sharing arrangements with suppliers which are estimated on achieving expected set margin targets and are expected to be utilised within the next 12 months. These are included as an expense in cost of sales.

17. Share Capital

Ordinary shares are classified as equity.

	2026 Shares	2025 Shares	2026 \$'000	2025 \$'000
Ordinary share capital	104,866,260	104,866,260	81,406	81,406
Less capital raising costs	-	-	(3,166)	(3,166)
Total	104,866,260	104,866,260	78,240	78,240

	2026 Shares	2025 Shares	2026 \$'000	2025 \$'000
Share capital at beginning of the year	104,866,260	104,866,260	78,240	78,240
Issue of ordinary shares for exercised share options	-	-	-	-
Total	104,866,260	104,866,260	78,240	78,240

Ordinary shares

No shares were issued during the period (2025: no shares were issued).

Staff share options

During the period no staff share options were exercised (2025: no staff share options were exercised.).

18. Earnings Per Share

	2026 \$'000	2025 \$'000
Earnings used in the calculation of basic and diluted earnings per share		
Profit after tax	14,730	11,962
Less Redeemable Preference shares dividend	-	-
Net Profit after tax attributable to Ordinary shareholders	14,730	11,962
Weighted average number of ordinary shares for the purposes of basic and diluted earnings per share	104,866,260	104,866,260
Earnings per share		
Basic profit per share (\$)	\$0.14	\$0.11
Diluted profit per share (\$)	\$0.14	\$0.11

AP

Basic earnings per share is computed by dividing net earnings by the weighted average number of ordinary shares outstanding during each period.

19. Dividends Per Share

On 4 July 2025 payment of a dividend of 1.8 cent per share or approximately \$1.9 million was paid, this was not imputed. A dividend of 1.6 cents per share, or approximately \$1.7 million, was declared to the ordinary shareholders during the prior year.

20. Staff Share Options

	2026		2025	
	Average exercise price \$ per share	Options	Average exercise price \$ per share	Options
Balance at beginning of year	3.46	164,400	3.46	510,000
Issued	3.46	-	3.46	-
Forfeited	3.46	-	3.46	-
Exercised *	3.46	-	3.46	-
Lapsed	3.46	-	3.46	(345,600)
Balance at end of year**	3.46	164,400	3.46	164,400

* Weighted average share price for options exercised during the period \$nil (2025: \$nil)

** Of the 164,400 outstanding options, none are currently exercisable (2025: nil)

Share options outstanding at the end of the year have the following expiry dates, exercise dates and exercise prices:

Expiry month	Exercisable month	Exercise price	2026	2025
May 2026	May 2024	3.46	-	-
May 2027	May 2025	3.46	-	-
May 2028	May 2026	3.46	164,400	164,400
Total share options outstanding			164,400	164,400

The weighted average remaining contractual life of options outstanding at the end of the period was 2.2 years (2025: 3.2 years)

	2026 \$'000	2025 \$'000
Share options reserve		
Balance at beginning of year	41	139
Current year amortisation	52	41
Options lapsed transferred to retained earnings	-	(139)
Balance at end of year	93	41

AP

The Company has a share option plan for employees of the Group. In accordance with the terms of the plan, as approved by the directors, certain employees on 5 May 2023 were granted share purchase options.

- Each employee share option converts into one ordinary share of the Company on exercise.
- No amounts are paid or payable by the recipient on receipt of the option.
- The options carry neither rights to dividends nor voting rights.
- Options may be exercised at any time from the date of vesting to the date of their expiry.
- The number of options granted is calculated in accordance with the performance-based formula approved by the directors at previous Board meetings.

The formula rewards employees to the extent of the Group's and the individual's achievement judged against both qualitative and quantitative criteria including the following financial and operational measures:

- Market share
- Net profit
- Target sales thresholds; and
- Product registration and licensing targets.

Staff share options are valued at fair value at the grant date as calculated using the Black Scholes model.

The fair value determined at the grant date of the equity-settled share-based payments is expensed on a straight-line basis over the vesting period, based on the Group's estimate of equity instruments that eventually vest, with a corresponding increase in equity. At the end of each reporting period, the Group revises its estimate of the number of equity instruments expected to vest. The impact of the revision of the original estimates, if any, is recognised in profit or loss such that the cumulative expense reflects the revised estimate, with a corresponding adjustment to the equity-settled employee benefits reserve.

21. Contingent Assets and Liabilities

The Group has provided a guarantee to Investec Limited for the lease premises AFT Pharmaceuticals (AU) PTY Limited occupies in Sydney, Australia. A deposit of AUD\$84,000 is held with NAB bank as security for this lease.

The Group has provided a guarantee to Robt Jones Investment Holdings Ltd of \$100,000 as security over the leased office premises at 129 Hurstmere Road, Takapuna, Auckland.

The Group placed NZD\$75,000 on term deposit with BNZ bank as security for a guarantee issued by BNZ in favour of the NZX.

22. Capital Commitments

The Group has no capital commitments at 31 March 2026 (31 March 2025: nil).

23. Financial Risk Management

Managing financial risk

The Group's activities expose it to various financial risks as detailed below.

• Market risk

Management is of the opinion that the Group's exposure to market risk at balance date is defined as:

Risk factor description	Description	Sensitivity
Currency risk	Exposure to changes in foreign exchange rates on assets, liabilities, revenue and expenses	As below
Interest rate risk	Exposure to changes in interest rates on borrowings	As below
Other price risk	No commodity securities are bought, sold or traded	Nil

• Foreign exchange risk

The Group benefits from the use of derivative financial instruments to manage foreign currency exposures. The fair value of forward exchange contracts is calculated by reference to current forward exchange rates at year end and the contract exchange rates, considered level 2 of the fair value hierarchy.

The Group sells and purchases goods and services to and from overseas customers and suppliers in several currencies, primarily AUD, USD, EUR and GBP which exposes the Group to foreign currency risk. The Group manages foreign currency risk through use of derivative arrangements, in particular forward exchange contracts. The exposure is monitored on a regular basis based on Group foreign exchange policies, which allow for up to 50% forward cover out for twelve months. Future revenues from markets outside Australasia will be denominated primarily in USD and EUR which will provide an increasing natural hedge against costs.

In the current year net foreign exchange losses totalled \$91k (2025: gain \$1,182k). The balance of gains/losses are derived from the restatement of monetary balances at the spot rate on the period-end balance date of 31 March 2026 and settlement of transactions during the period.

In total, the Group had financial assets and liabilities denominated in the following currencies:

Currency	2026		2025	
	Assets NZD\$'000	Liabilities NZD\$'000	Assets NZD\$'000	Liabilities NZD\$'000
AUD	52,936	6,450	41,353	4,859
USD	8,737	3,742	5,412	4,867
MYR	1,092	5	470	1
GBP	824	201	850	442
EUR	7,226	12,141	5,318	7,637
SGD	1,044	73	1,033	30
CNY	502	313	12	41
HKD	4	-	3	2
YEN	-	6	-	9
CAN	97	23	-	-
ZAR	869	289	-	-

The following forward foreign exchange contracts were held at 31 March 2026:

Forward Foreign Exchange Contracts

Buy currency	Buy currency amount '000	Sell amount NZD\$'000	Buy amount NZD\$'000	Fair value NZD\$'000
EUR	-	-	-	-
AUD	17,750	20,206	19,269	937
USD	-	-	-	-
Sell currency	Sell currency amount \$'000	Buy amount NZD\$'000	Sell amount NZD\$'000	Fair value NZD\$'000
AUD				-
Total asset as at 31 March 2026				-
Total liability as at 31 March 2026				937

The following forward foreign exchange contracts were held at 31 March 2025:

Forward Foreign Exchange Contracts

Buy currency	Buy currency amount '000	Sell amount NZD\$'000	Buy amount NZD\$'000	Fair value NZD\$'000
EUR	600	1,066	1,140	74
USD	500	816	874	58
Sell currency	Sell currency amount \$'000	Buy amount NZD\$'000	Sell amount NZD\$'000	Fair value NZD\$'000
AUD	11,400	12,580	12,520	60
Total asset as at 31 March 2025				192
Total liability as at 31 March 2025				-

• **Interest rate risk**

Borrowings are at a mixture of floating base rates plus a margin determined by the Group's performance against covenant adherence levels, which exposes the Group to cash flow interest rate risk. There are no specific derivative arrangements to manage this risk.

• **Credit risk**

Financial instruments, which potentially subject the Group to credit risk, principally consist of accounts receivable and cash and cash equivalents. Regular monitoring is undertaken to ensure that the credit exposure remains within the Group's normal terms of trade.

The Group has one significant concentration of credit risk at 31 March 2026, with the largest debtor being AU\$12.7m (31 March 2025: AU\$11.1m). The value is stated net of expected rebates. There has been no past experience of default and no indications of default in relation to this debtor.

The Group's cash and short-term deposits are placed with high credit quality financial institutions. Accordingly, the Group has no significant concentration of credit risk other than bank deposit. At balance date, bank deposits at each financial institution as a percentage of total assets were; an overdraft position with the Bank of New Zealand at 31 March 2026 (2025 1.9%), and 3.9% at NAB Bank (2025: 4.0%). The carrying value of financial assets represents the maximum exposure to credit risk.

• **Liquidity risk**

Liquidity risk is the risk that the Group may encounter difficulty in raising funds at short notice to meet its commitments and arises from the need to borrow funds for working capital. The directors monitor the risk on a regular basis and actively manage the cash available to ensure the net exposure to liquidity risk is minimised.

The liquidity/maturity profile of the liabilities (inclusive of derivative assets and liabilities) is as follows:

	< 1 year \$'000	1-2 years \$'000	2-5 years \$'000	> 5 years \$'000	TOTAL \$'000
31 March 2026					
Trade and other payables	(39,218)	-	-	-	(39,218)
Borrowings	(2,475)	(2,632)	(40,933)	-	(46,040)
Overdraft Facility	(9,884)	-	-	-	(9,884)
Related Party Loans	(1,694)	-	-	-	(1,694)
Lease liabilities	(1,107)	(780)	(1,742)	(427)	(4,056)
Derivative instruments (outbound)	(20,206)	-	-	-	(20,206)
Derivative instruments (inbound)	19,269	-	-	-	19,269
Total	(55,315)	(3,412)	(42,675)	(427)	(101,829)
	< 1 year \$'000	1-2 years \$'000	2-5 years \$'000	> 5 years \$'000	TOTAL \$'000
31 March 2025					
Trade and other payables	(33,105)	-	-	-	(33,105)
Borrowings	(2,248)	(27,015)	-	-	(29,263)
Lease liabilities	(1,073)	(948)	(1,772)	(1,271)	(5,064)
Related Party Loans	(1,083)	-	-	-	(1,083)
Derivative instruments (outbound)	(14,402)	-	-	-	(14,402)
Derivative instruments (inbound)	14,594	-	-	-	14,594
Total	(37,317)	(27,963)	(1,772)	(1,271)	(68,323)

Fair Values

The carrying values of trade receivables, trade payables and borrowings approximate their fair values because of their short terms to maturity or interest reset dates. Trade receivables are valued net of provision and trade payables are valued at their original amounts by contract.

24. Management of Capital

The Group's objectives when managing capital are to safeguard the Group's ability to continue as a going concern so that it can continue to provide returns to its shareholders and to maintain a strong capital base to support the development of its business. The Group meets these objectives through a mix of equity capital and borrowings. The level and mix of capital are determined by the Group's internal Corporate Governance policies.

Under the BNZ facility, there is a covenant requirement that the facility, comprising an overdraft and letter of credit facility, must not exceed the total of 70% of acceptable debtors plus 50% of acceptable stock. Additional covenants include a requirement for a minimum principal and interest cover ratio, a minimum net leverage ratio and a maximum capital expenditure (capex) and research and development (R&D) ratio. Covenant reporting is required on a quarterly basis. The Group was compliant with all BNZ covenants during the period.

25. Investment in Subsidiaries

	Interest held		Country of incorporation	Principal activities
	2026 %	2025 %		
AFT Pharmaceuticals (AU) Pty Ltd	100%	100%	Australia	Distribution of pharmaceuticals in Australia
AFT Pharmaceuticals (S.E. Asia) Sdn Bhd	100%	100%	Malaysia	Registration of pharmaceuticals in Malaysia
AFT Orphan Pharmaceuticals Limited	65%	65%	New Zealand	No activity
AFT Limited Partner Limited	100%	100%	New Zealand	Sole partner in Dermatology Specialties LP
Dermatology Specialties Limited Partnership	100%	100%	New Zealand	No activity
DSGP Limited	100%	100%	New Zealand	General partner of Dermatology Specialties LP
AFT Dermatology Limited	100%	100%	New Zealand	Distribution of pharmaceuticals
AFT Pharmaceuticals (EUR) Limited	100%	100%	Ireland	Distribution of pharmaceuticals in Europe
Kiwi Health Pty Ltd	100%	100%	Australia	Distribution of pharmaceuticals in Asia
AFT Pharma UK Limited	70%	70%	United Kingdom	Distribution of pharmaceuticals in UK
AFT Pharmaceuticals (HK) Limited	100%	100%	Hong Kong	No activity
AFT Pharmaceuticals (CAN) Limited	100%	100%	Canada	Distribution of pharmaceuticals in Canada
AFT Pharmaceuticals US Inc	100%	100%	USA	Distribution of pharmaceuticals in US
AFT Pharmaceuticals (SA) Limited	100%	100%	South Africa	Distribution of pharmaceuticals in SA
AFT Pharmaceuticals Sinoject Limited	70%	70%	New Zealand	Development and Licensing of Pharmaceuticals

AP

The consolidated financial statements incorporate the assets and liabilities and the results of the parent and its subsidiaries controlled during the period.

Subsidiaries are all entities over which the Group has control. The Group controls an entity when the Group is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power over the entity. Subsidiaries are fully consolidated from the date on which control is transferred to the Group. They are deconsolidated from the date that control ceases.

The acquisition method of accounting is used to account for the subsidiaries of the Group. The cost of an acquisition is measured as the fair value of the assets given, equity instruments issued and liabilities incurred or assumed at the date of exchange. Identifiable assets acquired and liabilities and contingent liabilities assumed in a business combination are measured initially at their fair values at the acquisition date. The excess of the cost of acquisition over the fair value of the Group's share of the identifiable net assets acquired is recorded as goodwill. If the cost of acquisition is less than the Group's share of the fair value of the identifiable net assets of the subsidiary acquired, the difference is recognised in profit or loss.

Inter-company transactions, balances and unrealised gains on transactions between subsidiary companies are eliminated. Unrealised losses are also eliminated unless the transaction provides evidence of the impairment of the asset transferred.

26. Significant Events After Balance Sheet Date

On 21 May 2026 the Board approved the payment of a dividend of 2.5 cents per share of approximately \$2.6 million.

On the 21st of April the Commissioner of Inland Revenue issued a private ruling under section 91 E of the Tax Administration Act, confirming the deductibility of product registration costs for tax purposes.

The Group is currently applying for amendments to returns filed for the 2019 to 2022 income years to claim tax deductions for capitalised registration costs not previously claimed supported by the positive binding ruling. Reductions in income tax payable will be accounted in the year IRD approves amendments if applicable

There were no other significant events after balance sheet date.

27. Related Parties

The Group had related party relationships with the following entities:

Related party	Nature of relationship
Atkinson Family Trust	AFT Chief Executive Officer, Hartley Atkinson, is a Trustee / Discretionary Beneficiary of Atkinson Family Trust. AFT Chief of Staff, Marree Atkinson, is a Discretionary Beneficiary of Atkinson Family Trust
Edge Group	Minority shareholder of AFT Pharma UK Limited. Related party loan (see note 14)

	2026 \$'000	2025 \$'000
Key management compensation		
Director fees	542	503
Executive salaries	1,809	1,756
Short term benefits	467	480
Key management compensation	2,818	2,739
Related Party Loan	1,694	1,083

Key management includes external directors, the Chief Executive Officer, the Chief of Staff, the Chief Financial Officer and the Director of International Business Development. These positions are mainly responsible for planning, controlling and directing the activities of the business.

Total remuneration of \$308k was paid by the Group to close family members of the key management personnel for individuals that were employed by the Group in the year ended 31 March 2026 (2025: \$264K)

Statutory Disclosures

DIRECTOR INTEREST DISCLOSURES

Shareholder Director Officer or Trustee

Directors have given general notices disclosing interests in the Company's Interest Register pursuant to section 140(2) of the Companies Act 1993. All of those interests (and any changes to interests) notified and recorded in the Interests Register during the financial year ended 31 March 2026 are set out below:

Director	Entity	Relationship
Hartley	AFT Orphan Pharmaceuticals Limited	Director
Atkinson	AFT Pharmaceuticals (AU) Pty Limited	Director
	AFT Pharmaceuticals (SE Asia) SDN BHD	Director
	Atkinson Family Trust	Trustee and Discretionary Beneficiary of the trust which holds shares in AFT
	AFT Limited Partner Limited	Director
	DSGP Limited	Director
	Dermatology Specialties, L.P.	Partner Limited
	AFT Dermatology Limited	Director
	AFT Pharmaceuticals (EUR) Limited	Director
	AFT Pharma UK Limited	Director
	Kiwi Health Pty Limited	Director
	AFT Pharmaceuticals (HK) Limited	Director
	AFT Pharmaceuticals (CAN) Limited	Director
	AFT Pharmaceuticals US, Inc	Director
	AFT Pharmaceuticals SA (Pty) Limited	Director
	AFT Pharmaceuticals Sinoject Limited	Director
	Hama Holdings	Director
Marree Atkinson	Atkinson Family Trust	Discretionary Beneficiary of the trust, which holds shares in AFT
	HAMA Holdings	Director
David Flacks	Vero Liability Insurance New Zealand Limited	Director and Chairman (Ceased September 2025)
	Flacks & Wong Limited	Director
	Vero Insurance New Zealand Limited	Chairman and Director (Ceased September 2025)
	Todd Corporation Limited	Director and Chairman (Assumed Chair September 2025)
	Angel Association of New Zealand	Chairman
Ted Witek	Trudell Medical International	Director
	Lumira Ventures	Special advisor
	TCB	Capital advisor
	Kuano Limited	Director
Allison Yorston	Suntory Beverage & Food Oceania	Chief Marketing Officer (Ceased 11 April 2025)
	Griffins Snacks	Director of Marketing, Griffins Snacks (14 Apr 2025)

Interest in Transactions With the Company and Use of Information

No directors have disclosed interests in transactions (1) of the Companies Act 1993 during the financial year requested to disclose or use Company Information required under section 145 (3) of the Companies Act.

Acquisitions or Disposals of Shares in AFT

During the year ending 31 March 2026, the following in AFT ordinary shares as required under sections 146-149:

- on 1 September 2025 David Mark Flacks & Adina Rita Betty Halpern as trustees of Waitemata Family Trust disclosed the acquisition of 17,722 shares
- on 4 July 2025 and 27 June respectively Hartley Atkinson (jointly with Colin McKay) as trustees of the Atkinson Family Trust, disclosed the acquisition of 17,755 shares in AFT and then 200,000 shares in AFT.

Relevant Interests in AFT's Shares

In accordance with the NZX Listing Rule 3.7.1 (d), at 31 March 2026 Directors had a relevant interest in AFT ordinary shares as follows:

Director	Shareholder	Number	Share of issued capital
Hartley Atkinson	Hartley Atkinson & Colin McKay	72,259,496	68.91%
	Hama Holdings Limited	867,826	0.86%
David Flacks	David Mark Flacks & Adina Rita Betty Halpern	158,764	0.15%
	JBWere (NZ) Nominees Limited	37,722	0.02%
Andrew Lane	Andrew Hamish Lane	95,000	0.091%

Remuneration and Other Benefits

Directors' remuneration and other benefits in the financial year ended 31 March 2026 are detailed in on pages 59 to 63 of this report. For the purposes of section entries were made in the Interests Register in relation to Directors during the financial year ended 31 March 2026.

Director	Remuneration and other benefits
David Flacks, Andrew Lane, Ted Witek	The increase in Directors fees to take effect on 1 April 2025, on the terms set out in the 20 May 2025 Board paper.
Hartley Atkinson, Marree Atkinson	The payment of remuneration and the provision of other benefits by the Company to each of Hartley Atkinson and Marree Atkinson on the terms set out in a letter of amendment to the relevant employment agreement and the 20 May 2025 Board paper.
Hartley Atkinson, Marree Atkinson	The payment of Short-Term Incentive (STI) remuneration by the Company to each of Hartley Atkinson and Marree Atkinson on the terms set out in a letter of STI notification.

Indemnity and Insurance

For the purposes of section 162 of the Companies Act 1993, an entry was made in the Interests Register in relation to insurance effected for Directors of AFT, in relation to any act or omission in their capacity as Directors on 31 October 2025. AFT provides insurance for Directors of AFT, in relation to any act or omission in their capacity as Directors on 31 October 2025 and costs incurred by that Director in relation to defending and settling a claim.

Subsidiary Company Directors

The following table lists the subsidiaries of AFT and the people held office as Directors of subsidiary companies as at 31 March 2026:

Subsidiary	Directors
AFT Pharmaceuticals (AU) Pty Limited	Hartley Atkinson, Raymond MacGregor, Donald Mackenzie.
AFT Pharmaceuticals (EUR) Limited	Hartley Atkinson, Eddie Townsley
AFT Pharma UK Limited	Hartley Atkinson, Vivian Hansen, Samer Taslaq.
AFT Pharmaceuticals (SE Asia) SDN BHD	Hartley Atkinson, Dion Seng Peng
AFT Limited Partner Limited	Hartley Atkinson
DSGP Limited	Hartley Atkinson
Dermatology Specialties, L.P.	DSGP
AFT Dermatology Limited	Hartley Atkinson
Kiwi Health Pty Limited	Hartley Atkinson, Raymond MacGregor.
AFT Pharmaceuticals (HK) Limited	Hartley Atkinson
AFT Pharmaceuticals (CAN) Limited	Hartley Atkinson
AFT Pharmaceuticals US, Inc	Hartley Atkinson
AFT Orphan Pharmaceuticals Limited	Hartley Atkinson, Andrew Moore, Giles Moss, Malcolm Tubby
AFT Pharmaceuticals (SA) Limited	Hartley Atkinson, Vivian Hansen
AFT Pharmaceuticals Sinoject Limited	Hartley Atkinson

Shareholdings

As at 30 April 2026 there were 104,866,260 ordinary shares on issue, each conferring on the registered holder the right to vote on any resolution at a meeting of shareholders, held as follows:

Size of shareholding	Holders	Proportion of total holders	Shares	Share of issued capital
1 - 1,000	894	45.31%	363,547	0.35%
1,001 - 5,000	648	32.84%	1,677,277	1.60%
5,001 - 10,000	225	11.40%	1,682,111	1.60%
10,001 - 50,000	156	7.91%	3,386,429	3.23%
50,001 - 100,000	21	1.06%	1,494,745	1.43%
100,001 - and over	29	1.47%	96,262,151	91.80%

As at 30 April 2026 there were 12 individuals holding a total of 164,400 options to acquire shares issued by AFT under its employee long-term incentive scheme. The options are unlisted and carry no voting rights.

Subsidiary Directors Remuneration

- Raymond McGregor received A\$12,000 during the year ended 31 March 2026 in his capacity as a Director of AFT Pharmaceuticals (AU) Pty limited.
- Donald MacKenzie received A\$50,000 during the year ended 31 March 2026 in his capacity as a Director of AFT Pharmaceuticals (AU) Pty limited.
- JED Pharma received EUR\$12,000 during the year ended 31 March 2026 in relation to Eddie Townsley acting as Directors of AFT Pharmaceuticals (EUR) Limited.

Top 20 Shareholders

The top twenty holders of AFT's ordinary shares as at 30 April 2026 are as follows:

Name	Shares	Share of issued capital
Hartley Atkinson & Colin Mckay	72,259,496	68.91%
Accident Compensation Corporation - NZCSD	7,397,399	7.05%
Forsyth Barr Custodians Limited	5,366,681	5.12%
Hsbc Nominees A/C Nz Superannuation Fund Nominees Limited - NZCSD	1,687,342	1.61%
Bnp Paribas Nominees (NZ) Limited - NZCSD	1,035,696	0.99%
Bnp Paribas Nominees (NZ) Limited - NZCSD	1,009,539	0.96%
New Zealand Depository Nominee Limited	916,622	0.87%
Queen Street Nominees Ltd No.6 - NZCSD	901,087	0.86%
Hama Holdings Limited	867,826	0.83%
Forsyth Barr Custodians Limited	845,129	0.81%
Queen Street Nominees Ltd No.2 - NZCSD	414,254	0.40%
Garrett Smythe Limited	390,912	0.37%
Custodial Services Limited	332,205	0.32%
FNZ Custodians Limited	328,622	0.31%
Jp Morgan Nominees Australia Limited	300,000	0.29%
Hsbc Nominees (New Zealand) Limited - NZCSD	223,644	0.21%
Joeri Yvonne Jozef Sels	212,832	0.20%
Queen Street Nominees Ltd No.4 - NZCSD	202,699	0.19%
Jbwere (NZ) Nominees Limited	201,040	0.19%
David Mark Flacks & Adina Rita Betty Halpern	158,764	0.15%

Substantial Product Holders

According to notices given to AFT under the Financial Markets Conduct Act 2013, the following persons were substantial product holders in AFT at 31 March 2026 in respect of the number of quoted voting products noted below. As at the balance date 31 March 2026 there were 104,866,260 ordinary shares on issue:

Substantial Product Holder	Number of ordinary shares in which the relevant interest is held	Share of class held as at the date of last notice
Hartley Campbell Atkinson and Colin McKay as Trustees of the Atkinson Family Trust	72,259,496	68.91%
Accident Compensation Corporation (ACC)	7,397,399	7.05%

NZX Waivers and Exercise of Powers

NZX RegCo did not grant any Waivers specific to AFT during the financial year ending 31 March 2026. Similarly, NZX did not exercise any of its powers under NZX Listing Rule 9.9.3 to cancel, halt or suspend the listing or quotation of AFT's Quoted Financial Products, or refer AFT, any of its Directors, or any Associated Person to the NZX Markets Disciplinary Tribunal or any statutory or government body.

Donations

During the financial reporting period AFT contributed \$5,000 to North Shore MP Simon Watts

Credit Rating

AFT does not currently have an external credit rating status.

For personal use only

APPENDICES

APPENDIX 1

CLIMATE RESILIENCE

METRICS AND TARGETS

GHG Emissions

GHG emissions are presented as tonnes of carbon dioxide equivalents (t CO₂e).


AFT Pharmaceuticals FY26 GHG Emissions by Region (t CO₂e)

Scope	Category	AFT (Consolidated) t CO ₂ e	NZ	AU	UK	US	CAN	HK	EU	ASIA
Scope 1	Mobile combustion	271.10	33.82	237.28	-	-	-	-	-	-
	Total Scope 1	271.10	33.82	237.28	-	-	-	-	-	-
Scope 2	Purchased electricity (location-based)	17.14	9.17	7.97	-	-	-	-	-	-
	Purchased electricity (market-based)	20.38	10.29	10.09	-	-	-	-	-	-
	Total Scope 2 (location-based)	17.14	9.17	7.97	-	-	-	-	-	-
	Total Scope 2 (market-based)	20.38	10.29	10.09	-	-	-	-	-	-
	Category 3: Fuel and energy- related activities	67.84	9.01	58.83	-	-	-	-	-	-
Scope 3	Category 4: Upstream transportation and distribution	2,340.56	1,146.95	991.44	0.73	129.99	2.53	21.09	47.41	0.42
	Category 6: Business travel	231.39	142.48	88.80	0.11	-	-	-	-	-
	Category 7: Employee commuting	59.98	49.89	7.93	2.16	-	-	-	-	-
	Total Scope 3	2,699.76	1,391.32	1,392.24	3.00	129.99	2.53	21.09	47.41	0.42
Total GHG Emissions (location-based)		2,988.00	1,391.32	1,392.24	3.00	129.99	2.53	21.09	47.41	0.42
Total GHG Emissions (market-based)		2,991.24	1,392.44	1,394.36	3.00	129.99	2.53	21.09	47.41	0.42

Measurement Details

Detail	Approach
Measurement period	1st April 2025 to 31st March 2026
Base year	1st April 2023 to 31st March 2024 (FY24)
Assurance	Reasonable assurance issued by Toitū Envirocare
Preparation standard	GHG Protocol Corporate Accounting and Reporting Standard (2004)
Consolidation approach	Operational Control consolidation approach
Organisational boundaries	AFT Pharmaceuticals Limited and each of its subsidiaries are included in the inventory. No entities have been excluded.
Emissions factors and Global Warming Potential (GWP) sources	NZ Ministry for the Environment 2025 (IPCC Fifth Assessment Report, GWP100); BraveTrace Residual Supply Mix 2023/24; Australia DCCEW 2025 (IPCC Fifth Assessment Report, GWP100)
Calculations	<p>GHG emissions were calculated using the following methodology: GHG emissions = activity data x emissions factor</p> <p>Where applicable, unit conversions applied when processing the activity data has been disclosed.</p> <p>There are systems and procedures in place that will ensure applied quantification methodologies will continue in future GHG emissions inventories.</p>
Exclusions	<p>Refrigerant leakages have been excluded as an emission source from our scope 1 inventory as it has been identified as de minimis (<1%). No facilities, operations or assets have been excluded from the Scope 1 and 2 inventory.</p> <p>Category 1: Purchased goods and services, Category 5: Waste generated in operations, Category 8: Downstream transportation and distribution, and Category 12: End-of-life treatment of sold products have been excluded from the Scope 3 inventory.</p>
Uncertainty	There is inherent uncertainty in measuring GHG emissions as the methodologies used are based on estimates, judgements and limited data. GHG quantification is subject to inherent uncertainty because of incomplete scientific knowledge used to determine emissions factors and the values needed to combine emissions of different gases.

GHG Emissions Reporting Boundaries



■ New Zealand Registered entities ■ Overseas registered entities □ Climate Reporting Operational Boundary

New Zealand and Australia form the primary operations within the GHG emissions reporting boundary. AFT’s other operations are distribution-based and do not include physical offices, controlled facilities, or vehicle fleets. As a result, there are no Scope 1 or Scope 2 emissions associated with these locations. Emissions related to these activities are primarily captured within Scope 3, reflecting the outsourced and value chain nature of these operations.

For personal use only

Emission Sources, Methodologies, Uncertainties, and Assumptions

AFT's emissions inventory is prepared on a 10+2 basis. Actual consumption and activity data is collected for the period 1 April 2025 – 31 January 2026. Emissions for the remaining two months (February, March) are estimated by applying average monthly emission intensities from the preceding 10-month period, adjusted where known material changes in operational activity are identified.

This method is applied consistently across all reported emission scopes and categories. Estimated figures are reconciled against actuals in the following year's inventory, with any material variances noted as prior-period adjustments, consistent with the GHG Protocol's guidance on recalculation.

Emission source	Activity	Methodologies, uncertainties and assumptions	Emission factor source
Scope 1			
Category: Direct emissions and removals			
Mobile combustion	Regular petrol; Premium petrol; Diesel	<p>Activity data has been sourced from supplier reports and internal finance systems.</p> <p>We have assumed all supplier reports are accurate and all additional fuel spend has been captured within our internal financial tracking systems.</p> <p>There is a high level of uncertainty in regard to the spend based activity data relative to the fuel card report, but it represents a smaller proportion of activity.</p> <p>Activity data was only available for 10 months of the reporting period. This has been extrapolated out to 12 months. We believe the available activity data is a fair representation of activity, but applying a 10+2 approach presents inherent uncertainty.</p>	Ministry for the Environment 2025 Guide (IPCC Fifth Assessment Report, GWP100)
Scope 2			
Category: Imported emissions from imported energy			
Purchased electricity	Purchased electricity	<p>Activity data has been sourced from supplier invoices.</p> <p>We have assumed all supplier invoices are accurate and electricity usage has been captured.</p> <p>Data was only available for 11 months of the reporting period for New Zealand specific data and 10 months for Australian specific data. These have been extrapolated out to 12 months. We believe the available activity data is a fair representation of activity, but applying a 10+2 approach presents inherent uncertainty.</p>	<p>Ministry for the Environment 2025 Guide (IPCC Fifth Assessment Report, GWP100)</p> <p>BraveTrace Residual Supply Mix 2024/25</p> <p>Australia DCCEW 2025 (IPCC Fifth Assessment Report, GWP100)</p>
Scope 3			
Category 3: Fuel and energy related activities			
Transmission losses	Electricity T&D losses	<p>Activity data has been sourced from supplier invoices.</p> <p>We have assumed all supplier invoices are accurate and electricity usage has been captured.</p> <p>Data was only available for 11 months of the reporting period for New Zealand specific data and 10 months for Australian specific data. These have been extrapolated out to 12 months. We believe the available activity data is a fair representation of activity, but applying a 10+2 approach presents inherent uncertainty.</p>	<p>Ministry for the Environment 2025 Guide (IPCC Fifth Assessment Report, GWP100)</p> <p>Australia DCCEW 2025 (IPCC Fifth Assessment Report, GWP100)</p>

Emission source	Activity	Methodologies, uncertainties and assumptions	Emission factor source
Well-to-tank of mobile fuel combusted	Well-to-tank (petrol), Well-to-tank (diesel)	<p>Activity data has been sourced from supplier reports and internal finance systems.</p> <p>We have assumed all supplier reports are accurate and all additional fuel spend has been captured within our internal financial tracking systems.</p> <p>There is a high level of uncertainty in regard to the spend based activity data relative to the fuel card report, but it represents a smaller proportion of activity.</p> <p>Activity data was only available for 10 months of the reporting period. This has been extrapolated out to 12 months. We believe the available activity data is a fair representation of activity, but applying a 10+2 approach presents inherent uncertainty.</p>	Australia DCCEW 2025 (IPCC Fifth Assessment Report, GWP100)

Category 4: Upstream transportation and distribution

Upstream freight	Road freight; Air Travel Freight: Short haul, Air Travel Freight: Long haul, Sea Freight	<p>Activity data has been sourced from supplier reports and information.</p> <p>We have assumed all supplier reports and information is accurate and all activity has been captured.</p> <p>In some instances, judgements have been made and distance travelled for consignments has been assumed.</p> <p>Default emission factors have been used are not vehicle specific which presents uncertainty.</p> <p>Activity data was only available for 10 months of the reporting period for some suppliers. This has been extrapolated out to 12 months. We believe the available activity data is a fair representation of activity, but applying a 10+2 approach presents inherent uncertainty.</p>	Ministry for the Environment 2025 Guide (IPCC Fifth Assessment Report, GWP100)
------------------	---	--	--

Category 6: Business travel

Staff air travel	Domestic, Int. Economy (<3,700km), Int. Business (<3,700km), Int. Economy (>3,700km), Int. Business (>3,700km)	<p>Activity data has been sourced from expense claims.</p> <p>We have assumed all supplier reports are accurate and all activity has been captured.</p> <p>Where domestic travel occurred outside of New Zealand, this has been measured as Int. Economy (<3,700km).</p> <p>Activity data was only available for 10 months of the reporting period. This has been extrapolated out to 12 months. We believe the available activity data is a fair representation of activity, but applying a 10+2 approach presents inherent uncertainty.</p>	Ministry for the Environment 2025 Guide (IPCC Fifth Assessment Report, GWP100)
------------------	--	--	--

Emission source	Activity	Methodologies, uncertainties and assumptions	Emission factor source
Staff accommodation	Accommodation New Zealand, Canada, China, France, Hong Kong, Japan, Singapore, United States, Australia, United Kingdom	<p>Activity data has been sourced from expense claims.</p> <p>Number of nights per country is calculated using a default cost per night.</p> <p>Assumes all accommodation is expensed correctly.</p> <p>Activity data was only available for 10 months of the reporting period. This has been extrapolated out to 12 months. We believe the available activity data is a fair representation of activity, but applying a 10+2 approach presents inherent uncertainty.</p>	Ministry for the Environment 2025 Guide (IPCC Fifth Assessment Report, GWP100)
Staff road travel	Uber, Taxis, or other rideshare, Rental Vehicle (Petrol)	<p>Activity data has been sourced from supplier reports.</p> <p>We have assumed all supplier reports are accurate and all activity has been captured.</p> <p>For rental vehicle activity, 50km travelled per day is assumed.</p> <p>Activity data was only available for 10 months of the reporting period. This has been extrapolated out to 12 months. We believe the available activity data is a fair representation of activity, but applying a 10+2 approach presents inherent uncertainty.</p> <p>Default factors have been used and are not vehicle specific which presents uncertainty.</p>	Ministry for the Environment 2025 Guide (IPCC Fifth Assessment Report, GWP100)
Category 7: Employee commuting			
Employee commuting	Personal petrol vehicle, public bus	<p>Activity data has been sourced from a commuting survey conducted internally.</p> <p>They survey participants included 10 staff members. Total employee commuting kms were extrapolated out represent all employee commuting.</p> <p>Assumes the survey responses are representative of the commuting behaviours of all AFT employees. Assumes survey participants provided accurate responses about commuting behaviours. Assumes participants' commuting behaviours are consistent over the reporting period. Assumes AFT's employee count remains static over the reporting period. Assumes employees are working in the office 230 times a year.</p> <p>High level of uncertainty as sample data has been used and employee commuting behaviours are likely to be inconsistent across the reporting period. Default factors have been used and are not vehicle specific which presents uncertainty.</p>	Ministry for the Environment 2025 Guide (IPCC Fifth Assessment Report, GWP100)

GHG Emissions Targets

As disclosed in last year's Annual Report, AFT set greenhouse gas (GHG) emissions reduction targets. These targets apply to AFT's UK subsidiary operations, reflecting specific requirements within that market. While AFT maintains emissions data across its broader operations, the establishment of formal emissions reduction targets has to date been limited to the UK business. AFT will continue to review the scope of its targets over time.

Term	Coverage	Performance against target	Alignment with limiting warming to 1.5 degrees Celsius	Use of offsets
Target Commitment 1:				
Reduce UK scope 1 GHG emissions by 42% by 2030 on a FY24 base year.				
Near-term	100% of scope 1	22.16% absolute decrease on FY24	<p>These targets have been set using the Science Based Targets initiative (SBTi) Corporate Near-Term Criteria. The target method used is the cross-sector absolute contraction approach.</p> <p>The scope 1 and 2 targets are consistent with reductions required to limit warming to below 1.5 degrees Celsius.</p>	Achievement of these targets do not rely on offsets.
Target Commitment 2:				
Reduce UK scope 2 (market-based) GHG emissions by 42% by 2030 on a FY24 base year.				
Near-term	100% of scope 2	15.01% absolute increase on FY24	The scope 1 and 2 targets are consistent with reductions required to limit warming to below 1.5 degrees Celsius.	Achievement of these targets do not rely on offsets.
Target Commitment 3:				
Reduce UK scope 3 GHG emissions by 42% by 2030 on a FY24 base year.				
Near-term	100% of scope 3*	Not reported as FY26 is the inaugural year AFT is reporting its GHG emissions by jurisdiction.	<p>The scope 3 targets are consistent with reductions to limit warming to below 1.5 degrees Celsius, but do not meet the SBTi's minimum boundary requirements as only a limited number of scope 3 emission sources are included.</p> <p>While the targets have been developed in line with this methodology by using the SBTi's publicly available Corporate Near-Term Criteria and Corporate Near-Term Tool, the targets have not been submitted to or validated by the SBTi.</p>	
Target Commitment 4:				
Reduce UK absolute scope 1, 2, and 3 GHG emissions by 90% by 2050 on a FY24 base year and neutralise residual GHG emissions through use of permanent removals.				
Long-term	100% of scope 1, 2, and 3*	Not reported as FY26 is the inaugural year AFT is reporting its GHG emissions by jurisdiction	<p>This target has been set using the Science Based Targets initiative (SBTi) Corporate Net-Zero Standard. The target method used is the cross-sector absolute reduction pathway, which is consistent with the reductions required to limit warming to below 1.5 degrees Celsius.</p> <p>The scope 3 boundary does not meet the SBTi's scope 3 minimum boundary requirements as only a limited number of scope 3 emission sources are included. While the target has been developed in line with this methodology by using the SBTi's publicly available Corporate Net-Zero Standard Criteria and Corporate Net-Zero Tool, the targets have not been submitted to or validated by the SBTi.</p>	<p>Achievement of the 90% reduction does not rely on offsets.</p> <p>The residual unabated 10% will be neutralised through the use of permanent removals and storage.</p>

* Limited categories only.

Industry-Based Metrics

Emission source	Scope	Unit	Consumption		
			FY24	FY25	FY26
Regular petrol	1	L	125,648.71	105,365.89	97,547.59
Premium petrol	1	L	15,201.70	14,057.29	15,326.44
Diesel	1	L	1,115.99	2,428.62	558.19
Electricity	2	kWh	117,787.00	111,610.99	103,130.69
Electricity T&D losses	3	kWh	-	-	103,130.69
Well-to-tank Petrol	3	L	-	-	112,874.03
Well-to-tank Diesel	3	L	-	-	558.19
Freight movements	3	tkm	-	-	36,419,485.50
Staff air travel	3	pkm	-	-	1,215,937.13
Staff hotel accommodation	3	Room per night	-	-	716.89
Staff road travel - ubers/taxis	3	\$	-	-	19,978.63
Staff road travel - Mileage reimbursements and rental vehicles	3	km	-	-	18,260.42

AFT has not reported HFC-134A refrigerant due to this emission source being excluded from our GHG emissions inventory on the basis that this has been identified as de minimis (<1%).

INDEPENDENT AUDIT OPINION

Toitū Verification

To the intended users

Organisation subject to audit: AFT Pharmaceuticals Limited

Greenhouse Gas Protocol: A Corporate Accounting and Standard (2004), GHG Protocol: Scope 2 Guidance, Greenhouse Gas Protocol: Corporate Value Chain

Audit Criteria: (Scope 3) Accounting and Reporting Standard
ISO 14064-3:2019
Technical Requirements – Audit V3

Responsible Party: AFT Pharmaceuticals Limited

Intended users: Senior leadership team
General public

Registered address: Level 1, 129 Hurstmere Road, Takapuna, Auckland, 0622, New Zealand

Inventory period: 1/04/2025 - 31/03/2026

Inventory report: AFT Pharmaceuticals - Emissions Inventory Report FY26.pdf

We have reviewed the greenhouse gas emissions inventory report (“the inventory report”) for the above named Responsible Party for the stated inventory period.

Responsible Party's Responsibilities

The Management of the Responsible Party is responsible for the preparation of the GHG statement in accordance with Greenhouse Gas Protocol. This responsibility includes the design, implementation and maintenance of internal controls relevant to the preparation of a GHG statement that is free from material misstatement.

Responsibilities of verifiers

Our responsibility as verifiers is to express a verification opinion to the agreed level of assurance on the GHG statement, based on the evidence we have obtained and in accordance with the audit criteria. We conducted our verification engagement as agreed in the audit letter, which define the scope, objectives, criteria and level of assurance of the verification.

The International Standard ISO 14064-3:2019 requires that we comply with ethical requirements and plan and perform the verification to obtain the agreed level of assurance that the GHG emissions, removals and storage in the GHG statement are free from material misstatement.

Reasonable assurance is a high level of assurance, but is not a guarantee that an audit carried out in accordance with the ISO 14064-3:2019 Standards will always detect a material misstatement when it exists. The procedures performed on a limited level of assurance vary in nature and timing from, and are less in extent compared to reasonable assurance, which is a high level of assurance. The procedures performed on a limited level of assurance vary in nature and timing from, and are less in extent compared to reasonable assurance, which is a high level of assurance. Misstatements are differences or omissions of amounts or disclosures, and can arise from fraud or error. Misstatements are considered material if, individually or in the aggregate, they could reasonably be expected to influence the decisions of readers, taken on the basis of the information we audited.

GHG quantification is subject to inherent uncertainty because of incomplete scientific knowledge used to determine emissions factors and the values needed to combine emissions of different gases.

Basis of verification opinion

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Verification

We have undertaken a verification engagement relating to the Greenhouse Gas Emissions Inventory Report (the 'Inventory Report')/Emissions Inventory and Management Report of the organisation listed at the top of this statement and described in the emissions inventory report for the period stated above.

The Inventory Report provides information about the greenhouse gas emissions of the organisation for the defined measurement period and is based on historical information. This information is stated in accordance with the requirements of Greenhouse Gas Protocol: A Corporate Accounting and Standard (2004), GHG Protocol: Scope 2 Guidance, Greenhouse Gas Protocol: Corporate Value Chain (Scope 3) Accounting and Reporting Standard.

Verification strategy

Our verification strategy used a combined data and controls testing approach. Evidence-gathering procedures included but were not limited to:

- activities to inspect the completeness of the inventory;
- interviews of site personnel to confirm operational behaviour and standard operating procedures;
- reviewing emission factors for accuracy and appropriateness;
- reconciliation of air and sea freight related emissions;

The data examined during the verification were historical in nature.

Basis for modified verification opinion

The following qualifications have been raised in relation to the verification opinion:

The opinion is unmodified.

Verification level of assurance

GHG PROTOCOL CATEGORIES

GHG SCOPE	LOCATION BASED tCO ₂ e	MARKET BASED tCO ₂ e	LEVEL OF ASSURANCE
Scope 1	271.10	271.10	Reasonable
Scope 2	17.14	20.38	Reasonable
Scope 3	2,699.76	2,699.76	Limited
TOTAL INVENTORY	2,988.00	2,991.24	

Responsible party's greenhouse gas assertion (claim)

AFT Pharmaceuticals Limited has measured its greenhouse gas emissions in accordance with GHG Protocol in respect of operations of its global organisation.

Verification conclusion

GHG Protocol

EMISSIONS - REASONABLE ASSURANCE

We have obtained all the information and explanations we have required. In our opinion, the emissions, removals and storage defined in the inventory report, in all material respects:

- comply with GHG Protocol: A Corporate Accounting and Reporting Standard ; and
- provide a true and fair view of the emissions inventory of the Responsible Party for the stated inventory period.

EMISSIONS - LIMITED ASSURANCE

Based on the procedures we have performed and the evidence we have obtained, nothing has come to our attention that causes us to believe that the emissions, removals and storage defined in the inventory report:



- do not comply with GHG Protocol: A Corporate Accounting and Reporting Standard ; and
- do not provide a true and fair view of the emissions inventory of the Responsible Party for the stated inventory period.

Other information

The responsible party is responsible for the provision of Other Information. The Other Information may include emissions management and reduction plan and purchase of carbon credits, but does not include the information we verified, and our auditor's opinion thereon.

Our opinion on the information we verified does not cover the Other Information and we do not express any form of audit opinion or assurance conclusion thereon. Our responsibility is to read and review the Other Information and consider it in terms of the inventory. In doing so, we consider whether the Other Information is materially inconsistent with the information we verified or our knowledge obtained during the verification.



	VERIFIED BY	AUTHORISED BY
Name:	Sen Ma	Ana Tatana
Position:	Verifier, Toitū Envirocare	Certifier, Toitū Envirocare
Signature:		

Date verification audit:

1 April 2026

Date opinion expressed:

20 April 2026

7 May 2026

APPENDIX 2

MATERIAL SUSTAINABILITY DEFINITION MATTERS

AFT has built its Sustainability Framework and ESG reporting programme on a robust process of assessing what is material to the company. As a publicly listed company, 'material' matters are those that a reasonable person would consider impacting the company's valuation or the sustainability of our operations.

In line with best practice ESG standards, we also considered those topics that reflect AFT's most significant impacts on the economy, environment, and people. We have followed a robust process to identify and manage the material sustainability matters. Our definitions of them are set out below.

Definition	Description
Consumer/patient good health	<ul style="list-style-type: none"> • Responsive to customer needs, health sector developments, and tracking consumer trends and purchasing habits. • Expanding the range of products aimed at enhancing the health and well-being of consumers. • Enhancing the proper use of products by healthcare professionals and patients. • Creating business value and social impact through the use of medicines. This topic includes AFT providing products that can provide alternative pain relief to opioids.
Product quality and safety of medicines	<ul style="list-style-type: none"> • Ensuring product safety and quality, including through design, traceability of materials, manufacture, communications, and reporting. • Disclosure of safety information. • Preventing the distribution of counterfeit drugs. • Mitigating the risk of a product recall, liability issues, loss of reputation, and reduced revenue. Relationships with regulators and regulatory compliance.
Product innovation / R&D	<ul style="list-style-type: none"> • Creating innovative medicines and medical solutions in areas with high unmet medical needs. Creating future value for the business. • Ensuring R&D and testing are done safely and in compliance with all regulatory requirements. • Ensuring the mental and physical health of employees and clinical trial participants. Meeting all animal welfare requirements.
Corporate governance, compliance, and transparency	<ul style="list-style-type: none"> • A commitment to comply with all laws, including competition laws and best practice governance and the recommended governance codes and rules that apply in each region. • Monitoring the supply chain for the same. • Compliance and transparency also refer to cyber security and privacy. • The independence and effectiveness of the Board of Directors are regularly reviewed. • Directors understand and monitor ESG strategy, metrics, and performance, including climate-related risks.
Ethical and sustainable supply chains (including environmental and labour standards)	<ul style="list-style-type: none"> • Working with suppliers on sustainability performance and managing risks for AFT's brand and operations. This is across the areas of ethics, labour, environment, health and safety, and management systems. Specifically on labour, this includes ensuring compliance with AFT's Modern Slavery Policy. On environment, this includes supplier compliance with our Supplier Code of Conduct, which includes water use.

Definition	Description
Ethical business practices (including anti-bribery & corruption, sales and marketing practices, lobbying)	<ul style="list-style-type: none"> • Policies and practices to prevent bribery, corruption, counterfeiting, and conflicts of interest. • A culture of openness and support with raising concerns. Ethical marketing - codes of ethics and shareholder transparency.
Employee health, safety, and wellbeing	<ul style="list-style-type: none"> • Ensuring compliance with local health and safety regulations. • Emergency and disaster preparedness, safe machinery, equipment and facilities, staff training, biosafety, and protection from hazardous substances and chemicals. Supportive return to work or post-accident policies. • Requiring best practices in the supply chain through Supplier Code of Conduct.
Workforce (Diversity and Inclusion, Retaining and Attraction)	<ul style="list-style-type: none"> • Ensuring equal opportunity regardless of race, nationality, gender, sexual orientation, age, religion, or disability, including into positions within management, the Board of Directors. Pay parity assessments are in place. • Policies to prevent sexual harassment and workplace bullying, a safe and supportive complaints process, code of conduct, and flexible working. Whistleblowing policy. Policies in place to attract and retain highly skilled employees.
Access to medicines	<ul style="list-style-type: none"> • Ensuring a stable and resilient supply of products to patients. Prioritising R&D in areas of specific need.
Climate change	<ul style="list-style-type: none"> • Climate change mitigation (reducing emissions through the value chain), climate change adaptation (assessing risks to the value chain associated with a changing climate), reporting emissions and climate-related risks, and compliance with regulatory requirements (Financial Sector (Climate-related Disclosures and Other Matters) Amendment Act).
Packaging (consumer and supply chain)	<ul style="list-style-type: none"> • Taking a life-cycle approach to packaging from manufacture to disposal, particularly of supply-chain/distribution packaging, consumer packaging, and hospital packaging

Directory

AFT is a company incorporated with limited liability (Companies Office registration number 873005).

Registered Offices	Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand. +64 9 488 0232 www.aftpharm.com 113 Wicks Road, North Ryde NSW 2113, Australia. +61 2 9420 0420
Principal Administration Offices	New Zealand: Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand. +64 9 488 0232 Australia: 113 Wicks Road, North Ryde NSW 2113, Australia. +61 2 9420 0420 United Kingdom: 133 Whitechapel High Street, London, UK
Directors	Dr Hartley Atkinson Marree Atkinson David Flacks Andrew Lane Dr Ted Witek Allison Yorston
Share Registrar:	Computershare Investor Services Limited Level 2, 159 Hurstmere Road, Takapuna, Auckland 0622, New Zealand. +64 9 488 8777 enquiry@computershare.co.nz Computershare Investor Services Pty Limited, Yarra Falls, 452 Johnston Street, Abbotsford VIC 3067, Australia. +61 3 9415 4083 enquiry@computershare.co.nz
Financial Auditor	Deloitte Limited Deloitte Centre, 1 Queen Street, Auckland 1140, New Zealand. +64 9 303 0700
Greenhouse Gas Auditor	Toitū Envirocare The Former, 87 Albert Street, Auckland Central, Auckland 1010, New Zealand. 0800 366 275
Legal Counsel	Harmos Horton Lusk Level 33, Vero Centre, 48 Shortland Street, Auckland 1140, New Zealand. +64 9 921 4300

Financial Calendar

Annual Shareholders' Meeting	August 2026
Half-year end	30 September 2026
Half year results announcement	November 2026
Financial year end	31 March 2027

For personal use only

Level 1, 129 Hurstmere Road
Takapuna
Auckland 0622
New Zealand
+64 9 488 0232
www.aftpharm.com

AFT *pharmaceuticals*
Working to improve your health